



ESCM

European Congress of C

Preliminary

Vienna, Austria

11-15 April 2025



<http://www.escmid.org/congress-e>

ESCMID Global

Clinical Microbiology & Infectious Diseases

Programme



[events/escmid-global](https://www.escmid.org/events/escmid-global)

ESCMID Global 2025 - Programme

Friday, 11 April 2025

SP1

08:30 – 10:30

Hall 0

CLN

Special Session

Antimicrobial Stewardship in Different Scenarios

Chairs

Murat Akova (Ankara, Türkiye)
Andre Fuchs (Augsburg, Germany)
Maddalena Giannella (Bologna, Italy)
Angela Huttner (Geneva, Switzerland)
Benedikt Huttner (Geneva, Switzerland)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
Holger Rohde (Hamburg, Germany)
Oana Sandulescu (Bucharest, Romania)
Jeroen Schouten (Nijmegen, Netherlands)
Valentijn Schweitzer (Utrecht, Netherlands)
Thomas Tängdén (Uppsala, Sweden)
Suzanne Van Asten (Nijmegen, Netherlands)
Dafna Yahav (Ramat-Gan, Israel)

Co-organised with: ESCMID Education Subcommittee

EW001

08:30 – 10:30

Hall 2

CLN IPC

Educational Session

Surgical site infections: principles and practice in the era of multidrug resistance

Chairs

Gabriel Birgand (Nantes, France)
Efthymia Giannitsioti (Athens, Greece)

W0001

08:30

Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?
Camilla Rodrigues (Mumbai, India)

W0002

08:50

Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance
Prasannakumar Palanikumar (Vellore, India)

W0003

09:10

Screening for MDR GNR colonisation: is there evidence for prophylaxis
Elisabeth Presterl (Vienna, Austria)

W0004

09:30

Perioperative prophylaxis in special populations in the era of MDR
Divyashree Shanthamurthy (Mumbai, India)

EW002

08:30 – 10:30

Hall 3

ANT

Educational Session

Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts

Chairs

Shampa Das (Liverpool, United Kingdom)
João Paulo Telles (Sao Paulo, Brazil)

W0005

08:30

Pharmacokinetics 101: navigating the basics for optimal dosing
Linda Aulin (Leiden, Netherlands)

W0006

08:50

The ABCs of population pharmacokinetic models
Erwin Dreesen (Leuven, Belgium)

W0007

09:10

Looking into the crystal ball: exploring the fabulous world of PK-PD simulations
Vincent Aranzana-Climent (Poitiers, France)

W0008

09:30

Decoding population pharmacokinetic papers: interpreting, comparing and discussing results
Iris K. Minichmayr (Vienna, Austria)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW003

08:30 – 10:30

Hall 5

DX

Educational Session

Challenges in identification and relevance of slow-growing pathogens

Chairs *Kerrie Davies (Leeds, United Kingdom)*
Yann Dumont (Nancy, France)

- W0009** **08:30** **Sampling and culturing anaerobes***Hugo Cruz (Porto, Portugal)*
- W0010** **08:50** **I have an anaerobe: what is it and does it matter?***Kathleen Boiten (Groningen, Netherlands)*
- W0011** **09:10** **Actinomyces in clinical samples: when is it worth the trouble?***Eija Inkeri Könönen (Turku, Finland)*
- W0012** **09:30** **Nocardiosis: when to test and how to manage results?***David Lebeaux (Paris, France)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)

EW004 **08:30 – 10:30** **Hall 6**

Educational Session

CLN DX IPC

A hard nut to crack in HIV

Chairs *Yoav Keynan (Winnipeg, Canada)*
Justyna Kowalska (Warsaw, Poland)

- W0013** **08:30** **Viral reservoir: what a physician should know***Ivailo Alexiev (Sofia, Bulgaria)*
- W0014** **08:50** **Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians***Jose Arribas (Madrid, Spain)*
- W0015** **09:10** **Chronic vascular and pulmonary disease and HIV: what can we do about it?***Susanne Dam Poulsen (Copenhagen, Denmark)*
- W0016** **09:30** **Opportunistic infections: most common and most deadly***Milena Stevanovikj (Sopje, North Macedonia, Republic of)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group

EW005 **08:30 – 10:30** **Hall 8**

Educational Session

DX

Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?

Chairs *Miriam José Álvarez-Martínez (Barcelona, Spain)*
Caroline Rönnberg (Stockholm, Sweden)

- W0017** **08:30** **Artificial Intelligence for the diagnosis of parasitic infections***Bobbi Pritt (Rochester, United States)*
- W0018** **08:50** **Histopathology of parasitic infections***Richard Bradbury (Townsville, Australia)*
- W0019** **09:10** **Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections***Sitara Sr Ajjampur (Vellore, India)*
- W0020** **09:30** **Paleoparasitology: what diagnostic tools?***Ayman El-Badry (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW006 **08:30 – 10:30** **Hall 9**

Educational Session

PRO PHEI

Vaccine hesitancy: from issues to solutions through developing communication skills

Chairs *Monia Chemais (Soignies, Belgium)*
Petar Velikov (Sofia, Bulgaria)

- W0021** **08:30** **Vaccine hesitancy and its consequences***Noni Macdonald (Halifax, Canada)*
- W0022** **08:50** **Why are patients and parents hesitant about vaccination?***Eve Dube (Quebec City, Canada)*
- W0023** **09:10** **Using social media to deal with vaccine hesitancy***Muge Cevik (St Andrews, United Kingdom)*

ESCMID Global 2025 - Programme

W0024	09:30	Strengthening vaccine confidence in patients and parents <i>Tba</i>
-------	-------	---

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SP2 **11:00 – 12:00** **Hall O**

Special Session

PRO

Principles of systematic reviews (with and without meta-analysis)

Chairs

Chiara Iaria (Palermo, Italy)
Miranda Langendam (Amsterdam, Netherlands)
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel)
Luigia Scudeller (Pavia, Italy)

Co-organised with: ESCMID Education Subcommittee

ME007	11:00 - 12:00	Hall 2
--------------	----------------------	---------------

Meet-the-Expert

AMR

DX

How to interpret resistance patterns from antibiograms

M0025 11:00 *Tommaso Giani (Florence, Italy)*

M0026 **11:12** *Diaz Lorena (Santiago, Chile)*

ME008 11:00 - 12:00 Hall 3

Meet-the-Expert

CLN

Children are not just small adults: interactive paediatric cases

M0027	11:00	<i>Julie Toubiana (Paris, France)</i>
--------------	--------------	---------------------------------------

M0028 **11:12** *Sanjay Patel (Winchester, United Kingdom)*

ME009	11:00 - 12:00	Hall 5
--------------	----------------------	---------------

Meet-the-Expert

IPC

How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections

M0029 **11:00** *Kushlani Jayatilleke (Battaramulla, Sri Lanka)*

M0030 **11:12** *Walter Zingg (Zurich, Switzerland)*

ME010 11:00 – 12:00 Hall 6

Meet-the-Expert

PHEI

Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience

M0031	11:00	<i>Ecaterina Noroc (Chisinau, Moldova, Republic of)</i>
--------------	--------------	---

M0032 11:12 *Fakhriddin Nizamov (Almaty, Kazakhstan)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)

ME011 11:00 - 12:00 Hall 8

Meet-the-Expert

CLN

Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare

M0033	11:00	<i>Jaime Esteban (Madrid, Spain)</i>
--------------	--------------	--------------------------------------

M0034 **11:12** *Philippe Morand (Paris, France)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)

ME012 11:00 – 12:00 Hall 9
Meet-the-Expert

PHEI

How to understand infectious disease risks in changing climates

M0035 11:00 Kimberly Fornace (Singapore, Singapore)
M0036 11:12 Rachel Lowe (Barcelona, Spain)

SP3 13:30 – 14:30 Hall 0
Special Session

IPC

Top five mistakes in Infection prevention and control

Chairs Maeve Doyle (Waterford, Ireland)
Barbara Juliane Holzkecht (Copenhagen, Denmark)
David Ong (Zoetermeer, Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)

Co-organised with: ESCMID Education Subcommittee

ME013 13:30 – 14:30 Hall 2
Meet-the-Expert

CLN TRN

Orthopaedic implant infections: new approaches for improved outcomes

M0037 13:30 Marjan Wouthuyzen-Bakker (Groningen, Netherlands)
M0038 13:42 Trisha Peel (Melbourne, Australia)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME014 13:30 – 14:30 Hall 3
Meet-the-Expert

CLN

Timing of antimicrobials in sepsis and septic shock - the sooner the better?

M0039 13:30 Laura Evans (Seattle, United States)
M0040 13:42 Evangelos Giamarellos-Bourboulis (Athens, Greece)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

ME015 13:30 – 14:30 Hall 5
Meet-the-Expert

CLN

PrEP in Europe: Current gaps and solutions

M0041 13:30 Teymur Noori (Stockholm, Sweden)
M0042 13:42 Milosz Parczewski (Szczecin, Poland)

Co-organised with: European AIDS Clinical Society (EACS)

ME016 13:30 – 14:30 Hall 6
Meet-the-Expert

CLN

Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines

M0053 14:45 *Luigia Scudeller (Pavia, Italy)*
M0054 14:57 *Blin Nagavci (Gjakove, Kosovo)*

Co-organised with: ESCMID Guidelines Subcommittee

ME022 14:45 – 15:45 Hall 6
Meet-the-Expert

CLN

Multidisciplinary management of bone and joint infections: Is there a recipe for success?

M0055 14:45 *Natividad Benito (Barcelona, Spain)*
M0056 14:57 *Tiziana Ascione (Naples, Italy)*

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

ME023 14:45 – 15:45 Hall 8
Meet-the-Expert

PHEI

How to manage and prevent travellers' diarrhoea

M0057 14:45 *Tinja Laaveri (Helsinki, Finland)*
M0058 14:57 *David Tribble (Bethesda, United States)*

ME024 14:45 – 15:45 Hall 9
Meet-the-Expert

CLN DX IPC

How to diagnose and treat infectious complications in critically ill patients receiving ECMO support

M0059 14:45 *Jordi Riera (Barcelona, Spain)*
M0060 14:57 *Giacomo Grasselli (Besana In Brianza, Italy)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

SP5 16:15 – 18:15 Hall 0
Special Session

CLN

Multidisciplinary approach to early sepsis management

Chairs *Markus Bald (Lüdenscheid, Germany)*
Aleksandra Davidovic (Luedenscheid, Germany)
Charalambos Dokos (Lüdenscheid, Germany)

Co-organised with: ESCMID Education Subcommittee

EW025 16:15 – 18:15 Hall 2
Educational Session

AMR DX

AMR surveillance: current challenges and new perspectives

Chair *Tomislav Mestrovic (Varazdin, Croatia)*

W0061 16:15 **The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden***Authia Gray (Washington, United States)*
W0062 16:35 **Networks for surveillance of AMR in animal pathogens***Lucie Collineau (Lyon, France)*
W0063 16:55 **Transition to genomic-based methodology for surveillance and outbreak detection to effectively combat AMR***Camilla Wiuff Coia (Copenhagen, Denmark)*
W0064 17:15 **Implementing and running hospital-wide genomic surveillance of pathogens***Alexander Mellmann*

ESCMID Global 2025 - Programme

(Münster, Germany)

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW026 **16:15 – 18:15** **Hall 3**
Educational Session

AMR

New insights into antifungal agents and resistance

Chairs *Anuradha Chowdhary (New Delhi, India)*
Jon Salmanton-Garcia (Cologne, Germany)

W0065 **16:15** **Emerging resistance in *Candida tropicalis*** *Sharon Chen (Sydney, Australia)*

W0066 **16:35** **Mechanisms of resistance in *Candida glabrata*** *David Perlin (Nutley, United States)*

W0067 **16:55** **Surveillance of resistance in *Aspergillus* species** *Maiken Cavling Arendrup (Copenhagen, Denmark)*

W0068 **17:15** **Environmental surveillance for antifungal resistance** *Eveline Snelders (Wageningen, Netherlands)*

EW027 **16:15 – 18:15** **Hall 5**
Educational Session

ANT CLN TRN

Going Viral! Phage Therapy Clinical rounds

Chairs *Gregory German (Maple, Canada)*
Ameneh Khatami (Sydney, Australia)

W0069 **16:15** **Clinical cases and lessons from the STAMP protocol** *Holly Sinclair (Nsw, Australia)*

W0070 **16:35** **Difficult cases treated with phages** *Ghady Haidar (Pittsburgh, United States)*

W0071 **16:55** **Challenging osteoarticular cases treated with phages** *Tristan Ferry (Lyon, France)*

W0072 **17:15** **Treating urinary tract infections with phages: dream or reality?** *Saima Aslam (San Diego, United States)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW028 **16:15 – 18:15** **Hall 6**
Educational Session

CLN VAX

Addressing infection challenges in immunocompromised patients: a case-based exploration

Chairs *Maddalena Giannella (Bologna, Italy)*
Asma Nasim (Karachi, Pakistan)

W0073 **16:15** **Challenges in managing gastrointestinal infections in patients with primary immunodeficiency** *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

W0074 **16:35** **Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies** *Gemma Reynolds (Heidelberg, Australia)*

W0075 **16:55** **Mycobacterial infections in patients with HIV infection** *Graeme Ayton Meintjes (Observatory, South Africa)*

W0076 **17:15** **Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation** *Dimitrios P. Kontoyiannis (Houston, Tx, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EW029 **16:15 – 18:15** **Hall 8**
Educational Session

TRN

Impact of diabetes on infectious diseases: what should we know?

<i>Chairs</i>		<i>Mark G. J. De Boer (Leiden, Netherlands)</i> <i>Suzanne Van Asten (Nijmegen, Netherlands)</i>
W0077	16:15	The impact of diabetes and host-pathogen interaction and gut microbiome <i>Reinout Van Crevel (Nijmegen, Netherlands)</i>
W0078	16:35	Diabetes and invasive fungal infections <i>Jochem Buil (Nijmegen, Netherlands)</i>
W0079	16:55	Viral infections and diabetes: is there a connection? <i>Malin Flodström-Tullberg (Stockholm, Sweden)</i>
W0080	17:15	Pathogenesis of diabetic wound infection <i>Tba</i>

EW030	16:15 – 18:15	Hall 9
Educational Session		

DX

IPC

Primer on infection prevention and control: the crucial support by clinical microbiology

<i>Chairs</i>		<i>Nico Tom Mutters (Bonn, Germany)</i> <i>Margreet C. Vos (Rotterdam, Netherlands)</i>
---------------	--	--

W0081	16:15	Microbial fundamentals: building blocks of infection prevention and control <i>Laurence Armand-Lefevre (Paris, France)</i>
W0082	16:35	Optimising environmental sampling in infection control: rational use of the microbiology laboratory <i>John E. Coia (Esbjerg, Denmark)</i>
W0083	16:55	The crucial role of molecular typing in infection control <i>Stefanie Kampmeier (Würzburg, Germany)</i>
W0084	17:15	How can we link diagnostic and antibiotic stewardship? <i>Constantinos Tsioutis (Nicosia, Cyprus)</i>

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Saturday, 12 April 2025

SY036	08:30 – 10:30	Hall 15
2-hour Symposium		

ANT

The quality of antibiotics used in the communities of LMICs

<i>Chairs</i>		<i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i> <i>Christina Obiero (Kilifi, Kenya)</i>
---------------	--	---

S0105	08:30	The quality of antibiotics and their potential impact on patient outcome and AMR <i>Paul Newton (Oxford, United Kingdom)</i>
S0106	09:00	Community antibiotic access and use in Sub-Sahara Africa <i>Samuel Afari-Asiedu (Kintampo, Ghana)</i>
S0107	09:30	Encountered challenges and reflections on conducting multi-country medicine quality studies <i>Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)</i>
S0108	10:00	Confusion in appearance of common used antibiotics in LMICs <i>Heiman Wertheim (Nijmegen, Netherlands)</i>

SY031	08:30 – 10:30	Hall 6
2-hour Symposium		

CLN

VAX

To screen or not to screen prior to transplant?

<i>Chairs</i>		<i>Laura Alicia Barcan (Buenos Aires, Argentina)</i> <i>Oscar Len (Barcelona, Spain)</i>
---------------	--	---

S0085	08:30	HHV-8 Screening <i>Alessandra Mularoni (Palermo, Italy)</i>
S0086	09:00	TB screening and prevention in endemic regions <i>Rubina Naqvi (Karachi, Pakistan)</i>

ESCMID Global 2025 - Programme

S0087	09:30	Screening for and prevention of chagas in immunocompromised hosts <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>
S0088	10:00	Screening of lung donors for Mollicutes <i>Michael G Ison (Derwood (MD), United States)</i>

EF003	08:30 – 09:30	Arena 1
	ePoster Flash Session	

CLN VAX

On the frontiers of vaccine driven prevention

Chair *Maria Ganczak (Zielona Gora, Poland)*

E0021	Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine <i>J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll</i>
E0022	A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine <i>P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li</i>
E0023	A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design <i>M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen</i>
E0024	Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years <i>M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R. Das</i>
E0025	Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms <i>S. Prieto Martín Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. Mcconnell</i>
E0026	Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics <i>T. Russell* (London, United Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr</i>
E0027	Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study <i>L. Mcgeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall</i>
E0028	Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration. <i>Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone</i>
E0029	The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania <i>S. Cristea* (Sibiu, Romania), C. Grigore</i>

EF004	08:30 – 09:30	Arena 3
	ePoster Flash Session	

ANT

Pharmacology from bench to the bedside

Chair *Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)*

E0030	<i>Enterococcus faecalis</i> impairs <i>Escherichia coli</i>
-------	--

		response to antibiotics in a dual-species intracellular infection model <i>F. Van Bambeke* (Brussels, Belgium), G. Wang</i>
E0031		In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing <i>Enterobacterales</i> clinical isolates <i>M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Sauco Carballo, J. Rodriguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha</i>
E0032		<i>In vivo</i> activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant <i>Pseudomonas aeruginosa</i> following subcutaneous administration <i>W. Wicha* (Bruck An Der Leitha, Austria), S. Paukner</i>
E0033		Synergistic Potency Unveiled: β -Lactam and β -Lactamase Inhibitor Combination against <i>Mycobacterium abscessus</i> with Dual Action of β -Lactamase Inhibition and Multi-Target Receptor Inactivation <i>E. Shin* (Cleveland, United States), K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo</i>
E0034		Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with <i>Mycobacterium abscessus</i> infection <i>W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane</i>
E0035		Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models <i>R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg</i>
E0036		Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study <i>P. Le Turnier* (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C. Deschanvres, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard</i>
E0037		No time to waste: hospital-wide assessment of IV-vial and line residuals and impact on target attainment. <i>D. Vanneste* (Leuven, Belgium), M. Gijssen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet</i>
E0038		Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection <i>D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer</i>

SY034	08:30 – 10:30	Hall 10
	2-hour Symposium	
	IPC	
Endoscopy: infection risks and mitigation		
Chairs <i>Elisabeth Presterl (Vienna, Austria)</i> <i>Gordon Ramage (Glasgow, United Kingdom)</i>		
S0097	08:30	Should we be concerned about infection from contaminated endoscopes? <i>Claire Aumeran (Clermont-Ferrand, France)</i>
S0098	09:00	Prevention of multidrug-resistant infections from contaminated duodenoscopes <i>Margreet C. Vos (Rotterdam, Netherlands)</i>
S0099	09:30	Understanding the causes of medical device contamination: it is all biofilm! <i>Roberto Rusconi (Milan, Italy)</i>
S0100	10:00	Does the European medical Device Regulation bring us safer duodenoscopes? <i>Markus Hell (Salzburg, Austria)</i>

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

ESCMID Global 2025 - Programme

OS002	08:30 – 10:30	Hall 11
	2-hour Oral Session	
	<div>DX</div>	
Translating metagenomics into clinical practice		
Chairs	Benjamin Peter Howden (Parkville (Victoria), Australia) Paula Mölling (Örebro, Sweden)	
00011	Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study <i>H.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen</i>	
00012	Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash. <i>J. Alexander* (Orlando, United States), A. Charles</i>	
00013	Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care <i>R. Hammond* (London, United Kingdom), A. Kopec, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer</i>	
00014	Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy <i>T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle</i>	
00015	Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes <i>E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser</i>	
00016	Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study <i>L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia</i>	
00017	Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU <i>B. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang</i>	
00018	Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence <i>C. Peng* (Shiyan, China), S. Qi, C. Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun</i>	
00019	A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS) <i>M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy</i>	
00020	Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study <i>M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona</i>	

SY035	08:30 – 10:30	Hall 12
	2-hour Symposium	
	<div>PHEI</div>	
Barriers to TB/HIV elimination in low- and high-incidence settings		
Chair	Daria Podlekareva (Copenhagen, Denmark)	
S0101	08:30	HIV and TB epidemic: the storm hasn't subsided yet <i>Tetiana Koval (Poltava, Ukraine)</i>
S0102	09:00	Approaches for latent and active TB screening in

		people living with HIV <i>Raimonda Matulionyte (Vilnius, Lithuania)</i>
S0103	09:30	Integration of HIV and TB care to improve patient outcome in resource-limited settings <i>Akaki Abutidze (Tbilisi, Georgia)</i>
S0104	10:00	How researchers can influence policy and practice in HIV/TB care <i>Jens D. Lundgren (Copenhagen, Denmark)</i>

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group

EW041	08:30 – 10:30	Hall 13
	Educational Session	

CLN DX VAX

RSV infections: diagnosis, surveillance and treatment in the advent of vaccines

Chair *Monika Redlberger-Fritz (Vienna, Austria)*

W0126	08:30	Costs of RSV infection, compared to other respiratory viruses <i>Barbara Rath (Besançon, France)</i>
W0127	08:50	Virology and host interactions of RSV
W0128	09:10	RSV surveillance in the EU/EEA in the vaccine era <i>Eeva Broberg (Solna, Sweden)</i>
W0129	09:30	RSV fusion inhibitors and monoclonals: current status and future developments <i>Peter Openshaw (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

EW042	08:30 – 10:30	Hall 14
	Educational Session	

CLN

Traumatic wound infections: diagnosis and treatment options

Chairs *Amparo Fernández-Rodríguez (Madrid, Spain)*
Veroniek Saegeman (Sint-Niklaas, Belgium)

W0130	08:30	Multidrug-resistant infections after trauma in warzone <i>Shehan Hettiaratchy (Hampton, United Kingdom)</i>
W0131	08:50	Fungal infections during natural disasters <i>Anuradha Chowdhary (New Delhi, India)</i>
W0132	09:10	Bacteriophage therapy for multidrug-resistant wound infections in trauma <i>Tristan Ferry (Lyon, France)</i>
W0133	09:30	Infection of burn wounds <i>Nur Benzonana (Istanbul, Türkiye)</i>

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clínica), International Society of Antimicrobial Chemotherapy (ISAC)

SY037	08:30 – 10:30	Hall 16
	2-hour Symposium	

CLN DX

Unveiling the challenges: nosocomial infections in ECMO-supported patients

Chairs *Antonios Katsounas (Bochum, Germany)*
Jordi Riera (Barcelona, Spain)

S0109	08:30	Source of infection and pathogens <i>Christian Eckmann (Hannover, Germany)</i>
S0110	09:00	Prophylaxis and empiric treatment <i>Giacomo Grasselli (Besana In Brianza, Italy)</i>
S0111	09:30	Diagnostic criteria and definitions <i>Graeme Maclaren (Singapore, Singapore)</i>
S0112	10:00	Microbial films <i>Marta Hernández-Meneses (Barcelona, Spain)</i>

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

ESCMID Global 2025 - Programme

EW039		08:30 – 10:30		Hall 2
		Educational Session		
		CLN DX		
Are urinary tract infections still the same?				
Chairs		Suzanne Geerlings (Amsterdam, Netherlands) Agnes Maria Sonnevend (Pécs, Hungary)		
W0118	08:30	Update on paediatric UTI	Michael Buettcher (Luzern, Switzerland)	
W0119	08:50	Diagnosis and treatment of UTI in the era of antimicrobial resistance	Jennifer Kranz (Aachen, Germany)	
W0120	09:10	Can UTI be prevented?	Chris Harding (Newcastle Upon Tyne, United Kingdom)	
W0121	09:30	Fungal and parasitic infections of the urinary tract	Gladys Mbwanji (Mwanza, Tanzania, United republic of)	
EW040		08:30 – 10:30		Hall 3
		Educational Session		
		ANT CLN		
OPAT: from aged wine to new vintage				
Chairs		Birgit Koch (Rotterdam, Netherlands) Sonia Luque (Barcelona, Spain)		
W0122	08:30	OPAT: principles, practice and checklists	Charlotte Quintens (Leuven, Belgium)	
W0123	08:50	COPAT: complex outpatient parenteral antimicrobial therapy	Ronald Andrew Seaton (Glasgow, United Kingdom)	
W0124	09:10	Antimicrobial stability and other challenges for OPAT practice?	Mark Gilchrist (London, United Kingdom)	
W0125	09:30	New OPAT safety and efficacy data to guide practice	Matthew Rawlins (Murdoch, Australia)	
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)				
EW038		08:30 – 11:30		Hall 4
		Educational Session		
		AMR DX		
EUCAST Educational Workshop				
Chairs		Marlene Amara (Le Chesnay Cedex, France) Alasdair P. Macgowan (Bristol, United Kingdom)		
W0113	08:30	EUCAST update	Sören G. Gatermann (Bochum, Germany)	
W0114	08:50	Setting clinical breakpoints, assessing evidence	Anouk Edwina Muller (The Hague, Netherlands)	
W0115	09:10	Benzylpenicillin susceptibility testing of <i>S. pneumoniae</i> by disk diffusion	Gunnar Kahlmeter (Tävelsås, Sweden)	
W0116	09:30	What to do when there are no breakpoints	Barbara Juliane Holzknecht (Copenhagen, Denmark)	
W0117	09:50	Detection of resistance mechanisms	Christian Giske (Stockholm, Sweden)	
Co-organised with: EUCAST Steering Committee				
OS001		08:30 – 10:30		Hall 5
		2-hour Oral Session		
		AMR PHEI TRN		
One Health means resistance everywhere				
Chairs		Alessandra Carattoli (Rome, Italy) Prasannakumar Palanikumar (Vellore, India)		

O0001	Decoding the role of <i>bla</i>_{CPE}-carrying plasmids on wings: A holistic view using the One Health approach <i>S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres</i>
O0002	A novel isolation room model leveraging culture-independent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs <i>V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng</i>
O0003	Deciphering the pathogenic potentials and epidemiological identities of <i>Staphylococcus pseudintermedius</i> colonizing companion dogs in Sao Paulo <i>I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales</i>
O0004	Recent progress towards integrated surveillance of antimicrobial resistance in France <i>L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin</i>
O0005	Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination <i>B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczkó, G. Kardos</i>
O0006	Emergence of mobile colistin resistance in <i>Klebsiella</i> at human-animal-environment interface in Bangladesh <i>S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana</i>
O0007	Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective <i>I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja</i>
O0008	Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples <i>E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos</i>
O0009	One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison <i>G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaite, D. Belay, J. Guitian, M. Dione, E. Emes</i>
O0010	Clinically important sequence types and resistance genes in <i>Enterobacteriaceae</i> from coastal environments and gulls <i>V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas</i>

SY032	08:30 – 10:30	Hall 7
	2-hour Symposium	
	TRN	
New insights into <i>Candida</i> pathogenesis		
<i>Chairs</i> <i>Aleksandra Barac (Belgrade, Serbia)</i> <i>Joshua Nosanchuk (Bronx, United States)</i>		
S0089	08:30	Insights into the evolution of <i>Candida</i> under antifungal pressure <i>Attila Gacser (Szeged, Hungary)</i>
S0090	09:00	How do <i>Candida</i> extracellular vesicles modify virulence during disease? <i>Leonardo Nimrichter (Rio De Janeiro, Brazil)</i>
S0091	09:30	The commensal to pathogen transition: kind to killer <i>Ilse D. Jacobsen (Jena, Germany)</i>
S0092	10:00	Fungal-bacterial interactions: who wins? <i>Rebecca Hall (Canterbury, United Kingdom)</i>

ESCMID Global 2025 - Programme

SY033		08:30 – 10:30	Hall 8
		2-hour Symposium	
		TRN	
Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.			
Chairs		Christian Stephan Lentz (Tromsø, Norway) Annelies Zinkernagel (Zurich, Switzerland)	
S0093	08:30	Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infectionsChristoph Ernst (Cologne, Germany)	
S0094	09:00	Single-cell imaging and heterogeneity in antimicrobial resistanceStefano Pagliara (Exeter, United Kingdom)	
S0095	09:30	Single-cell RNAseq and heterogeneity in bacterial transcriptionAnna Kuchina (Seattle, United States)	
S0096	10:00	Dissecting the function of individual bacteria in their spatial contextKnut Drescher (Basel, Switzerland)	
SY043		09:30 – 10:30	Hall 1
		1-hour Symposium	
		IPC	
Year in infection control			
Chairs		Nico Tom Mutters (Bonn, Germany) Ermira Tartari (Msida, Malta)	
S0134	09:30	Andrew James Stewardson (Melbourne, Victoria, Australia)	
S0135	10:00	Kalisvar Marimuthu (Singapore, Singapore)	
EF005		09:30 – 10:30	Arena 2
		ePoster Flash Session	
		CLN DX	
It's all in the blood			
Chair		Colin R. Mackenzie (Neuss, Germany)	
E0039	Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivityL. Hardy* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet		
E0040	Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital networkC. Hall* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main		
E0041	Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood culturesD. Crilly* (London, United Kingdom), A. Bapat, J. Youngs, G. Maloney, E. Drakes		
E0042	Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of resultsC. Magri* (Rome, Italy), C. Magri, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti		
E0043	Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient ManagementS. Buyukberber* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan		
E0044	Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of TürkiyeÖ. Türkmen Recen* (Izmir, Türkiye), M. Kiplapınar, H. Özdemir, S. Kurutepe, H. Gazi		
E0045	Performance of direct pathogen and β -lactamase detection workflow using MALDI-TOF MS from positive blood culture specimensK. Kosai* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara		
E0046	Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infectionsL. Van Balen* (Maastricht, Netherlands), R. Koeck		

E0047 Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in Europe *C. Pina-Vaz* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva*

EF006 09:30 – 10:30 **Arena 4**

AMR ANT CLN

ePoster Flash Session

Emerging developments in antifungal pharmacology

Chair Roger Brüggemann (Nijmegen, Netherlands)

- E0048** **NATURE-US: the natural history of antifungal failure in invasive candidiasis** *L. Ostrosky-Zeichner* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo*
- E0049** **The antidepressant vortioxetine enhances resistance toward multiple azoles** *S. Rizzo* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli*
- E0050** **Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration** *A. Desai* (Northbrook, United States), L. Kovanda*
- E0051** **Identification of efflux inhibitors for *Candida albicans* through a drug repurposing strategy** *D. Marques* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues*
- E0052** **Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of *Candida auris* fungemia** *J. Hou* (Chicago, IL, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega*
- E0053** **Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis** *G.R. Thompson* (Davis, California, United States), A. Soriano, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely*
- E0054** **Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by *Candida auris*: a multicentre, open-label study (CARES)** *M.H. Miceli* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson III, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breed, N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M. Middle, M. Hoenigl*
- E0055** **High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis** *S. Wurster* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis*
- E0056** **Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits** *R. Petraitiene* (New York, United States), E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pockevicius, M. Zimmerman, A.H. Groll, T.J. Walsh, V. Petraitis*

FO050 11:00 – 12:00 **Arena 1**

PHEI

Open Forum

HIV: a global ethical Conundrum

Chair Seif Al-Abri (Muscat, Oman)

- F0147** 11:00 **HIV, from key population to general population: a Pandora's Box** *Syed Faisal Mahmood (Karachi, Pakistan)*
- F0148** 11:10 **Ethical considerations in preventing mother-to-child HIV transmission** *Glory Alexander (Bangalore, India)*
- F0149** 11:20 **HIV drug trials in Africa: ethical concerns** *Shah Reena*

ESCMID Global 2025 - Programme

(Nairobi, Kenya)

F0150 11:30 HIV-related stigma and discrimination in the healthcare setting *Teymur Noori (Stockholm, Sweden)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

EF014 11:00 – 12:00 Arena 2
ePoster Flash Session

IPC PHEI

Infection control and prevention around the World

Chair Divyashree Shanthamurthy (Mumbai, India)

E0092 WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets *P. Bischoff* (Geneva, Switzerland), S. Tomczyk, G. Satta, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi*

E0093 Healthcare-associated infections in african intensive care units: A multicentre prospective cohort study *B. Gaye* (Dakar, Senegal), N. Madani, J. Ben Khliil, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Najja, M. Kahloul, R. Herch, R. Tourni, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoun, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly*

E0094 Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022. *E. Liddy* (Dublin, Ireland), A. Vellinga, D. Amin*

E0095 Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network *I. Kopsidas* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou*

E0096 Characterisation of plasmids disseminating antibiotic resistance in *Klebsiella pneumoniae* isolates from Pretoria, South Africa *T. Govender* (Pretoria, South Africa), A. Moultrie, M. Moodley, J. Featherston, M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock*

E0097 Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin *K. Sintondji* (Abomey-Calavi, Benin), V. Dognon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou*

E0098 Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units. *M. Salomão* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao*

E0099 Genomic Insights into the Rapid Rise of *Pseudomonas aeruginosa* ST463: A High-Risk Clone's Adaptive Strategy in China *X. Dong**

(Hangzhou, China)

EF0100

Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study*D. Nagy** (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K. Hopkins, C. Jones, T. Nexus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown

EF015

11:00 – 12:00

Arena 3

ePoster Flash Session

ANT

CLN

DX

Advances in the diagnosis and treatment of skin, bone, and joint infections

Chair

Norma Jung (Köln, Germany)

EF0101

Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic*F. Petri** (Milan, Italy), F. Borgonovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari

EF0102

Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection*B.J.H. Frank** (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter

EF0103

Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis*F. Olearo** (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker

EF0104

Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study*G. Franceschi** (Modena, Italy), M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi, A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina

EF0105

Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study*A. Diarra** (Tourcoing, France), V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O. Robineau, E. Senneville

EF0106

Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infections.*R. Escudero-Sánchez** (Madrid, Spain), S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tacias Pitarch, M. Salaver Lletí, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guío Carrion, J. Gomez Junyent, M.L. Sorli, F. Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote Rivas, B. De La Torre Escuredo, J. Cobo

EF0107

Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial*M. Dudareva** (Oxford, United Kingdom), M. Scarborough, M. McNally, M. Kumin, C. Scarborough, W. Vach, J. Ferguson

EF0108

Clinical and Antibacterial Diversity of *Staphylococcal* Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective.*F. Zeeshan** (Karachi, Pakistan), A. Naeem, F. Uddin

EF0109

Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study.*F. Romani** (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, G. Franceschi, B. Fontana, M. Sarti, C. Mussini

ESCMID Global 2025 - Programme

EF016

11:00 – 12:00

Arena 4

ePoster Flash Session

AMR CLN PHEI

Rising threats: antimicrobial resistance in STIs

Chair Marcos Rust (Feldkirch, Austria)

- E0110

Important rise of antibiotic resistance of *Mycoplasma genitalium*, a sexually transmitted pathogen, in a French University hospital*F. Doucet Populaire* (Clamart, France), W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos*
- E0111

Molecular characterization of antimicrobial resistance and genotyping of *Mycoplasma genitalium* positive samples of the Lisbon area, Portugal*M. Barros* (Lisbon, Portugal), F. Pereira, L. Rodrigues*
- E0112

Antimicrobial Resistance in *Mycoplasma genitalium*: Surveillance and Management in São Paulo, Brazil*V. Passarelli* (São Paulo, Brazil), F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa*
- E0113

Impact of genotypic substitutions on treatment failure for *Mycoplasma genitalium* infection*N.B. Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti*
- E0114

Macrolide-resistant *Mycoplasma genitalium*: an emerging threat to public health?*J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas*
- E0115

Comparison of carbapenem MIC in wild-type, MDR and XDR *Neisseria gonorrhoeae* isolates*J. Brousseau* (Paris, France), A. Braille, M. Mainardis, F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot*
- E0116

Unsettling surge in antimicrobial resistance patterns of *Neisseria gonorrhoeae* - A study from national reference centre in India*D. Sharma* (Delhi, India), S. Muralidhar, N. Joshi*
- E0117

Surveillance of *Neisseria gonorrhoeae* antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024*M. Giovanni* (Singapore, Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan*
- E0118

Molecular surveillance results of *N. gonorrhoeae* in Korea*K.H. Roh* (Goyang, Korea, Republic of), C. Liu, Y.H. Suh, H. Lee, K. Lee*

KN044

11:00 – 12:00

Hall 1

Keynote Lecture

AMR PHEI

Asia: an AMR Hot Zone

Chairs Giulia De Angelis (Rome, Italy)
Robert Leo Skov (Copenhagen, Denmark)

K0136

11:00

David L. Paterson (Singapore, Singapore)

OS010

11:00 – 12:00

Hall 10

1-hour Case Session

CLN

Antimicrobial drugs in action

Chairs Katy Jeannot (Besançon, France)
Timothy R. Walsh (Oxford, United Kingdom)

- O0072

In vivo* cefiderocol resistance due to *cirA* modification during treatmentE. Carretto* (Reggio Emilia, Italy), P. Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M. Bardaro, N.C. Faccioloongo, S. Mezzadri, T. Walsh*
- O0073

Long-term outcomes in dalbavancin-treated patients with vascular graft infection*A. Specklin* (Reims,*

		France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien
O0074		Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant <i>E.coli</i> on peritonitis in a pediatric liver transplant recipient <i>R. Morales Junior*</i> (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio
O0075		Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by <i>Cutibacterium acnes</i> – a case series <i>M. Karolyi*</i> (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fiscoeder, M. Ortler, C. Wenisch
O0076		Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant <i>K. pneumoniae</i> shunt-related ventriculitis: two case reports <i>G. Giuliano*</i> (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello

SY047	11:00 – 12:00	Hall 11
	1-hour Symposium	

IPC		
How long should contact isolation precautions be continued?		
Chairs	Cansu Cimen (Oldenburg, Germany) Kyriaki Tryfinopoulou (Heraklion, Greece)	

S0141	11:00	Contact isolation in patients with MDR organisms: Why, when, where? <i>Gabriel Birgand</i> (Nantes, France)
S0142	11:30	Is discontinuation of contact precautions associated with an increase in infections? <i>Daniel Diekema</i> (Harpeswell, United States)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS

ME048	11:00 – 12:00	Hall 12
	Meet-the-Expert	

DX		
Cut a long story short: choosing NGS platforms		

M0143	11:00	Etienne Ruppe (Paris, France)
M0144	11:12	Stefan Green (Chicago, United States)

OS011	11:00 – 12:00	Hall 13
	1-hour Oral Session	

ANT TRN		
Around the lab in 80 ways: a journey through innovative therapeutics		
Chairs	Zuzanna Drulis-Kawa (Wroclaw, Poland) Helena Zemlickova (Prague, Czech Republic)	

O0077		In vivo expression of an mRNA encoded multi-mechanistic mAb combination against <i>Staphylococcus aureus</i> and protection in a disease model <i>C. Tkaczyk*</i> (Gaithersburg, United States), N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret
O0078		Hijacking intrinsic resistance in <i>Mycobacterium abscessus</i> <i>G. Phelps*</i> (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee
O0079		Tripartite bacteriophage-based strategy to combat human clinical pathogens <i>P. Kalatzis*</i> (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén

ESCMID Global 2025 - Programme

00080	Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy <i>Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu</i>
00081	Identification of compounds capable of removing established bacterial biofilms <i>T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar</i>

ME049	11:00 – 12:00	Hall 14
	Meet-the-Expert	

PRO

How to perform clinical trials in mycoses?

M0145	11:00	<i>Monica Slavin (Melbourne, Australia)</i>
M0146	11:12	<i>Nkechi Azie (Barrington, United States)</i>
Co-organised with: ESCMID Fungal Infection Study Group (EFISG)		

OS012	11:00 – 12:00	Hall 15
	1-hour Oral Session	

PHEI

Climate Impact and One Health Approaches Against Infectious Diseases

<i>Chair</i>	<i>Chadia Wannous (Paris, France)</i>
--------------	---------------------------------------

00082	Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective <i>C. Royo-Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero</i>
00083	Effects of climate change on Aedes aegypti abundance and dengue transmission <i>L. Geng* (Singapore, Singapore)</i>
00084	Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia <i>M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshtkar-Jahromi</i>
00085	Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning <i>E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear</i>
00086	Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater <i>M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni</i>

OS013	11:00 – 12:00	Hall 16
	1-hour Oral Session	

CLN

DX

Viral challenges in organ transplantation

<i>Chairs</i>	<i>Ghady Haidar (Pittsburgh, United States) Cristiana Oprea (Bucharest, Romania)</i>
---------------	--

00087	Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients <i>I. Rodríguez-Goncer* (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Goncer</i>
00088	Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients <i>A. Mughrabi* (Rochester, Minnesota, United States), B. Bisoño-Garcia, S. Chesdachai, N. Ranganath, R. Razonable</i>
00089	Real-world administration of maribavir beyond the eight weeks established in the clinical trial <i>D.</i>

Martínez-Simón (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len*

O0090 **Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients***M. Solis* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer*

O0091 **Dengue in solid organ transplant recipients***S.I. Galian* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin, G. Werber*

SY045 **11:00 – 12:00** **Hall 2**
 1-hour Symposium

CLN

What happens following TB infection?

*Chairs Catherine Ong (Singapore, Singapore)
 Sean Wasserman (London, United Kingdom)*

S0137 **11:00** **Post-TB disease: burden and treatment strategies***Deborah Chong (London, United Kingdom)*

S0138 **11:30** **TB sequelae and fungal infection***Helmut Salzer (Linz, Austria)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet

YIA **11:00 – 12:00** **Hall 3**
 Awards

PRO

Young Investigator Award Session

A001 **11:00** **Deciphering the pathogenic traits and epidemiological identities of *Staphylococcus pseudintermedius*: an emerging and underestimated zoonotic pathogen***Ikechukwu Benjamin Moses (Abakaliki, Nigeria)*

A002 **11:12** **Drugs for Vector-borne Infections: Facts and Fibrillations***Xin Hui Chan (Oxford, United Kingdom)*

A003 **11:24** **Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet?***Matthaios Papadimitriou Olivgeris (Sion, Switzerland)*

A004 **11:36** **Finding a place for observational studies in infectious diseases research***Anthony Bai (Kingston, Canada)*

A005 **11:48** **Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis***Simon Feys (Leuven, Belgium)*

SY046 **11:00 – 12:00** **Hall 5**
 1-hour Symposium

TRN VAX

New frontiers in bacterial pathogenesis

*Chairs Silvio Daniel Brugger (Zurich, Switzerland)
 Abdou Hachani (Melbourne, Australia)*

S0139 **11:00** **Bacterial infections and cellular immunity***Charlotte Odendall (London, United Kingdom)*

S0140 **11:20** **Immuno-metabolism in bacterial diseases***Tania Wong (New York, United States)*

OS007 **11:00 – 12:00** **Hall 6**
 1-hour Oral Session

ANT CLN VAX

New developments in prophylaxis and treatment of COVID-19

*Chairs Gülsen Özkaya Sahin (Lund, Sweden)
 Snjezana Zidovec Lepej (Zagreb, Croatia)*

ESCMID Global 2025 - Programme

O0057	Ensirelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP <i>F. Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara</i>
O0058	Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial <i>R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri</i>
O0059	COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach. <i>T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, C. Garcia-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R. Méndez, E. Calbo, M. Ballesterro-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano</i>
O0060	Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis <i>C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola</i>
O0061	Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial <i>C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader</i>

OS008	11:00 – 12:00	Hall 7
	1-hour Oral Session	

CLN TRN

Advancing Malaria Research: From Molecular Insights to Clinical Challenges

<i>Chairs</i>	<i>Kamruddin Ahmed (Kota Kinabalu, Malaysia)</i> <i>Giri Shan Rajahram (Kota Kinabalu, Malaysia)</i>
---------------	---

O0062	Influence of second blood meals on <i>Plasmodium vivax</i> development and infectivity in mosquitoes <i>S. Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. Sattabongkot, C. Kumpitak</i>
O0064	Severe imported <i>Plasmodium falciparum</i> malaria with hyperparasitaemia: evaluation of predictors for critical disease <i>T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth</i>
O0065	The current status of <i>Plasmodium falciparum</i> chloroquine resistance transporter gene (K76T) and <i>Plasmodium falciparum</i> multi-drug resistance gene 1 (N86Y) in Cameroon <i>M. Fru* (Buea, Cameroon)</i>
O0066	SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed <i>E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes</i>

OS009	11:00 – 12:00	Hall 8
	1-hour Case Session	

CLN

Osteoarticular uninvited guests

<i>Chairs</i>	<i>Tiziana Ascione (Naples, Italy)</i> <i>Jaime Esteban (Madrid, Spain)</i>
---------------	--

O0067	Antibiotic-refractory oligoarthritis in an adolescent caused by <i>Borrelia bavariensis</i> in Croatia <i>N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović</i>
O0068	Progression of vertebral echinococcosis despite radiotherapy treatment <i>M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D.</i>

Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-Molina

- O0069** **Two cases of septic osteoarthritis of *Cutibacterium acnes* detected by 16S rRNA gene sequencing in immunocompetent adolescents***H. Okuno** (Osaka, Japan), *K. Shiota, K. Amo*
- O0070** **A UK case of Melioidosis with osteomyelitis two years after geographical exposure***C. Darlow** (Liverpool, United Kingdom), *L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis*
- O0071** **When Infection Masquerades as Malignancy: A Case of Disseminated *Mycobacterium fortuitum* complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN- γ Immunodeficiency Syndrome***N. Hiranburana** (Bangkok, Thailand), *S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul*

LB001 **11:00 – 12:00** **Hall 9**
1-hour Oral Session

Advances in vaccine effectiveness for viral respiratory infections

Chair *Jean Paul Stahl (Corenc, France)*

- L0001** **Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants***A. Figueroa** (Cambridge, United States), *D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt*
- L0002** **JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE***H.R. Volkman** (New York, United States), *L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. McLaughlin, K. Bollaerts*
- L0003** **Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults ≥ 65 years of age in the United States***A. Miles** (New York, United States), *J.T. Vietri, S. Rosenstock, H. Li, J. Vojcic, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani*
- L0004** **Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure***D. Jenkin** (Oxford, United Kingdom), *E. Sheehan, R. Huq, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhadeh, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson*
- L0005** **Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals***J. Atwell** (New York, United States), *R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner*

SY051 **13:30 – 14:30** **Hall 1**
1-hour Symposium

CLN

Year in infectious diseases

Chairs *Nur Benzonana (Istanbul, Türkiye)*
Evelina Tacconelli (Verona, Italy)

- S0151** **13:30** *Yoav Keynan (Winnipeg, Canada)*
- S0152** **14:00** *Elisa Cordero Matia (Seville, Spain)*

ESCMID Global 2025 - Programme

SY053

13:30 – 14:30

Hall 16

PRO

1-hour Symposium

Developing guidelines with AI tools: are they ready for prime time?

Chairs

Miranda Langendam (Amsterdam, Netherlands)
Blin Nagavci (Gjakove, Kosovo)

- S0155

13:30

The PROs and CONs of using AI tools for developing guidelines
Holger Schuenemann (Milano, Italy)
- S0156

14:00

AI in action: validated tools for speeding up your systematic reviews and how to use them
Sara Fernandez (Oslo, Norway)

Co-organised with: ESCMID Guidelines Subcommittee

SY052

13:30 – 14:30

Hall 2

IPC PHEI

1-hour Symposium

Exploring children's role in infection spread

Chairs

Angelika Berger
Sanjay Patel (Winchester, United Kingdom)

- S0153

13:30

Are children really super-spreaders of respiratory viruses?
Emmanuel André (Leuven, Belgium)
- S0154

14:00

Should schools be closed at the start of the next pandemic?
Vittoria Colizza (Paris, France)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

EF021

13:30 – 14:30

Arena 1

AMR CLN DX

ePoster Flash Session

Infections in hemato-oncological hosts: from bacterial to viral

Chair

Genovefa Papanicolaou (New York, United States)

- E0139

Vancomycin-resistant *Enterococcus faecium* bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study
J. Fung (Vancouver, Canada), K. Aldhaferi, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga*
- E0140

Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.
I. Grafia (Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco-Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde*
- E0141

Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy
C. Charalampidis (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsirigotis, K. Thomas*
- E0143

The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy
B. Teh (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin*
- E0144

Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity
P. Bono (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri*
- E0145

Safety and tolerability of SYN-004 in allogeneic

	hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T) <i>E. Dubberke* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M. Moenk, V. Wachter, M. Kaleko, J. Kutj, M. Olsen</i>
E0146	Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients <i>S. De Aragón De La Cruz* (Basel, Switzerland), C.S. Walti, N. Khanna, K. Leuzinger, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck</i>
E0147	Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients. <i>J. Boan Perez* (Madrid, Spain), J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoain, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado</i>

EF022	13:30 – 14:30	Arena 2
	ePoster Flash Session	

DX

Syndromic testing is still coming of age

Chair Tommaso Giani (Florence, Italy)

E0148	Bacterial infections of the central nervous system: addressing the diagnostic gap in non- community-acquired meningitis <i>G. Menchinelli* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti</i>
E0149	Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform <i>M. Rey* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona</i>
E0150	Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital <i>S. Subedi* (Brisbane, Australia), P. Harris, D. Paterson</i>
E0151	Performance evaluation of the NxTAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital. <i>S. Gibaud* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec</i>
E0152	Correct discrimination of Monkeypox virus clades by fast syndromic testing <i>S. Reister* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen</i>
E0153	Managing a <i>Mycoplasma pneumoniae</i> Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies <i>L. Brusca* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-Borrás, G. Santillana-Cernuda, M. Ballesterro-Tellez, A. Boronat, J. Perez</i>
E0154	Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysis <i>R. Riccardi* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella</i>
E0155	Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia. <i>S. Chantharasut* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaisuttikul</i>
E0156	BacteREVEAL: Analytical performance and contribution of BioFire® BCID2 and Vitek® REVEAL™ in intensive care patients with Gram-negative bloodstream infections <i>C. Roger* (Nîmes, France), L. Oudiane, M. Benyahia, F. Salipante, A.</i>

ESCMID Global 2025 - Programme

Dubois, L. Muller, J.P. Lavigne, A. Pantel

EF023

13:30 – 14:30

Arena 3

ePoster Flash Session

DX

Effective microbiology for the management of sepsis

Chair Maurizio Sanguinetti (Rome, Italy)

- E0157

Molecular epidemiology of *Klebsiella* bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study*D. Nagy** (Oxford, United Kingdom), *N. Stoesser, S. Lipworth, V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown*
- E0158

Investigating seasonality of antibiotic resistance associated with *E. coli* and *Klebsiella pneumoniae* bloodstream infections*S. Lipworth** (Oxford, United Kingdom), *L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner*
- E0159

Sensitivity of a host-protein test for microbiologically confirmed bacterial infections*R. Navon** (Tirat Carmel, Israel), *E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide*
- E0160

Comparative genomics of *Klebsiella pneumoniae* from gut colonisation and bloodstream infections reveal novel genetic associations*M. Hetland** (Stavanger, Norway), *K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr*
- E0161

Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study*G. Sanlıdag İsbilen** (Izmir, Türkiye), *G. Şanlıdağ İşbilen, B. Akkul, C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi*
- E0162

Contribution of *Escherichia coli* microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study*N. Maldonado** (Seville, Spain), *I. López-Hernández, L.E. López-Cortes, P.M. Martínez Pérez-Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-Kindelán, J.M. Reguera Iglesias, C. Armiñanzas-Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-Hernández, J. Rodríguez-Baño*
- E0163

Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP*C. Treille** (Saclay, France), *K. Perez-Toralla, H. Boutal, X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland*
- E0164

Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australia*K. Laupland** (Herston, Australia), *A. Stewart, F. Edwards, P. Harris, S. Coulter*
- E0165

Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery*S. Soueges** (Lyon, France), *A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-Schiava, U. Huvelle, A. Millon, F. Valour*

EF024

13:30 – 14:30

Arena 4

ePoster Flash Session

AMR TRN

A never-ending evolution of antimicrobial resistance

Chair Antonio Oliver (Palma De Mallorca, Spain)

E0166	Gfa, a novel integron-born fosfomycin resistance mechanism <i>N. Kieffer*</i> (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, J.A. Escudero
E0167	Regulons of RamA, RarA and SoxS mediated tigecycline resistance and oxidative stress among <i>in vitro</i> tigecycline resistant evolution trajectory of <i>Klebsiella pneumoniae</i>. <i>X. Wang*</i> (Beijing, China), J. Kuai, Y. Zhao
E0168	Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing <i>Escherichia coli</i>. <i>C. Tellapragada*</i> (Stockholm, Sweden), P. Jonsson, C. Giske
E0170	<i>Enterococcus faecalis</i> penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration <i>O. Funk*</i> (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano
E0171	Uncommon genomic rearrangements drive vancomycin resistance in <i>vanB</i>-positive <i>Enterococcus faecium</i> <i>K. Xanthopoulou*</i> (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins
E0172	Heteroresistance in <i>Enterococcus faecalis</i>: prevalence and mechanistic insights across clinically relevant antibiotics <i>S. Heidarian*</i> (Uppsala, Sweden), S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I. Andersson
E0173	Side effects of rifampicin resistance: transcriptome modulation by <i>rpoB</i> mutations in <i>Staphylococcus aureus</i> <i>M. Roch*</i> (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenko, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley
E0174	Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance <i>T. Echelmeyer*</i> (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenscher, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufler, E. Eger

OS018	13:30 – 14:30	Hall 11
	1-hour Oral Session	



Battling the Spore: *C. difficile* epidemiology and management

<i>Chairs</i>	<i>Nicolas Benech</i> (Lyon, France) <i>Fidelma Fitzpatrick</i> (Dublin, Ireland)
---------------	--

O0124	Molecular epidemiology and antimicrobial resistome of <i>Clostridioides difficile</i> from private and public healthcare settings in three provinces in South Africa <i>H. Shirinda*</i> (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers
O0125	Screening for <i>Clostridioides difficile</i> colonization at admission and during hospitalization <i>N. Khanafer*</i> (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems
O0126	Revolutionizing CDI treatment: Are shorter antibiotic regimens the future <i>M. Duricek*</i> (Prague, Czech Republic), J. Benes, K. Halmova
O0127	Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of <i>Clostridioides difficile</i> infection <i>E. Rubio-Martín*</i> (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tacias, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M.

ESCMID Global 2025 - Programme

Montero, D. Echeverría-Esnal, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo

00128 Gut phageome profiling in *Clostridioides difficile* infection and faecal microbiota transplantation C. Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine

OS019 13:30 – 14:30 Hall 12
1-hour Oral Session

TRN

Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential

Chairs Mauricio Farfan (Santiago, Chile)
Eija Inkeri Könönen (Turku, Finland)

00129 Multi-omics integrated analysis revealed the key role of *Fusobacterium periodonticum* in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis. X. Chu* (Beijing, China), Q. Yang

00130 Exploring the respiratory microbiome in COPD patients: The role of *Haemophilus* spp. in disease pathogenesis P. Camps-Massa* (Barcelona, Spain), L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Núñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Domínguez, S. Santos, S. Martí

00131 Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes I. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley

00132 Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health M. Thorp* (Gent, Belgium), C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke

00133 Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria? K. Villageois-Tran* (Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé

ME055 13:30 – 14:30 Hall 14
Meet-the-Expert

CLN

Long acting injectables to treat and prevent infections: an example from HIV field

M0159 13:30 Monica Gandhi (Salt Lake City, United States)
M0160 13:42 Pedro Cahn (Buenos Aires, Argentina)

OS020 13:30 – 14:30 Hall 15
1-hour Oral Session

ANT

How to evaluate AMS programs

Chairs Esther Calbo (Terrassa, Spain)
Sabiha Essack (Durban, South Africa)

00134 Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data N. Nguyen* (Oxford, United Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S. Wordsworth

00135 Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study B. Moshy* (London, United Kingdom), R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan

O0136		Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital <i>V. Huang*</i> (Glendale, United States), <i>T. Pham, A. Vogler, H. Chhen, C. Vandenberg</i>
O0137		Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting <i>A. Hopkins*</i> (Livingston, United States), <i>A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime</i>
O0138		Timing of Novel β-Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings <i>E. Yucel*</i> (Rahway, United States), <i>J. Min, Y. Wang, M. Vendetti, Y. Emre, R.K. Shields</i>

ME054	13:30 – 14:30	Hall 3
	Meet-the-Expert	
	AMR	TRN
How antimicrobial tolerance impacts polymicrobial biofilm-associated infections		
M0157	13:30	<i>Hans Steenackers (Leuven, Belgium)</i>
M0158	13:42	<i>Brian Conlon (Chapel Hill, United States)</i>

OS017	13:30 – 14:30	Hall 5
	1-hour Case Session	
	CLN	
Bad bacteria		
<i>Chairs</i>	<i>Maristela P. Freire (Sao Paulo, Brazil)</i> <i>Siegbert Rieg (Freiburg, Germany)</i>	

O0119		Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug <i>R. Gupta (bagga)*</i> (London, Canada), <i>R. Gupta, A. Cabrera, A. Kanyua, F. Almutawa, J. Delpont, K. Kavanoor Sridhar</i>
O0120		Whipple’s disease: one of medicine’s great imitators <i>S. Kesavan*</i> (Nottingham, United Kingdom), <i>F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson</i>
O0121		Phage Therapy as a Rescue Treatment for Recurrent <i>Pseudomonas aeruginosa</i> Bentall Infection <i>V. Eiferman*</i> (Paris, France), <i>P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu</i>
O0122		A clinical case of <i>Legionella longbeachae</i> pneumonia featuring unique epidemiological features in a major italian hospital <i>S. Guerriero*</i> (Rome, Italy), <i>M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti</i>
O0123		<i>Francisella tularensis</i> – First autochthonous case in the UK <i>G. Vanstone*</i> (Truro, United Kingdom), <i>A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou</i>

ME061	14:45 – 15:45	Hall 3
	Meet-the-Expert	
	PHEI	TRN
How to use large language models and machine learning for improving One Health		
M0170	14:45	<i>Javier Fernández (Oviedo, Spain)</i>
M0171	14:57	<i>Nicolas Radomski (Teramo, Italy)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)

ESCMID Global 2025 - Programme

FO063

14:45 – 15:45

Arena 1

Open Forum

PRO

Science communication in a noisy world: podcasting and social media in ID/CM

Chair Emily G. McDonald (Montreal, Canada)

- FO174

14:45

The ID:IOTS guide to creating a successful CM/ID podcast" Callum Mutch (Edinburgh, United Kingdom)
- FO175

14:55

Using social media for CM/ID educationScott Jake (Oakland, United States)
- FO176

15:05

Podcasting and social media for antimicrobial stewardship and pharmacyErin McCreary (Pittsburgh, United States)

Co-organised with: CMI Communications Board of Editors

EF029

14:45 – 15:45

Arena 2

ePoster Flash Session

VAX

Vaccination uptake-challenges and opportunities

Chair Joanne M. Langley (Halifax, Canada)

- E0195

Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patientsN.D. Johansen* (Hellerup, Denmark), M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, E.L. Dueger, S. Samson, M.M. Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, T. Biering-Sørensen
- E0196

Psychological Predictors of Influenza Vaccination Intent Among Healthcare Workers in BulgariaP. Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenov[], D. Ivanov, A. Zasheva, A. Hori
- E0197

Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort studyQ. Hofsink* (Amsterdam, Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof
- E0199

Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programmeA.C.M. Breschel* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersend
- E0200

Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024M. Hakim* (Hayat Abad Peshawar Kp Pakistan, Pakistan)
- E0201

Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIVD. Yaman* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin
- E0202

Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018–2022A. Palmborg* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar
- E0203

Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkeyC. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal

EF030

14:45 – 15:45

Arena 3

ePoster Flash Session

CLN DX PHEI

Viruses crossing the blood-brain barrier

E0204	Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study <i>L. Duerlund*</i> (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen
E0205	Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study <i>S. Lant*</i> (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tullius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon
E0206	Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology <i>C. Marin*</i> (Bucharest, Romania), A. Paun, E. Nedu, S. Tetrarov, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu
E0207	Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model <i>Z. Ou*</i> (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng
E0208	Intrathecal immunoglobulin synthesis in tick-borne encephalitis <i>S. Grygorczuk*</i> (Bialystok, Poland), P. Czupryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska
E0209	B and T cell responses to Tick-borne Encephalitis Virus <i>N. Mayola Danes*</i> (Stockholm, Sweden), R. Varnaité, N. Mayola Danés, K. Blom, H.G. Ljunggren, S. Gredmark-Russ
E0210	Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights <i>D. Sharma*</i> (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh
E0211	Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitis <i>M. Mohata*</i> (New Delhi, India), V. Suri, P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K. Soni, K. Gupta
E0212	<i>Toxoplasma gondii</i> IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era <i>T. Ou*</i> (New Taipei City, Taiwan, China), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung

EF031	14:45 – 15:45	Arena 4
-------	---------------	---------

ANT CLN

ePoster Flash Session

AMS around the world: know your data!

Chair Eoghan De Barra (Dublin, Ireland)

E0213	Duration of antibiotic treatment for respiratory tract infections in primary care. <i>C. Llor*</i> (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis
E0214	Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys <i>N. Nguyen*</i> (Oxford, United Kingdom), K. Pouwels, M. Sharland, S. Mangla, A. Cook, M. Thorn, P. Stephens
E0215	Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys <i>N. Nguyen*</i> (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland
E0216	Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription <i>R. Koizumi*</i>

ESCMID Global 2025 - Programme

		(Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari
E0217		Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey. <i>C. Palos*</i> (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa
E0218		Evaluating the impact on 28-day mortality of different empiric AWARe antibiotic treatment strategies for hospital-acquired infections across different hospital settings. <i>C. Lim*</i> (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper
E0219		Update on WHO's Global antibiotic use surveillance system (GLASS-AMU) <i>B. Huttner*</i> (Geneva, Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Tong
E0220		Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPSA. <i>Versporten*</i> (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
E0221		Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital <i>N. Sandoval*</i> (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa
<hr/>		
KN056	14:45 – 15:45	Hall 1
	<div><div>PHEI</div>Keynote Lecture</div>	
Defending against dengue: global epidemiology and strategies for prevention and control		
<i>Chairs</i>	<i>Anu Kantele (Helsinki, Finland)</i> <i>Carlos Seas (Lima, Peru)</i>	
K0161	14:45	<i>Fernanda Boulos (São Paulo, Brazil)</i>
<hr/>		
OS026	14:45 – 15:45	Hall 11
	<div><div>AMR</div><div>ANT</div><div>CLN</div>1-hour Oral Session</div>	
Carbapenem resistance Gram-negatives, what's new in treatment?		
<i>Chair</i>	<i>Maria Milagro Montero (Barcelona, Spain)</i>	
O0180	Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be? <i>Y. Verma*</i> (Hisar, India), K. Narang, D. Bandlish, C. Sharma	
O0181	Sulbactam-durlobactam as an effective alternative option against NDM-producing <i>Escherichia coli</i> including cefiderocol and aztreonam-avibactam-resistant isolates in Switzerland <i>C. Le Terrier*</i> (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel	
O0182	Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by <i>in vitro</i> Antibiotic Combination Testing <i>T. Lim*</i> (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa	
O0183	Management of infections caused by ST308 New Delhi metallo-β-lactamase-producing <i>Pseudomonas aeruginosa</i> with <i>in vitro</i>-guided combination antibiotic therapy <i>J. Teo*</i> (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa	
O0184	<i>In vitro</i> activity of cefepime/enmetazobactam against clinical isolates of <i>Enterobacterales</i> in Portugal: A multicentre retrospective study <i>H. Cruz*</i> (Porto, Portugal), C. Chaves, L. Carneiro	
<hr/>		
OS027	14:45 – 15:45	Hall 12

***Staphylococcus aureus*: colonisation, virulence, and persistence**

Chair

Stefano Giulieri (Melbourne, Australia)

- O0185** **The nasal microbiome redefines and predicts *Staphylococcus aureus* nasal colonisation status**
*D. Aggarwal** (London, United Kingdom), *K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. McMahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison*
- O0186** **Development of a *Staphylococcus aureus* human nasal colonisation model**
*A. Hachani** (Melbourne, Australia), *B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan*
- O0187** **Selection-free, virulence gene promoter-controlled CRISPR interference system for *in vivo* pathogenesis study of *Staphylococcus aureus* - A proof of concept**
*R. Miah** (Tromsø, Norway), *M. Johannessen, M. Kjos, C. Lentz*
- O0188** **Placebo-controlled study of competitive exclusion using *Lactococcus lactis* to reduce transmission of LA-MRSA from pigs to humans**
*B. Duim** (Utrecht, Netherlands), *A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar*
- O0189** **Rifampicin-induced *Staphylococcus aureus* persister formation is driven by CodY and oxidative stress level**
*N. Pordone** (Lyon, France), *J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven*

SY059 **14:45 – 15:45** **Hall 13**
 1-hour Symposium

IPC

Value-based syndromic diagnostics in medical microbiology: Pro / Con debate

Chairs

Hege Vangstein Aamot (Lørenskog, Norway)
Eric Claas (Leiden, Netherlands)

- S0166** **14:45** **Pro: clinical benefit and potential for improved patient outcomes**
Kirstine K. Sogaard (Aalborg, Denmark)
- S0167** **15:15** **Con: limitations, costs, and possible overuse of syndromic panels**
Gilbert Greub (Lausanne, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

SY060 **14:45 – 15:45** **Hall 14**
 1-hour Symposium

IPC

We need to talk about toilets...

Chairs

Stephanie J. Dancer (Glasgow, United Kingdom)
Juliette Severin (Rotterdam, Netherlands)

- S0168** **14:45** **Infection risks from sanitation engineering**
Davey Jones (Bangor, United Kingdom)
- S0169** **15:15** **Ventilation in toilets: how can we improve it?**
Michael Gormley (Edinburgh, United Kingdom)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

OS028 **14:45 – 15:45** **Hall 15**
 1-hour Oral Session

DX

ESCMID Global 2025 - Programme

Unlocking the potential of the human microbiome for clinical diagnostics

Chairs John W. A. Rossen (Groningen, Netherlands)
Maria Vehreschild (Frankfurt Am Main, Germany)

- 00190

Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions*O. Nalbantoglu* (Kayseri, Türkiye), A. Gundogdu, B.H. Ermis*
- 00191

Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis*E. Rubio García* (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual*
- 00192

Donor for fecal microbiota transplantation: a challenging research.*B.S. Orena* (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani*
- 00193

Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy*N. Boutouchent* (Rouen, France), S. Kennedy*
- 00194

Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology*A. Gundogdu* (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture*

ME062

14:45 – 15:45

Hall 16

ANTCLN

Meet-the-Expert

Untangling the web: antimicrobial dose adjustments in renal impairment

- M0172

14:45

Claire Roger (Nimes, France)
- M0173

14:57

Isabel Spriet (Leuven, Belgium)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

SY057

14:45 – 15:45

Hall 2

ANTCLN

1-hour Symposium

Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

Chairs Marc J.M. Bonten (Utrecht, Netherlands)
Karin Thursky (Carlton, Australia)

- S0162

14:45

Pro: maximising outcomes with evidence-based use*Evangelos Giamarellos-Bourboulis (Athens, Greece)*
- S0163

15:15

Con: the risks of routine (over)use*Aurélien Dinh (Garches, France)*

SY058

14:45 – 15:45

Hall 4

VAX

1-hour Symposium

Top papers in transplant ID

Chairs Nicolas Mueller (Zurich, Switzerland)
Alessandra Mularoni (Palermo, Italy)

- S0164

14:45

Top 10 papers in infections in SOT*Patricia Munoz (Madrid, Spain)*
- S0165

15:15

Top 10 paper in infections in HCT and cellular therapy*Joshua Hill (Seattle, United States)*

OS025

14:45 – 15:45

Hall 5

1-hour Oral Session

DX IPC

Bacterial battles: a paediatric perspective on infections and interventions

Chairs

Angelika Berger
Julie Toubiana (Paris, France)

O0175

Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections
D. Dona (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito*

O0176

Correlation between antibiotic consumption and digestive colonization with multidrug-resistant *Enterobacterales* in a paediatric haematology department
S. Frigui Ep Oueslati (Tunis, Tunisia), N. Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour*

O0177

Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study
Sean Olann Whelan (Dublin, Ireland)

O0178

Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center
E. Vaugon (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard*

O0179

Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre
M. De Luca (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti*

EW071

16:15 – 18:15

Hall 15

Educational Session

PRO

The rare art of writing scientific articles: from conception to submission

Chairs

Marlieke De Kraker (Geneva, Switzerland)
Mical Paul (Haifa, Israel)

W0205

16:15

Expressing yourself correctly: writing tips
Angela Huttner (Geneva, Switzerland)

W0206

16:35

Constructing your manuscript for an original article
Jesús Rodríguez-Baño (Seville, Spain)

W0207

16:55

The use of artificial intelligence tools for writing articles: what to do and not to do
Erlangga Yusuf (Rotterdam, Netherlands)

W0208

17:15

Selecting the best journal for my manuscript
Andre Kalil (Omaha, United States)

Co-organised with: CMI Board of Editors

SY069

16:15 – 18:15

Hall 16

2-hour Symposium

TRN

Controlled human infection models

Chairs

Frederick Hayden (Charlottesville, United States)
Nikolai Siemens (Greifswald, Germany)

S0197

16:15

Updates on the dengue human infection model
Kirsten Lyke (Baltimore, United States)

S0198

16:45

CHIM in endemic countries
Melissa Kapulu (Kilifi, Kenya)

S0199

17:15

Controlled human infection models of parasitic infections
Meta Roestenberg (Leiden, Netherlands)

S0200

17:45

Controlled human infection models of non-typhoidal *Salmonella*
Malick Gibani (London, United Kingdom)

Co-organised with: British Infection Association (BIA)

ESCMID Global 2025 - Programme

EF033

16:15 – 17:15

Arena 2

ePoster Flash Session

AMR ANT CLN

Current treatment options for Invasive fungal infections

Chair

Andreas H. Groll (Münster, Germany)

E0232

The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates*Z.D. Pana* (Nicosia, Cyprus), A.H. Groll, A. Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely*

E0233

Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers*C. Palamin Buonafine* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo*

E0234

Rezafungin showed high *in vitro* activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024*J. Guinea* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz*

E0235

Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight*R.E. Wrishko* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch*

E0236

Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis*H. Kang* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooze, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson*

E0237

Activity of manogepix against a worldwide collection of mould isolates from 2023*M. Winkler* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira*

E0239

Candida auris* displays an inoculum effect with multiple antifungal drug classesR. Ben-Ami* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi*

E0240

In vitro* olorofim activity against *Aspergillus* spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEN II and III)J. Guinea* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz*

EF034

16:15 – 17:15

Arena 4

ePoster Flash Session

AMR IPC

Surgical site infections: epidemiology, risk factors, and prevention strategies

Chair

Trisha Peel (Melbourne, Australia)

E0241

Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France*P. Astagneau* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-Trannoy, J. Auraix, K. Lebascle*

E0242

Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients*S. Largiadèr* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. Harbarth, R. Sommerstein*

E0245

Cutibacterium* species in Neurosurgical Infections: Not Such a "Cute" Pathogen After AllJ. Donnelly* (Dublin, Ireland), B. Dinesh, S. O'donnell*

E0246

The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome*K.*

		<i>Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y. Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands</i>
E0247		Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis <i>A. Abialevich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich</i>
E0249		Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses <i>C.M. Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R. Gabunada, Z. Alano</i>

SY067	16:15 – 18:15	Hall 11
	2-hour Symposium	
	<div>PHEI</div>	
STIs: an ongoing crisis		
<i>Chairs</i>	<i>Dagmar Heuer (Berlin, Germany)</i> <i>Tomislav Mestrovic (Varazdin, Croatia)</i>	
S0189	16:15	STI treatment options are running out due to AMR <i>Magnus Unemo (Örebro, Sweden)</i>
S0190	16:45	Genomic surveillance of <i>Neisseria gonorrhoeae</i> strains <i>Petra Wolffs (Maastricht, Netherlands)</i>
S0191	17:15	Evolutionary insights into syphilis and <i>Treponema pallidum</i> <i>Mathew Beale (Hinxton, United Kingdom)</i>
S0192	17:45	Challenges in chlamydial STI infections <i>Cecile Bebear (Bordeaux, France)</i>
Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie		

SY068	16:15 – 18:15	Hall 12
	2-hour Symposium	
	<div>CLN DX VAX</div>	
Tick-borne encephalitis: contemporary diagnosis and management		
<i>Chairs</i>	<i>Joanna Maria Zajkowska (Białystok, Poland)</i> <i>Dace Zavadska (Riga, Latvia)</i>	
S0193	16:15	Tick-borne encephalitis: immune response and clinical experience <i>Sara Gredmark Russ (Stockholm, Sweden)</i>
S0194	16:45	TBE immune responses and vaccine effectiveness <i>Karin Stiasny (Vienna, Austria)</i>
S0195	17:15	NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection <i>Gerhard Dobler (Munich, Germany)</i>
S0196	17:45	Treatment for TBE: where do we stand? <i>Daniel Ruzek (Brno, Czech Republic)</i>

LB006	16:15 – 18:15	Hall 13
	2-hour Oral Session	
The Trial Run: recent trials on <i>S. aureus</i> bacteraemia management		
<i>Chairs</i>	<i>Julia Anna Bielicki (London, United Kingdom)</i> <i>Vance Fowler (Durham, United States)</i>	
L0031	16:15	Introduction , <i>Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)</i>
L0032	16:20	Description of SNAP trial
L0033	16:30	Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial of the <i>S. aureus</i> network adaptive platform (SNAP) <i>S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group</i>
L0034	16:45	Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial within the <i>S. aureus</i> network adaptive platform (SNAP) <i>J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group</i>

ESCMID Global 2025 - Programme

L0035	17:00	Cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trial <i>X. Lescure* (Paris, France), F. Vandenesch, X. Duval, S. Tubiana, C. Burdet, N. Saïdani, A. Lemaignien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin</i>
L0036	17:15	Trial Discussion <i>Julia Anna Bielicki (London, United Kingdom)</i>
L0037	17:30	Trial Discussion <i>Vance Fowler (Durham, United States)</i>
L0038	17:45	Open Discussion and Q&A

OS032	16:15 – 18:15	Hall 14
-------	---------------	---------

2-hour Oral Session



Unravelling respiratory viruses, 2025

<i>Chairs</i>	<i>Eeva Broberg (Solna, Sweden)</i> <i>Florian Krammer (New York, United States)</i>
O0222	Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France <i>P. Loubet* (Nîmes, France), S. Guillon, R. Simon, L. Lefrançois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay</i>
O0223	Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids <i>F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert</i>
O0224	Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection. <i>B. Huckestein* (Memphis, United States), P. Thomas</i>
O0225	Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France <i>S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand-Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Regoche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i>
O0226	Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort <i>C. Geurts Van Kessel* (Rotterdam, Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel</i>
O0227	Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems <i>J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye</i>
O0228	Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study <i>Stanislava Bratkovic (Copenhagen, Denmark)</i>
O0229	The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study <i>E. Carter* (Liverpool, United Kingdom), H. Hill, D. Ferreira, A. Collins, C. Solórzano, L. McLellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J.</i>

Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P. Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn

O0230

Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers M. Knoll* (Hinxton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison

SY064

16:15 – 18:15

Hall 2

2-hour Symposium

AMR ANT

PK/PD to avoid emergence of resistance?

Chairs

Anne-Grete Märtsen (Leiden, Netherlands)
Joseph Meletiadis (Athens, Greece)

S0177

16:15

PK/PD and antibacterial therapy Dolores Soy-Muner (Barcelona, Spain)

S0178

16:45

PK/PD and antifungal therapy Roger Brüggemann (Nijmegen, Netherlands)

S0179

17:15

PK/PD and antiviral therapy Joe Standing (London, United Kingdom)

S0180

17:45

PK/PD considerations in anthelmintic treatment Jennifer Keiser (Allschwil, Switzerland)

EW070

16:15 – 18:15

Hall 3

Educational Session

AMR CLN DX

Malaria: when the drugs don't work Management of treatment failure in non-endemic countries

Chairs

Laura Nabarro (London, United Kingdom)
Caroline Rönnerberg (Stockholm, Sweden)

W0201

16:15

Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure Emmanuel Bottieau (Antwerp, Belgium)

W0202

16:35

Malaria resistance mutations in the non-endemic setting: role of genomic surveillance Anna Rosanas Urgell (Antwerp, Belgium)

W0203

16:55

How to manage *Plasmodium Knowlesi* infection Giri Shan Rajahram (Kota Kinabalu, Malaysia)

W0204

17:15

Epidemiology and control of *Plasmodium Knowlesi* Kimberly Fornace (Singapore, Singapore)

Co-organised with: British Infection Association (BIA)

SY065

16:15 – 18:15

Hall 4

2-hour Symposium

AMR

Gram-positives, are they still going?

Chairs

Diederik Bathoorn (Groningen, Netherlands)
Stefania Stefani (Catania, Italy)

S0181

16:15

The vanco chronicles: enterococci's global journey Guido Werner (Wernigerode, Germany)

S0182

16:45

Pitfall in susceptibility testing of Gram-positives Helena Zemlickova (Prague, Czech Republic)

S0183

17:15

Drivers for daptomycin and linezolid resistance in Gram-positives Glen Carter (Melbourne, Australia)

S0184

17:45

What is new in treatment against MDR Gram-positives? Alex Soriano (Barcelona, Spain)

SY066

16:15 – 18:15

Hall 5

2-hour Symposium

CLN DX

ESCMID Global 2025 - Programme

Biomarker testing to manage respiratory infections in primary care in low resource settings

<i>Chairs</i>		<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Heiman Wertheim (Nijmegen, Netherlands)</i>
S0185	16:15	The Vietnamese experience with CRP testing in the community setting <i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i>
S0186	16:45	The Nigerian experience with CRP testing in the community setting <i>Augustine Onwunduba (Awka, Nigeria)</i>
S0187	17:15	CRP testing in diagnosing tuberculosis in Zambia and South Africa <i>Helen Ayles (Lusaka, Zambia)</i>
S0188	17:45	The health economics of CRP testing in LMICs <i>Yoel Lubell (Bangkok, Thailand)</i>

EF035	17:15 – 18:15	Arena 1
ePoster Flash Session		

DX **PHEI**

Genomics in pathogen surveillance

<i>Chair</i>		<i>Vitor Borges (Lisbon, Portugal)</i>
E0250	Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden <i>L. Cipolla* (Buenos Aires, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto</i>	
E0251	Understanding the population structure of <i>Moraxella catarrhalis</i> using core-genome multilocus sequence typing <i>I. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann</i>	
E0252	Impact of the COVID-19 pandemic on the <i>Streptococcus pyogenes</i> clones causing adult invasive infections <i>M. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections</i>	
E0253	Unveiling the Hidden Complexity of <i>Providencia</i>: Genomic Insights into Species Reclassification and Antibiotic Resistance <i>X. Dong* (Hangzhou, China)</i>	
E0254	Genomic description of outbreak of VIM-1 carrying <i>Enterobacter</i> in Switzerland suggests plasmid transmission between sequence types <i>H. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli</i>	
E0255	Genomic epidemiology of <i>Klebsiella pneumoniae</i> bloodstream infections in a german tertiary centre: increased virulence in carbapenem-resistant strains <i>L. Kneigendorf* (Hannover, Germany), M. Lindenberg, C. Baier, J. Erdmann, S. Häußler, D. Schlüter</i>	
E0256	Phylogenetic mixing and undetected circulation of multiple <i>Candida auris</i> lineages following recognition of imported cases in Italy <i>V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna</i>	
E0257	Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater <i>A.K. Bari* (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, T.T. Severs, M.J. Cardoso, M. Savin</i>	
E0258	Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technology <i>S. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli</i>	

EF036	17:15 – 18:15	Arena 3
ePoster Flash Session		

CLN

Heads up! CNS infections

<i>Chair</i>		<i>Jacob Bodilsen (Aalborg, Denmark)</i>
--------------	--	--

E0259	Central Nervous System Involvement by <i>Mycobacterium avium</i> Complex in Advanced HIV: A Rare and Underdiagnosed Challenge <i>E. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta</i>
E0260	Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports & Review of Literature <i>M. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia</i>
E0261	<i>Streptococcus equi</i> Subspecies <i>zooepidemicus</i> Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review <i>D. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina</i>
E0262	Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections <i>F. Prataviera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini</i>
E0263	Multidrug-Resistant <i>Klebsiella pneumoniae</i> Meningitis in the Absence of Intracranial Devices: A Case Report <i>M. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano</i>
E0264	Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with <i>Morganella morganii</i>, <i>Acinetobacter baumannii</i>, and Vancomycin-resistant <i>Enterococcus faecium</i> <i>Y. Çakır Kıymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldi</i>
E0265	Invasive pulmonary <i>Arthrophagus kalrae</i> infection with cerebral abscesses in an immunocompromised child <i>B. Winkel* (Utrecht, Netherlands), J. Jans, M. Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen</i>
E0266	Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient <i>A. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt</i>
E0267	A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult <i>N.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra</i>

Sunday, 13 April 2025

SY075	08:30 – 10:30	Hall 15
	2-hour Symposium	
	<div>PHEI</div>	
Diphtheria: from re-emergence to vaccine strategies		
Chairs	Helena Seth-Smith (Zurich, Switzerland) Julie Toubiana (Paris, France)	
S0221	08:30	Diphtheria: from clinical picture to medical management <i>Regina Oladokun (Oyo, Nigeria)</i>
S0222	09:00	The epidemiology of diphtheria worldwide over the last half-century: more than one comeback <i>Andreas Hofer (Solna, Sweden)</i>
S0223	09:30	There’s more than one toxigenic <i>Corynebacterium</i> : the current genomics landscape of diphtheria-associated strains <i>Sylvain Brisse (Paris, France)</i>
S0224	10:00	Diphtheria vaccination: a reappraisal <i>Gayatri Amirthalingam (London, United Kingdom)</i>
Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)		

EF039	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	<div>CLN PHEI TRN</div>	

ESCMID Global 2025 - Programme

Novel approaches to antiviral therapy

Chair

Pinyo Rattanaumpawan (Bangkok, Thailand)

- E0288

Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection.*J. Pitts* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello*
- E0289

EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study.*J. Devincenzo* (Watertown, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus*
- E0290

A Combined *In Silico* and *In Vitro* Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A Virus.*C.L. Pierri* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi*
- E0291

Bernifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus *in vitro*.*D. Grandgirard* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib*
- E0292

Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses.*S. Ellis* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer*
- E0293

The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants.*A. Gagar* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi*
- E0294

Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time.*L. Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C. Van Hasselt, A.G. Märtson*
- E0295

Efficacy of molnupiravir and baloxavir against Influenza A H1N1 infection *in vitro* and *in vivo*.*D. Liu* (Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung*
- E0296

Human defensin derived peptide showing broad antiviral activity against human adenoviruses.*X. Wang* (Hongkong, China), H. Zhao*

EF040

08:30 – 09:30

Arena 3

ePoster Flash Session

CLN TRN

New frontiers in parasitic disease and migrant health research

- E0298

Targeting metabolic bioenergetics: the 'Achilles' heel' of *Leishmania*.*D. Sarkar* (Kolkata, India)*
- E0299

Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?*M.D. Hernández Rabadán* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García*
- E0300

Schistosoma haematobium* infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment.Anna Mertelsmann (Zürich, Switzerland)*
- E0301

Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?*G. Lam* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P.*

	<i>Mawa, J. Friedman, A. Bustinduy</i>	
E0302	Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024 <i>G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller</i>	
E0303	NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut <i>B. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N. Buchon, O. Sparagano, P. Butaye</i>	
E0304	Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in <i>Onchocerca volvulus</i> <i>A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil</i>	
E0305	Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis <i>G. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro</i>	

EW079	08:30 – 10:30	Hall 11
	Educational Session	

CLN DX		
New guidelignes for management of brain infections		
Chairs	<i>Jacob Bodilsen (Aalborg, Denmark)</i> <i>Kartika Maharani (Jakarta, Indonesia)</i>	

W0237	08:30	Tuberculous meningitis: what can we learn from the first global guidelines? <i>Joseph Donovan (Ho Chi Minh City, Vietnam)</i>
W0238	08:50	WHO guidelines on bacterial meningitis: change of clinical practice? <i>Matthijs Brouwer (Amsterdam, Netherlands)</i>
W0239	09:10	ESCMID encephalitis guidelines 2024: what's new? <i>Tom Solomon (Liverpool, United Kingdom)</i>
W0240	09:30	WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation <i>Nelesh Govender (Johannesburg, South Africa)</i>

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

SY073	08:30 – 10:30	Hall 12
	2-hour Symposium	

AMR ANT		
Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship		
Chairs	<i>Bhanu Sinha (Groningen, Netherlands)</i> <i>Annelies Verbon (Bosch En Duin, Netherlands)</i>	

S0213	08:30	A broad spectrum of possibilities: spectrum scores as a unifying metric <i>Céline Pulcini (Nancy, France)</i>
S0214	09:00	Proxy indicators to estimate appropriateness of antibiotic prescriptions <i>Diane Ashiru-Oredope (London, United Kingdom)</i>
S0215	09:30	How to bridge the gap between surveillance and antimicrobial stewardship <i>Mark G. J. De Boer (Leiden, Netherlands)</i>
S0216	10:00	Health economics, surveillance and antimicrobial stewardship <i>Zhu Nina Jiayue (London, United Kingdom)</i>

Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)

SY074	08:30 – 10:30	Hall 13
-------	---------------	---------

ESCMID Global 2025 - Programme

CLN IPC

2-hour Symposium

Difficile to treat: advanced management strategies in difficult to treat CDI

Chairs *Frédéric Barbut (Paris, France)*
Kerrie Davies (Leeds, United Kingdom)

S0217	08:30	Severe CDI: when standard protocols fail <i>Hynek Bartos (Prague, Czech Republic)</i>
S0218	09:00	Therapies for complicated CDI <i>Emma Bishop (Clayton Vic, Australia)</i>
S0219	09:30	Recurrent CDI: Breaking the cycle <i>Andrea Marino (Catania, Italy)</i>
S0220	10:00	Live biotherapeutic products for <i>Clostridioides difficile</i> infection <i>Simon Goldenberg (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

OS038 08:30 – 10:30 Hall 14

AMR DX

2-hour Oral Session

Making fast for making better: AMR rapid diagnostics

Chairs *Giulia De Angelis (Rome, Italy)*
Onur Karatuna (Växjö, Sweden)

00278	Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections. <i>J. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch</i>
00279	Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria <i>C. Moguet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas</i>
00280	The NitroSpeed Taniborbactam NP test; easy detection of β-lactamase sensitivity to taniborbactam <i>O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poiriel, P. Nordmann</i>
00281	Rapid detection of β-lactamase-mediated resistance to aminopenicillins from urines. <i>P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poiriel, R. Dessein</i>
00282	Rapid detection of antibiotic resistance in direct urine samples <i>M. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer</i>
00283	Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs <i>E. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum</i>
00284	Screening for ceftriaxone-resistant <i>Neisseria gonorrhoeae</i> with the Urogenital and Resistance kit (AusDiagnostic) <i>A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot</i>
00285	Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures <i>D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti</i>
00286	Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy <i>K. Chaudhary* (New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar</i>

SY076 08:30 – 10:30 Hall 16

AMR

2-hour Symposium

AMR Surveillance in low resource countries: Insights into clinical and policy translation

Chairs *Kwame Ohene Buabeng (Ho, Ghana)*
H. Rogier Van Doorn (Hanoi, Vietnam)

S0225	08:30	New indicators in national monitoring and evaluation of AMR supported by improved data utilisation <i>Direk Limmathurotsakul (Bangkok, Thailand)</i>
S0226	09:00	Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections <i>Stephen Mshana (Mwanza, Tanzania, United republic of)</i>
S0227	09:30	A clinically-oriented AMR surveillance network: case-based surveillance and implementation <i>Paul Turner (Siem Reap, Cambodia)</i>
S0228	10:00	National prescribing guidelines based on AMR surveillance data <i>Vilada Chansamouth (Vientiane, Lao People's democratic republic)</i>

Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW077	08:30 – 10:30	Hall 2
	Educational Session	

CLN DX

New tools in acute bacterial infections and sepsis: from machine learning to precision medicine

Chairs Benjamin Mcfadden (Perth, Australia)
Rita Murri (Rome, Italy)

W0229	08:30	Differentiating acute infection, sepsis and sepsis mimics in the ED? <i>Lisa Mellhammar (Lund, Sweden)</i>
W0230	08:50	Machine learning for early recognition of sepsis <i>Karsten Borgwardt (Martinsried, Germany)</i>
W0231	09:10	How to avoid common mistakes in randomised clinical study design <i>Yin Mo (Singapore, Singapore)</i>
W0232	09:30	Improved clinical trials in community-acquired pneumonia using precision medicine <i>Lennie Derde (Utrecht, Netherlands)</i>

Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro

SY072	08:30 – 10:30	Hall 3
	2-hour Symposium	

PHEI VAX

Tackling the emergence of dengue and other *Aedes*-borne diseases in Europe

Chairs Fernanda Boulos (São Paulo, Brazil)
Martin P. Grobusch (Amsterdam, Netherlands)

S0209	08:30	How dengue, chikungunya and zika virus disease became emerging threats to Europe <i>Celine Gossner (Solna, Sweden)</i>
S0210	09:00	Surveillance of dengue in urbanised tropical regions <i>Vincent Junxiong Pang (Singapore, Singapore)</i>
S0211	09:30	Mosquito surveillance and control: opportunities and challenges <i>Tba</i>
S0212	10:00	Tracking autochthonous arboviral infection <i>Luisa Barzon (Padua, Italy)</i>

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

EW078	08:30 – 10:30	Hall 4
	Educational Session	

DX

Implementing metagenomics in my lab and mistakes to avoid

Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Claudio Neidhöfer (Bonn, Germany)

W0233	08:30	Is metagenomics right for my lab? <i>Paula Mölling (Örebro, Sweden)</i>
-------	-------	--

ESCMID Global 2025 - Programme

W0234	08:50	Understanding the experimental and certification aspects of metagenomics <i>Mads Albertsen (Aalborg, Denmark)</i>
W0235	09:10	Navigating tools, techniques, and procurement <i>Basil Britto Xavier (Groningen, Netherlands)</i>
W0236	09:30	Setting realistic goals and outcomes for metagenomics integration <i>Claire Bertelli (Lausanne, Switzerland)</i>
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee		

OS037	08:30 – 10:30	Hall 5
	2-hour Oral Session	

DX **IPC**

Whole genome sequencing: tracking transmission and reservoirs in outbreaks

<i>Chairs</i>	<i>Eric Claas (Leiden, Netherlands)</i> <i>Paul G. Higgins (Cologne, Germany)</i>
---------------	--

00268	From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting <i>N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer</i>
00269	Why do routine genome-oriented surveillance for <i>Pseudomonas aeruginosa</i>? <i>A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert</i>
00270	TreeTime estimation depicts transmission dynamics of clinical and environmental <i>Pseudomonas aeruginosa</i> from common reservoirs in healthcare environment through whole genome sequencing (WGS) <i>Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson</i>
00271	Understanding <i>Serratia</i> transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis <i>K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Hayş, J.P. Rasigade</i>
00272	Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing <i>C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin</i>
00273	Genome-oriented analysis of the first outbreaks involving the novel <i>Serratia sarumanii</i> at a neonatal unit <i>A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert</i>
00274	Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTYPE Study <i>J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Mookerjee, M. Krutikov</i>
00275	Outbreak of Carbapenem-Resistant <i>Acinetobacter seifertii</i> in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance. <i>D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochewis, R. Paiva, K. Tragnago, A. Barth, A. Martins</i>
00276	Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the ICU environment <i>X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu</i>
00277	Survey of Infection Prevention staff perception of WGS integration into routine IPC practice <i>D. Ling* (Melbourne, Australia), B. Baral, V. Madigan</i>

EF041	09:30 – 10:30	Arena 2
	ePoster Flash Session	

AMR **CLN** **DX**

Contemporary diagnostic approaches for fungal infections

Chair

Ilse D. Jacobsen (Jena, Germany)

- E0306** **Evaluation of persistence of *C. auris* colonization in a cohort of patients discharged from a *C. auris* endemic area***M. Bavastro* (Genoa, Italy), L. Mezzogori, M. Bonaffini, L. Magnasco, F. Centorrino, V. Di Pilato, E. Willison, F. Portunato, D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska, M. Bassetti*
- E0307** **A pilot study of digital retinal photography (DRP) and tele-ophthalmology of patients with candidemia.***C. Clancy* (Pittsburgh, United States), C. Hadi, E. Waxman, J.A. Viehman, A. Eller, M. O'donnell, F. Silveira, P. Samantha, B. Smith, S. Padival, V. Nauriyal, M.H.T. Nguyen*
- E0308** **Epidemiology and diagnosis of Pneumocystis pneumonia : a 11 years-surveillance in France***A. Alanio* (Paris, France), K. Boukris-Sitbon, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier, O. Lortholary*
- E0309** **Chronic pulmonary aspergillosis coexisting with pulmonary cystic echinococcosis: a global systematic review***A. Adhikari* (Chame, Nepal), F. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan, N.V. Rhijn, D. Denning*
- E0310** **Implementation and performance of a universal Mucorales PCR assay for diagnosis of mucormycosis***A. Haas* (Salt Lake City, United States), K. Hanson*
- E0311** **Blood cultures (BCs) contain populations of genetically diverse *Candida* strains that may differ in antifungal resistance and tolerance***C. Clancy* (Pittsburgh, United States), S. Cheng, H. Badrane, B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H. Nguyen*
- E0312** **Clinical validation of a urinary antigen test as an aid to diagnose invasive aspergillosis in hematology patients***Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, T. Mercier, E. Boon, G. Gysember, E. Houben, K. Lagrou, J. Maertens*
- E0313** **Genomic epidemiology of Greek *Candida auris* clinical isolates***M. Siopi* (Athens, Greece), B. Spruijtenburg, I. Anagnostakis, C. Anthoulaki, A. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P. Giannopoulou, K. Gartzonika, M. Damala, I. Daskalakis, I. Dendrinou, V. Dimitriou, E. Dimitroulia, L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V. Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A. Katsaka, A. Katsiaflaka, E. Kafkoulas, M. Kimouli, I. Lamprou, O. Legga, V. Mamali, M. Martsoukou, G. Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E. Oikonomopoulou, M. Orfanidou, F. Paliogianni, E. Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki, M. Papadogianni, K. Papaefstathiou, P. Papanikolaou, J. Papaparaskevas, G. Parvouleskou, E. Perivolioti, S. Pournaras, C. Silleli, T. Skolidis, E. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P. Tsolakidou, N. Charalampaki, E. Chinou, G.S. Christodoulatos, G. Chronopoulou, E. Chrysou, E. Meijer, A. Tsakris, J. Meletiadis, G. Vrioni*

EF042

09:30 – 10:30

Arena 4

ePoster Flash Session

CLN

Prosthetic and device-associated infections

Chair

Marjan Wouthuyzen-Bakker (Groningen, Netherlands)

- E0315** **Case series of gluteal Apophysomycosis post intramuscular injection***R. Sivasankaran* (Vellore, India), R. Bandyopadhyay*
- E0316** **MIGRATING mesh - an unusual cause of pyogenic liver abscess***M. Caris* (Leiden, Netherlands), J. Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers*
- E0317** **Ceftaroline salvage monotherapy: successful**

ESCMID Global 2025 - Programme

		treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant <i>Staphylococcus epidermidis</i> strain <i>M.D. Di Trapani* (Bozen, Italy), T. Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R. Aschbacher</i>
E0318		Timeline of early infections post porcine xenothymokidney transplant <i>H. Neumann* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta</i>
E0319		Invasive Non-tuberculous mycobacteria Infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar <i>M. Khan* (Peshawar, Pakistan)</i>
E0320		Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience <i>A. Pagotto* (Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini</i>
E0321		PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections <i>C. Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, A. Friedrichs</i>
E0322		A complex case of pelvic bone infection caused by carbapenem-resistant <i>Acinetobacter baumannii</i> successfully treated with eravacycline <i>M. Zagarrigo* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale</i>
E0323		Oritavancin in a patient with recurrent endocarditis by <i>Enterococcus faecalis</i>: a new therapeutic option? <i>M. Bongiovanni* (Lugano, Switzerland), B. Barda, E. Bernasconi</i>

KN080	09:30 – 10:30	Hall 1
	Keynote Lecture	

VAX

Infections after solid organ transplantation: past, present and future

<i>Chairs</i>	<i>Nina Khanna (Basel, Switzerland)</i> <i>Priscilla Rupali (Vellore, India)</i>
---------------	---

K0241	09:30	Jay Fishman (Boston, United States)
-------	-------	-------------------------------------

SY082	11:00 – 12:00	Hall 6
	1-hour Symposium	

PRO

PHEI

How to address anti-science in our community?

<i>Chairs</i>	<i>Tuba Dal (Ankara, Türkiye)</i> <i>Tyra Grove Krause (Copenhagen, Denmark)</i>
---------------	---

S0243	11:00	The rise of anti-science: lessons for the future scientist <i>Marion Koopmans (Rotterdam, Netherlands)</i>
S0244	11:30	Open science for public trust <i>Lisa Hansen (Ottawa, Canada)</i>

FO090	11:00 – 12:00	Arena 1
	Open Forum	

PRO

European CM/ID exam: going forward

<i>Chair</i>	<i>Siri Goepel (Tuebingen, Germany)</i>
--------------	---

F0259	11:00	View from medical microbiology <i>Maeve Doyle (Waterford, Ireland)</i>
F0260	11:10	view from infectious diseases <i>Eoghan De Barra (Dublin, Ireland)</i>
F0261	11:20	view from trainees (TAE) <i>Christian Kraef (Copenhagen, Denmark)</i>
F0262	11:30	European exam - how to prepare? <i>Annelies Verbon (Bosch En Duin, Netherlands)</i>

EF049 11:00 – 12:00 Arena 2

ePoster Flash Session

CLN DX VAX

Sometimes it's hard to be a woman

Chair *Debora Konopnicki (Brussels, Belgium)*

- E0354** **Interleukins 17 and 18: Key players in Cervical Cancer Progression in Indian Population***P. Gupta** (Bhopal, India), A. Vyas, A. Halder, S. Purwar
- E0355** **Risk evaluation of iatrogenic transmission of Human Papillomavirus (HPV) during gynaecological procedures***B. Casini** (Pisa, Italy), F. Chiovelli, Y. Ferchichi, E. Esposito, M. Basile, G. Del Bravo, A. Giannini, T. Simoncini
- E0357** **Rubella screening in pregnancy – Slovakian one-center retrospective analysis around COVID-19 pandemic***Z. Paraličová** (Kosice, Slovakia), D. Javorská
- E0358** **The impact of maternal influenza infection and vaccination during pregnancy on birth outcomes***B. Goundappa** (Pittsburgh, United States), X. Zhang, B. Gk, H.E.A. D'agostino, H. Liu, A.M. Rick
- E0359** **Use of valaciclovir therapy during pregnancy for the prevention of congenital cytomegalovirus infection: a monocentric experience***G. Lorenzetti** (Rome, Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S. Mercadante, C. Tripiciano, A. Krzysztofiak, C. Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò Carducci
- E0360** **Multi-systemic long-term sequelae following SARS-CoV-2 Omicron infection in pregnancy: a population-based cohort study***Y.Y. Tan** (Singapore, Singapore), E.X.H. Loy, A.T. Tay, J.T. Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee
- E0361** **The Impact of OAS1 rs4766664 and OAS3 rs10735079 Polymorphisms on the Clinical Course of COVID-19 in Pregnant Women***S. Kirik Yilmaz** (Konya, Türkiye), S. Kırık Yılmaz, S. Sumer, N. Demir Aktug, O. Ural, E. Ozdemir Marzioglu, O. Secilmis, T. Cora
- E0362** **Sex-stratified analysis of T cell activation, exhaustion, proliferation and HIV reservoir among PLWH***L. Santinelli** (Rome, Italy), M. Andreotti, L. Maddaloni, Z. Michelini, G. Bugani, F. Romano, E. Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D'ettorre

EF050 11:00 – 12:00 Arena 3

ePoster Flash Session

DX

Expanding MALDI-TOF applications

Chair *Belen Rodriguez-Sanchez (Madrid, Spain)*

- E0363** **Application of MALDI-TOF Mass Spectrometry and Machine Learning for the Detection of Vancomycin-Resistant *Enterococcus faecium****M. Sánchez Cueto** (Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-Sánchez, M. Marín, E. Cercenado, P. Muñoz, B. Rodríguez-Sánchez, D. Rodríguez-Temporal
- E0364** **Early detection of ampicillin susceptibility in *Enterococcus faecium* with MALDI-TOF MS and machine learning***T. Pichl** (Munich, Germany), L. Miranda, N. Wantia, K. Borgwardt, J. Sattler
- E0365** **Rapid antifungal resistance prediction based on MALDI TOF mass spectrometry***D. Duroux** (Zurich, Switzerland), Y. Yang, J. Sattler, A. Egli
- E0366** **Rapid prediction of fluconazole resistance by machine-learning analysis of *Candida parapsilosis* MALDI-TOF mass profiles***C. Magri** (Rome, Italy), C. Magri, V. Ivagnes, M. Sanguinetti, E. De Carolis

ESCMID Global 2025 - Programme

E0367	Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification <i>R. Huang*</i> (Shenzhen, China), <i>Y. Li, Y. He, T. Ma, F. Lu</i>
E0368	Rapid detection of colistin resistance in <i>Acinetobacter baumannii</i> by a MALDI-TOF MS-based assay <i>E. Kırbaş*</i> (Van, Türkiye), <i>I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Haşçelik, B. Sancak</i>
E0369	Discrimination of clinical <i>Pseudomonas</i> strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MSK <i>Teramoto*</i> (Kyoto, Japan), <i>Y. Sekiguchi, L. Sellami, M. Tohya, T. Kirikae</i>
E0370	Automatic differentiation of <i>Clostridioides difficile</i> ribotypes using MALDI-TOF MS and web-based classification models <i>M. Blazquez Sanchez*</i> (Madrid, Spain), <i>M.C. Blazquez-Sanchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodríguez-Temporal, B. Rodríguez-Sanchez</i>
E0371	Identification of sepsis-causing bacteria using shotgun proteomics <i>L. Meekes*</i> (Rotterdam, Netherlands), <i>D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens</i>

EF051	11:00 – 12:00	Arena 4
	ePoster Flash Session	

ANT TRN

The enemy of my enemy: From Jumbo phages to cocktails for difficult to treat infections

Chair *Paul G. Higgins (Cologne, Germany)*

E0372	Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent <i>Klebsiella pneumoniae</i> <i>M. Roch*</i> (Geneva, Switzerland), <i>R. Sierra, D. Andrey</i>
E0373	Jumbo <i>Klebsiella</i> bacteriophage demonstrates efficient multidrug-resistant <i>Klebsiella pneumoniae</i> killing and significant clinical potential <i>Y. Liu*</i> (Singapore, Singapore), <i>Y. Zhong, S. Thong, L.H.A. Kwa</i>
E0374	A new phage cocktail targeting at <i>Klebsiella pneumoniae</i> <i>X. Yin*</i> (Chengdu, China), <i>Y. Feng, H. Luo, Z. Zong</i>
E0375	Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant <i>Klebsiella pneumoniae</i> in murine models <i>A.M. Örmälä-Tiznado*</i> (Stockholm, Sweden), <i>S. Patpatia, J. Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske</i>
E0376	A novel broad-spectrum phage cocktail effective for carbapenem resistant <i>Acinetobacter baumannii</i> of capsular type 104/2/7 in vitro <i>L. Wei*</i> (Chengdu, China), <i>Y. Feng, Z. Zong</i>
E0377	Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting <i>Pseudomonas aeruginosa</i> <i>S. Unlu*</i> (Ankara, Türkiye), <i>A. Uskudar Guclu</i>
E0378	Phages as innovative adjuvants of antibiotics therapy against <i>S. aureus</i> and <i>P. aeruginosa</i> in the context of Cystic Fibrosis <i>A. Glorieux*</i> (Brussels, Belgium), <i>S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke</i>
E0379	Evaluation of bacteriophages against <i>Staphylococcus aureus</i> strains isolated from orthopaedic infections <i>S. Patpatia*</i> (Helsinki, Finland), <i>A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado</i>
E0380	Anti-<i>Staphylococcus aureus</i> phages: assessing the risk of bacterial resistance emergence through selective pressure <i>M. Degreze*</i> (Lyon, France), <i>M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda</i>

KN081	11:00 – 12:00	Hall 1
	Keynote Lecture	

AMR ANT

The new frontiers in antimicrobial stewardship

Chairs *Jose Ramon Pano-Pardo (Zaragoza, Spain)*
Jeroen Schouten (Nijmegen, Netherlands)

K0242 **11:00** *Karin Thursky (Carlton, Australia)*

SY084 **11:00 – 12:00** **Hall 10**

1-hour Symposium

CLN

Sleeping sickness and Chagas: a tale of the two trypanosomes

Chairs *Hanne Brekke (Oslo, Norway)*
Irene Losada Galvan (Barcelona, Spain)

S0247 **11:00** **Human African Trypanosomiasis: recent diagnostic and medical practices** *Jean-Mathieu Bart (Conakry, Guinea)*

S0248 **11:30** **American Trypanosomiasis: Diagnosis, screening and management** *Tba*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

OS047 **11:00 – 12:00** **Hall 11**

1-hour Oral Session

CLN

Clinical studies in UTI

Chairs *Iva Butic (Zagreb, Croatia)*
Paul Christoffer Lindemann (Bergen, Norway)

O0344 **Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs** *I. Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H. Dallahsheh, M. Paul*

O0345 **Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecraid POS-cUTI study** *C. Kats* (Utrecht, Netherlands), J.M. Bravo-Ferrer, T.T. Doesschate, P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio, P. Clevenbergh, A. Barac, A. Cano, E. Merino, P. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D. Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D. Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J. Rodríguez-Baño*

O0346 **Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study** *L. Onorato* (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B. Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R. Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello Vicario, R. Nasti, A. Voza, N. Coppola*

O0347 **Weekly sequential antibioprophylaxis for UTI in neurogenic bladder** *R. Calin* (Paris, France), C. Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F. Adda, C. Palacios, G. Amarenco, G. Pialoux*

O0348 **Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review** *L. Cordes* (Geneva, Switzerland), A. Huttner, R. Calin, K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B. Trautner*

OS048 **11:00 – 12:00** **Hall 12**

1-hour Oral Session

AMR

CLN

Complexities of infections in solid organ transplantation

Chair *Silvia Corcione (Turin, Italy)*

O0349 **Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales** *A. Cona* (Palermo, Italy), C.*

ESCMID Global 2025 - Programme

Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni

O0350	Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers <i>M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella</i>
O0351	Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors. <i>O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette</i>
O0352	Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients <i>A. Dahl* (København V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg</i>
O0353	Burden of non-microbiologically confirmed infections in solid organ transplant recipients <i>M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos</i>

SY085	11:00 – 12:00	Hall 13
	1-hour Symposium	

Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination

<i>Chairs</i>	<i>Mojca Maticic (Ljubljana, Slovenia)</i> <i>Snjezana Zidovec Lepej (Zagreb, Croatia)</i>
---------------	---

S0249	11:00	Role of reflex testing strategies in identifying patients with chronic viral hepatitis <i>Oana Sandulescu (Bucharest, Romania)</i>
S0250	11:30	Management and elimination of hepatitis in hard-to-reach persons <i>Suda Tekin (Istanbul, Türkiye)</i>

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS

SY086	11:00 – 12:00	Hall 14
	1-hour Symposium	

Impact on including a measure of viability in molecular diagnostic tests

<i>Chairs</i>	<i>Fusun Can (Istanbul, Türkiye)</i> <i>Denise O'sullivan (Teddington, United Kingdom)</i>
---------------	---

S0251	11:00	Viability markers in support of development of <i>Chlamydia</i> screening recommendations <i>Petra Wolffs (Maastricht, Netherlands)</i>
S0252	11:30	Measuring viability to improve the correlation of AMR markers and clinical outcomes in <i>Neisseria gonorrhoeae</i> <i>Tatum Mortimer (Athens, United States)</i>

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

ME089	11:00 – 12:00	Hall 15
	Meet-the-Expert	

How to teach Medical Mycology

M0257	11:00	<i>Katrien Lagrou (Leuven, Belgium)</i>
M0258	11:12	<i>Mihai Mares (Iasi, Romania)</i>
Co-organised with: European Confederation of Medical Mycology (ECMM)		

SY087 11:00 – 12:00 Hall 16
1-hour Symposium

ANT TRN

Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology

Chair Laurent Poirel (Fribourg, Switzerland)

S0253 11:00 **Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials?** Morreale Francesca Ester (London, United Kingdom)

S0254 11:30 **Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface** Christian Stephan Lentz (Tromsø, Norway)

ME088 11:00 – 12:00 Hall 2
Meet-the-Expert

AMR

Global AMR Policy after UNGA: what do we do now!

M0255 11:00 Gisela Robles Aguilar (Oxford, United Kingdom)

M0256 11:12 Mike Sharland (London, United Kingdom)

OS043 11:00 – 12:00 Hall 3
1-hour Oral Session

AMR IPC

Navigating disinfection challenges: resistance, outbreaks, and efficacy

Chairs Hillary A. Craddock (Dublin, Ireland)
Stephanie J. Dancer (Glasgow, United Kingdom)

O0324 **Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review** Â.R. Fernandes* (Porto, Portugal), A. Gonçalves Rodrigues, L. Cobrado

O0325 **Sink-associated outbreak of verona integron-encoded metallo- β -lactamase-producing carbapenem-resistant *Pseudomonas aeruginosa* in a Dutch intensive care unit** M. Van Den Bos Kromhout* (Zwolle, Netherlands), S. Debast, M. Van Den Bos-Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter, B. Immerker, K. Zuur, M. Hijmering, J.W.A. Rossen

O0326 **Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience** A.L. Engsbros* (Slagelse, Denmark), K.H. Hansen, M.F.J. Larsen, N. Kling, H.T. Larsen, R. Kjølsten, B. Hansen, L.K. Vejrum, A.L. Laugesen, M. Kemp

O0327 **Tolerance of *Klebsiella pneumoniae* biofilms to disinfection with peracetic acid** M. Arvand* (Berlin, Germany), A.M. Richter, D. Csertő, K. Konrat

O0328 **Bringing balance to the formulation: disinfection efficacy and material compatibility** J. Jennings* (Halifax, United Kingdom), T. Langford, H. Mansbridge, E. Fraser, I. Poles, J. Clarke

LB002 11:00 – 12:00 Hall 4
1-hour Oral Session

Investigation of intriguing outbreaks

L0006 **Molecular surveillance of artemisinin and sulfadoxine-pyrimethamine resistance in *Plasmodium falciparum* isolates from Uganda: results of ERASE study** M. L'episcopia* (Rome, Italy), F.V. Segala, J. Ictho, R. Papagni, I. Obua, E. De Vita, N. Olang, R. Novara, V. Totaro, L. Olal, G. Patti, C. Bignom, C. Agaro, G. Dall'oglio, B. Ngole, S. Okori, P. Lochoro, G.

ESCMID Global 2025 - Programme

	<i>Putoto, F. Di Gennaro, C. Severini, A. Saracino</i>
L0007	Investigation of an international pseudo-outbreak involving <i>Paraburkholderia fungorum</i> blood culture contamination <i>J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone</i>
L0008	Evolving cluster of severe infective endocarditis with non-toxicogenic <i>C. diphtheriae</i> amongst people experiencing homelessness and substance misuse in the UK <i>R. Cordery* (London, United Kingdom), T. Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham</i>
L0009	AI-driven live cough rate tracking for public health surveillance <i>M. Kågeback* (Göteborg, Sweden), E. Carlsson</i>

OS044	11:00 – 12:00	Hall 5
	1-hour Case Session	

CLN

Unusual presentations of unusual parasites

<i>Chairs</i>	<i>Emmanuel Bottieau (Antwerp, Belgium)</i> <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>
---------------	--

O0329	Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting <i>D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum</i>
O0330	An Itchy awakening due to <i>Dermanyssus</i> infestation <i>J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque</i>
O0331	Uterine Myiasis: A Rare Case of External Genitourinary Myiasis <i>R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua</i>
O0332	Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation <i>C. Norsungnarn* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong</i>
O0333	If at first, you don't succeed... Treatment-resistant Fascioliasis: case report <i>W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro</i>

SY083	11:00 – 12:00	Hall 7
	1-hour Symposium	

CLN

DX

Lyme neuroborreliosis: challenges in diagnosis and treatment

<i>Chairs</i>	<i>Alexandra Mailles (Paris, France)</i> <i>Joanna Maria Zajkowska (Białystok, Poland)</i>
---------------	---

S0245	11:00	Challenges in diagnosis of Lyme neuroborreliosis <i>Rick Dersch (Freiburg, Germany)</i>
S0246	11:30	Challenges in treatment of Lyme neuroborreliosis <i>Anne Marit Solheim (Kristiansand, Norway)</i>

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)

OS045	11:00 – 12:00	Hall 8
	1-hour Oral Session	

AMR

Social behavioural dynamics of antibiotic use and AMR

<i>Chairs</i>	<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Filippo Mediolì (Milan, Italy)</i>
---------------	--

O0334	Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey <i>A. Abbara* (London, United Kingdom)</i>
-------	---

Kingdom), H. Alhosni, F. Alahdab

- O0335** **Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ???S.**
Mahadevaiah (Mysore, India), C. Es, K. Anil, Y. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs, K. Gautam*
- O0336** **Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024.***S. Vantava* (Vientiane Capital, Lao People's democratic republic), K. Thilakoun, D. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B. Phetsamone, S. Bangthong, K. Sengchanh, S. Latsamy, S. Vanphanom, L. Annick, S. Somphou*
- O0337** **High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis.***D. Samria* (Bangalore, India), D. Batheja, A. Nandi*
- O0338** **Gender gaps in knowledge of antibiotics and antimicrobial resistance: Evidence from India.***D. Batheja* (Delhi, India), S.R. Umenthala, S. Goel, D. Samria, R. Bhagawati, B. Deepshikha*

OS046 **11:00 – 12:00** **Hall 9**

1-hour Oral Session

PHEI VAX

Vaccines and prophylaxis against respiratory viral infections

Chairs *Ana Atti (London, United Kingdom)*
Sophie Schneitler (Homburg, Germany)

- O0339** **Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study (www.nirsegal.es/en)***F. Martinón-Torres* (Santiago De Compostela, Spain), N. Mallah, J. Pardo-Seco, O. Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, Á. Manzanares-Casteleiro*
- O0340** **Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial.***K. Feldballe Bernholm* (Copenhagen, Denmark), N. Dyrby Johansen, C. Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon, S. Samson, M.M. Loiacono, R. Harris, C. Schade Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B.L. Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-Sørensen*
- O0341** **Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses.***C. Grassi* (Cambridge, United States), S. Chalkias, P. Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R. Handforth, N. Vicic, A. Rossi, R. Wahid, D. Edwards, J. Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B. Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das*
- O0342** **Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains.***N. Shirin* (Ramat Gan, Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T. Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon, M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M. Mandelboim*
- O0343** **Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation.***C. Bennett* (Gaithersburg, United States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F. Mahkhoul, A.M. Marchese, I. Cho, L. Fries, W. Woo*

ESCMID Global 2025 - Programme

SY093

13:30 – 14:30

Hall 11

1-hour Symposium

TRN

VAX

Immunosenescence and immune response to vaccination

Chairs

Petar Velikov (Sofia, Bulgaria)

Dafna Yahav (Ramat-Gan, Israel)

- S0267

13:30

How immunosenescence impacts vaccine responseAndrea Cossarizza (Modena, Italy)
- S0268

14:00

Strategies to tackle immunosenescence and improve immune response to vaccination in the elderlyInna Ovsyannikova (Rochester, United States)

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)

EW096

13:30 – 15:30

Hall 15

Educational Session

PRO

Tools for successful development as a medical educator

Chairs

Giorgia Caruana (Sion, Switzerland)

Yoav Keynan (Winnipeg, Canada)

- W0273

13:30

Developing your educator professional identityTodd Cassese (Bronx, United States)
- W0274

13:50

What do IPC doctors need to learn to be preparedSimone Scheithauer (Göttingen, Germany)
- W0275

14:10

Communities of practice: successful experience of a transformative collaboration and roadmapErin Bonura (Portland, United States)
- W0276

14:30

The critical need for ongoing innovations in medical educationClémentine Schilte (Paris, France)

Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology

FO097

13:30 – 14:30

Arena 1

Open Forum

DX

Essential diagnostics in Low-Resource Settings: why are we still talking?

Chair

Truls Michael Leegaard (Lørenskog, Norway)

- F0277

13:30

Training skilled personnel in LMIC and brain drain: is the solution the problem?Sipho Kenneth Dlamini (Observatory, South Africa)
- F0278

13:40

Leveraging surveillance networks to strengthen basic bacteriologyDissou Affolabi (Cotonou, Benin)
- F0279

13:50

Clinical bacteriology laboratories in low-resource settings: considerations for sustainabilityMakeda Semret (Montreal, Canada)

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiolo

FO098

13:30 – 14:30

Arena 2

Open Forum

PRO

Best of ID Week

Chair

Tina Tan (Chicago, United States)

- F0280

, Seth Cohen (Seattle, United States), Erin McCreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel)

EF054

13:30 – 14:30

Arena 3

ePoster Flash Session

AMR IPC PHEI

Beware the sink! Pathogen reservoirs in drains and waste water

Chair

Stephan Juergen Harbarth (Geneva, Switzerland)

E0391

Genomic Epidemiology to Investigate Healthcare Environment as Reservoir for Carbapenem-Resistant Organisms in an Academic Hospital in Miami, Florida. A. Jimenez* (Miami, United States), S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O. Martinez, J. Colson, A. Richardson, T. Ferreira, B. Shukla

E0392

Two clusters of carbapenemase-producing Enterobacterales linked to hospital wastewater drainage in utility rooms – an outbreak investigation. I. Vock* (Basel, Switzerland), G. Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster, N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter

E0393

Assessing the burden of carbapenemase and colistin antimicrobial resistance genes in hospital wastewater. E. Au* (Calgary, Canada), N. Acosta, B. Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M. Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B. Missaghi, O. Larios, J. Vayalumkal, J. Leal, E. Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L. Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R. Hubert, M. Parkins

E0394

Hospital wastewater as a reservoir for carbapenemase-producing organisms. A. Anantharajah* (Brussels, Belgium), C. Altintas, T. Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A. Bennert, C. Schirvel, A. Verroken, H. Rodriguez-Villalobos

E0396

Reversing and controlling microbial proliferation in the water system of a high-risk hospital ward after extended closure and reconstruction. D. Chaput* (Glasgow, United Kingdom), K. Clarkson, L. Bagnard, A. Marek, D. Kelly, D. Watson, A. Leanord, T. Steele

E0397

Whole-genome sequencing as part of the tracking and managing Carbapenemase producing Enterobacterales transmission in an acute hospital setting. D. Coffey* (Cork, Ireland), R. Waldron, D. Neshev, M. Cormican, C. Clarke, L. Hayes

E0398

Is there a solution for hospital acquired infections due to the aquatic reservoir in the near patient environment? H. Zayyad* (Poriya, Israel), R. Khouri, N. Saleh, A. Peretz

E0399

Reducing Antimicrobial Resistance (AMR) across the One Health Landscape: Diverse Perspectives on AMR risks and their mitigation in sinks, drains, and wastewater. H.A. Craddock* (Dublin, Ireland), A. Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D. Fitzgerald-Hughes

EF055

13:30 – 14:30

Arena 4

ePoster Flash Session

ANT CLN PHEI

The cutting edge in tuberculosis

Chair

Graeme Ayton Meintjes (Observatory, South Africa)

E0400

Personalised risk predictions for incident TB and preventive treatment uptake. R. Rose-Key* (London, United Kingdom), R. Gupta, M. Noursadeghi

E0401

Programmatic migrant screening for tuberculosis identifies a spectrum of clinical phenotypes and outcomes: cohort data from a national migrant screening programme. M. Gohar* (Leicester, United Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel, L. Ahyow, B. Srin, G. Rishi, P. Mark, S. Niles, C. Trevithick, K. Pierun, M. Wiselka, L. Gray, I. Abubakar, R. Baggaley, A. Cooper, P. Haldar, M. Pareek

E0402

An investigation into the relationship between human and animal *Mycobacterium bovis* isolates

ESCMID Global 2025 - Programme

	using whole genome analysis. <i>M. Mansfield*</i> (Dublin, Ireland), <i>E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers</i>
E0403	Distinguishing relapse from reinfection in tuberculosis patients from Lithuania <i>L. Vasiliauskaite*</i> (Vilnius, Lithuania), <i>L. Vasiliauskaitė, A. Zinola, F. Di Marco, V.E. Davidavičienė, B. Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T. Kačergius</i>
E0404	Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study <i>P. Chheda*</i> (Mumbai, India), <i>S. Shivaprakash, T. Dama, G. Thandassery</i>
E0405	Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment <i>A. Van Laarhoven*</i> (Nijmegen, Netherlands), <i>L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullingsh, C. Magis Escurra, W. Hoefsloot, R. Van Crevel</i>
E0406	Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis <i>C. Kim*</i> (London, United Kingdom), <i>S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid</i>
E0407	A longitudinal study on the evolution of drug resistance during tuberculosis treatment <i>E. Danso*</i> (Accra, Ghana), <i>P. Asare, P. Tetteh, A. Tetteh, A.A. Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah-Manu</i>
E0408	Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers <i>A.K. Pandey*</i> (Chandigarh, India), <i>N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma</i>

SEL	13:30 – 15:30	Hall 1
	Special Session	

PRO

Selective Pressure

<i>Chairs</i>	<i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Joshua Nosanchuk (Bronx, United States)</i> <i>Jose Ramon Pano-Pardo (Zaragoza, Spain)</i> <i>Jesús Rodríguez-Baño (Seville, Spain)</i> <i>Anja Šterbenc (Ljubljana, Slovenia)</i> <i>Suzanne Van Asten (Nijmegen, Netherlands)</i> <i>David Van Duin (Chapel Hill, Nc, United States)</i>
---------------	---

JS1	13:30 – 14:30	Hall 12
	Journal Session	

Late-breaker research from CMI and CMI Communications

J001	13:30	Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023) <i>Gaetan Gavazzi (Grenoble, France)</i>
J002	13:45	Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial <i>Thomas Holland (Durham, United States)</i>
J003	14:00	The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study <i>Elise Mitri (Heidelberg, Australia)</i>
J004	14:15	Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis <i>Tba</i>

LB003 13:30 – 14:30 Hall 13
1-hour Oral Session

New solutions for difficult-to-treat infection

- L0011** **Antimicrobial CRISPR-Cas9-based treatment against antibiotic resistant extraintestinal pathogenic *E. coli* (ExPEC) ST131***C. Morros-Bernaus** (Penryn, United Kingdom), *J. Westley, E. R. Wyrsh, S. P. Djordjevic, A. F.C. Leonard, D. Sünderhauf, S. Van Houte*
- L0012** **Ultra-narrow spectrum antibiotic against multi-drug resistant gonococci with novel mode of action***N. Nguyen** (Vienna, Austria), *N. Nhung, A.K. Mix*
- L0013** **Multivalent OMV-based vaccine against *Klebsiella pneumoniae****B. Cano Castaño** (Madrid, Spain), *B. Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto Martin-Gil, D. Fousteris, L. Del Pozo Acebo, F. Docando Sánchez, E. Gato, A. Pérez, M.J. Mcconnell*
- L0014** **Epidermicin NI01, a first-in-class peptide antibiotic candidate, has potent efficacy in a robust MRSA wound infection model and low allergic reaction liabilities***M. Upton** (Plymouth, United Kingdom), *G. Barker, V. Bennett, I. Fotheringham, S. Baxter, H. Curry*
- L0015** **Minimum inhibitory concentrations of quabodepistat in *Mycobacterium tuberculosis* clinical isolates from patients with drug-susceptible pulmonary tuberculosis***I. Kontsevaya** (Munich, Germany), *Y. Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva*

SY094 13:30 – 14:30 Hall 14
1-hour Symposium

AMR PHEI

Farm to fork: food-borne antimicrobial resistance

Chairs *Beatriz Guerra Román (Parma, Spain)*
Joel Mossong (Luxembourg, Luxembourg)

- S0269** **13:30** **Foodborne risk in meat and fishery products and impact on AMR***Anders Dalsgaard (Frederiksberg C, Denmark)*
- S0270** **14:00** **Control challenges associated with food-borne multidrug resistance***Luisa Maria Vieira Peixe (Porto, Portugal)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)

ME095 13:30 – 14:30 Hall 16
Meet-the-Expert

AMR CLN

Local antimicrobials for deep infections

- M0271** **13:30** *Karolina Akinosoglou (Patra, Greece)*
- M0272** **13:42** *Pierre Tattevin (Rennes, France)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

OS052 13:30 – 14:30 Hall 2
1-hour Oral Session

CLN DX

AI in infectious diseases: the lab and beyond

Chair *Miranda Langendam (Amsterdam, Netherlands)*

- O0381** **Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra***N. Macesis** (Melbourne, Australia), *H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe*

ESCMID Global 2025 - Programme

O0382	CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacterales Using Disk-Diffusion <i>L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht</i>
O0383	AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE) <i>G. Danoe* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brilman, L.L. Peters, M.S. Berends</i>
O0384	Predicting potentially infection-related findings in structured radiology reports <i>J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre</i>
O0385	Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections <i>H. Zhang* (Shanghai, China), X. Xu, J. Ai</i>

OS053	13:30 – 14:30	Hall 3
	1-hour Oral Session	

TRN

Immune evasion and intracellular survival strategies

<i>Chairs</i>	<i>Juliane Bubeck Wardenburg (St. Louis, United States) Giovanni Delogu (Rome, Italy)</i>
---------------	---

O0386	Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in <i>Acinetobacter baumannii</i> <i>H. Wang* (Beijing, China), C. Jiang</i>
O0387	Intracellular lifestyle of <i>Acinetobacter baumannii</i>. Role of phospholipase A2 and transcriptional factor EB (TFEB) <i>Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha</i>
O0388	The role of peg344 of hypervirulent <i>Klebsiella pneumoniae</i> on suppressing autophagy responses of macrophages <i>Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinci, F. Can</i>
O0389	c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection <i>C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth</i>
O0390	Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology <i>J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong</i>

SY091	13:30 – 14:30	Hall 4
	1-hour Symposium	

PHEI

Emerging infectious diseases: staying informed and prepared in a globalised world

<i>Chairs</i>	<i>Nitin Gupta (Manipal, India) Pikka Jokelainen (Copenhagen, Denmark)</i>
---------------	--

S0263	13:30	Lessons learnt from previous outbreaks <i>Tba</i>
S0264	14:00	Disease X: preparedness for the next pandemic <i>Yee Sin Leo (Singapore, Singapore)</i>

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY092	13:30 – 14:30	Hall 5
	1-hour Symposium	

CLN

Sex differences in management and outcome of patients with serious bacterial infections

<i>Chairs</i>	<i>Michele Bartoletti (Milan, Italy) Merel Lambregts (Leiden, Netherlands)</i>
---------------	--

S0265	13:30	Sex impacts incidence, management, and outcome in bacteraemia <i>Annette Westgeest (Leiden, Netherlands)</i>
S0266	14:00	The complex interplay between gender and sepsis <i>Ines Lakbar (Montpellier, France)</i>
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)		

ME101	14:45 – 15:45	Hall 14
	Meet-the-Expert	
	PRO	

How to master conflict management and negotiation in healthcare

M0285	14:45	<i>Esther Calbo (Terrassa, Spain)</i>
M0286	14:57	<i>Jan A.J.W. Kluytmans (Utrecht, Netherlands)</i>

FO102	14:45 – 15:45	Arena 1
	Open Forum	
	PHEI	

Navigating the future of pandemics across One Health

ChairXavier Lescure (Paris, France)

F0287	14:45	Status of the One Health Joint Plan of Action by the Quadripartite <i>Chadia Wannous (Paris, France)</i>
F0288	14:55	National surveillance responsibilities under the updated international health regulations <i>Tba</i>
F0289	15:05	Long-term consequences of emerging viral diseases <i>Alfonso J. Rodriguez-Morales (Pereira, Colombia)</i>

Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine

EF059	14:45 – 15:45	Arena 2
	ePoster Flash Session	
	CLN PHEI	

Bacterial infections in the post pandemic era

ChairÖzlem Kurt Azap (Ankara, Türkiye)

E0424	Genomic epidemiology of invasive meningococcal disease in Scotland: The impact of the COVID-19 pandemic <i>N. Ahmad* (London, United Kingdom), C. Rodrigues, A. Smith, C. Cameron, L. Macdonald, R. Ure, M. Maiden</i>	
E0425	Targeted probe-capture culture-independent sequencing identifies emergence of Macrolide-Resistant <i>Bordetella pertussis</i> in Australia <i>W. Fong* (Westmead, Australia), R. Rockett, K. Tam, T. Nguyen, E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D. Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A. Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner, A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley, Q. Wang, N. Jeffreys, S. Chen, K. Basile, T. Golubchik, J. Kok, V. Sintchenko</i>	
E0426	Invasive pneumococcal disease in Spanish adults. Multicenter analysis of serotypes and lineages in the post-pandemic period. <i>R. España Bonilla* (Barcelona, Spain), R. España-Bonilla, A. González-Díaz, J.M. Marimón, A. Manzanal, E. Cercenado, S. De La Villa, B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D. Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á. Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí, J. Càmara, C. Ardanuy</i>	
E0427	Group A streptococcal infections in Germany from 2017 to 2024: a post-pandemic rebound above expected numbers? <i>A. Von Laer* (Berlin, Germany), J. Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A. Hoffmann, I. Noll</i>	

ESCMID Global 2025 - Programme

E0428	Invasive group A streptococcus infections is often preceded by seasonal influenza. <i>J. Westin*</i> (Gothenburg, Sweden), <i>M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell</i>	
E0429	Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates <i>A. Cannas*</i> (Rome, Italy), <i>V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana</i>	
E0430	Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age <i>D. Gandhi*</i> (Mumbai, India), <i>I. Shah, R. Ansari, H. Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. Mattoo, M. Bodhanwala</i>	
E0431	Incidence of Invasive <i>Escherichia coli</i> Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records <i>M. Blum*</i> (Leuven, Belgium), <i>C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen</i>	
E0432	A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers <i>F. Voit*</i> (München, Germany), <i>D. Schult-Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider</i>	
EF060	14:45 – 15:45 ePoster Flash Session	Arena 3
<div>AMRCLN</div> AMR in the community		
Chair	<i>Camilla Wiuff Coia (Copenhagen, Denmark)</i>	
E0433	Socio-demographic factors associated with community-acquired extended spectrum β-lactamase producing <i>E. coli</i>/urinary tract infections at intermunicipal level in France <i>M. Prime*</i> (Nantes, France), <i>O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand</i>	
E0434	Prolonged community outbreak of OXA-48-producing <i>Escherichia coli</i>/linked to a food premises: Lower Hutt, New Zealand, 2018-2022 <i>C. Thornley*</i> (Lower Hutt, New Zealand), <i>M. Kelly, M. Bloomfield, A. Nesdale, R. White</i>	
E0435	Low rates of macrolide resistance found in <i>Mycoplasma pneumoniae</i> cases in Australia <i>R. Rockett*</i> (Westmead, Australia), <i>J. Kok, K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen</i>	
E0436	Epidemiology of antibiotic resistance associated with <i>E. coli</i>/Klebsiella pneumoniae bloodstream infections in England 2012-2023 <i>S. Lipworth*</i> (Oxford, United Kingdom), <i>L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy</i>	
E0437	The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children. <i>C. Brand*</i> (Cape Town, South Africa), <i>R. Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw</i>	
E0438	Risk factors and prevalence of AntiMicrobial Resistant microbes In the English Community (AMRIC) <i>D. Lecky*</i> (Gloucester, United Kingdom), <i>Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown</i>	
E0439	Risk factors for antimicrobial resistance in community commensal <i>Staphylococcus aureus</i> isolates, a sub-analysis of the AMRIC project. <i>M. Joyce*</i> (Manchester, United Kingdom), <i>Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky</i>	
E0440	Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014-2023) <i>A. Mcgeer*</i> (Toronto, Canada), <i>A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W.</i>	

Gold, R. Lovinsky, M. Muller, K. Ostrowska, D. Ricciuto, D. Richardson, C. Vermeiren, K. Hassan, M. Lefebvre, A.X. Li, N. Malik, M. Pejkovska, A. Sultana, T. Vikulova, C. Kandel, Z. Zhong

E0441

Antimicrobial resistance in *Streptococcus pneumoniae* in the Netherlands: an 11-year trend analysis of surveillance data. I. Nauta* (Bilthoven, Netherlands), W. Altorf-Van Der Kuil, D.W. Notermans, A.F. Schoffelen

EF061

14:45 – 15:45

Arena 4

ePoster Flash Session

CLN DX

Infections in the immunocompromised: a multifaceted overview

Chair

Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)

E0442

Impact of Donor Colonization or Infection, or preservation fluid contamination with Multiresistant Bacteria and Fungi in Solid Organ Transplantation. Multicenter registry of Argentina. L. Barcan* (Buenos Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N. Pujato, M. Martinez, S. Villamandos, C. Niveyro, N. Lasserre

E0443

Analysis of viral load kinetics and risk factors for Epstein-Barr virus DNAemia and Post-transplant lymphoproliferative disorders in pediatric liver transplant recipients - a single centre experience. B. Kasztelewicz* (Warsaw, Poland), K. Skrok, I. Jankowska, P. Kaliciński, K. Dzierżanowska-Fangrat

E0444

Impact of pre-transplant infection on post-transplant morbidity and graft survival in liver transplant recipients: a prospective cohort study. L. Mani-Perren* (Bern, Switzerland), S.F. Perrodin, A. Berzigotti, V. Banz, C. Hirzel, L.N. Walti

E0445

Risks of live-attenuated vaccines in children with primary immunodeficiency. S. Frigui Ep Oueslati* (Tunis, Tunisia), S. Ben Jaafar, S. Frigui, Y. Chebbi, M. Ouederni, W. Achour

E0446

Chagas reactivation/ transmission in kidney transplantation. M. Radisic* (Buenos Aires, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del Grosso

E0447

Clinical presentation and treatment of tuberculosis in solid organ transplant recipients: a multicentric retrospective analysis. J. Moltó* (Barcelona, Spain), I. Los-Arcos, D. Ruiz Cabrera, L. López González, M. Fayos Pérez, R. Rodríguez-Alvarez, M. Murga De La Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J. Espinosa, O. Len, A. Sánchez-Montalva

E0448

Clinical presentation, risk factors and outcome of non-tuberculous mycobacteria infection in hematopoietic stem-cell transplant recipients: a multinational case-control study. M. Fernandez Ruiz* (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L. Carver, S. Rutjanawech, L.F. Aranha-Camargo, R. Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S. Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J. Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino, A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek, R. Bou Mjahed, O. Manuel, N. Kamar, A. Calvo-Cano, L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S. Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A. Y. Classen, C. Mejía-Chew, F. López-Medrano

E0449

Impact of bronchoalveolar lavage results on clinical decision-making among immunocompromised, critically ill patients. C. Fanelli* (Sassari, Italy), R. Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales, M.M. Vera, E. Kattan

E0450

***Campylobacter* spp. bloodstream infections: preliminary results from a multicenter differential clinical analysis in immunocompromised and immunocompetent patients**. M. Paniagua-García* (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-Espejo, S. Salto-Alejandre, A. Valiente, M.C. Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-Manrique De Lara, C. Marti-Castellote, M. Monsonis-

ESCMID Global 2025 - Programme

Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed-Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martínez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía

SY100 **14:45 – 15:45** **Hall 12**

TRN

1-hour Symposium

The challenge of a healthy microbiota in neonates

Chairs *Maria Vehreschild (Frankfurt Am Main, Germany)*
Walter Zingg (Zurich, Switzerland)

- S0283** **14:45** **Infant gut microbiome development***Debby Bogaert (Edinburgh, United Kingdom)*
- S0284** **15:15** **Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates***Gautam Dantas (Saint Louis, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

OS058 **14:45 – 15:45** **Hall 16**

CLN

1-hour Case Session

In the field with fungi

Chairs *Beatriz L. Gomez (Bogota, Colombia)*
Leonardo Nimrichter (Rio De Janeiro, Brazil)

- O0419** **Fosmanogepix expanded access in patients with *Fusarium* infections***S. Dadwal* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner*
- O0420** **Voriconazole's hidden toll: unveiling periostitis in a heart transplant recipient and a hematologic patient.***G. Motoa* (Boston, United States), A. Woolley, N. Issa*
- O0421** **Unveiling the Uncommon: Managing *Geotrichum candidum* in Pancreatic Necrosis***L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause*
- O0422** **Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections***V. Havlicek* (Prague, Czech Republic), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens*
- O0423** **Efficacy of novel antifungal therapies in refractory *Candida* and *Aspergillus* infections: insights from compassionate use and clinical trials***S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes*

OS056 **14:45 – 15:45** **Hall 2**

PHEI

1-hour Oral Session

Emerging trends in viral hepatitis across Europe

Chairs *Federico Garcia (Granada, Spain)*
Neven Papic (Zagreb, Croatia)

- O0409** **One of the largest outbreak of hepatitis A in the 21st century in Europe***I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian*
- O0410** **Higher prevalence of Cytomegalovirus and Epstein–**

	Barr virus in acute-on-chronic liver failure – cause or consequence? <i>J. Sonnenberg*</i> (Muenster, Germany), <i>K. Thiyagarajah, E. Görgülü, P. Lembeck, M. Glitscher, F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein, M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N. Kraus, M. Praktinjo, J. Fischer, H.P. Erasmus, J. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka, S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer</i>
O0411	Delta in Denmark: current prevalence of hepatitis delta virus infection <i>H. Watson*</i> (Lyon, France), <i>P. Jepsen, H. Vilstrup, H. Krarup</i>
O0412	RatHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study <i>A. Rivero-Juarez*</i> (Córdoba, Spain), <i>M. Casares, B. Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-Álvarez De Luna, I. Viciano, M.D.C. Domínguez, M. Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez</i>
O0413	Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir <i>I. Hasanoglu*</i> (Ankara, Türkiye), <i>R. Guner, E. Zerdali, A. Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I. Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki, T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N. Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz, S. Kaya, O. Karabay, S. Alkan, F. Tabak</i>

OS057	14:45 – 15:45	Hall 3
	1-hour Oral Session	

ANT

Precision Medicine: from models to patient care

<i>Chairs</i>	<i>Anouk Edwina Muller (The Hague, Netherlands)</i> <i>Sebastian Wicha (Hamburg, Germany)</i>
---------------	--

O0414	Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TBF <i>Kloprogge*</i> (London, United Kingdom), <i>B.T. Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S. Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D. Moore</i>
O0415	Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data <i>Y. Chen*</i> (Shanghai, China), <i>J. Zhao, J. Zhang</i>
O0416	Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant <i>Klebsiella pneumoniae</i> in response to polymyxin B/zidovudine combination <i>J. Zhao*</i> (Melbourne, Australia), <i>Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li</i>
O0417	Agent-based model predictions of polymyxin B activity on <i>Acinetobacter baumannii</i> <i>H. Soeorg*</i> (London, United Kingdom), <i>Y. Yuan, J. Readman, J.F. Standing</i>
O0418	Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis <i>C. Volk*</i> (Madison, United States), <i>W. Kufel, P. Hutson, R. Mahapatra, W. Rose</i>

SY099	14:45 – 15:45	Hall 4
	1-hour Symposium	

AMR IPC

How innovations of AMR and HAI surveillance systems help the clinical practice

<i>Chairs</i>	<i>Pascal Astagneau (Paris, France)</i> <i>Mandy Wootton (Cardiff, United Kingdom)</i>
---------------	---

S0281	14:45	The EUCAST system in surveillance of AMR <i>Sören G. Gatermann (Bochum, Germany)</i>
S0282	15:15	Insights into developments in the surveillance of HAIs <i>Diamantis Plachouras (Solna, Sweden)</i>

Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)

ESCMID Global 2025 - Programme

Movie Session	15:00 – 18:30	Hall 5
Special Session		

Behind the scenes: Contagion

Chairs	William Hanage (Boston, United States) Luigia Scudeller (Pavia, Italy)
--------	---

SY107	16:15 – 17:15	Hall 15
1-hour Symposium		

PRO PHEI

Communicating (your) ID science for policy and societal impact

Chairs	Leonard Leibovici (Petah-Tiqva, Israel) Ines Steffens (Solna, Sweden)
--------	--

S0297	16:15	Communicating to policy makers and for societal impact <i>Balázs Babarczy (Budapest, Hungary)</i>
S0298	16:45	Influencing behaviour through the media and a multichannel communications strategy <i>Charlotte Hutchinson (London, United Kingdom)</i>

Co-organised with: CMI Board of Editors

EW109	16:15 – 18:15	Hall 2
Educational Session		

CLN VAX

Infections in cancer patients: tips for daily practice

Chairs	José Molina Gil-Bermejo (Seville, Spain) Stefan Schwartz (Berlin, Germany)
--------	---

W0301	16:15	Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi <i>Janne Vehreschild (Frankfurt, Germany)</i>
W0302	16:35	Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours <i>Tba</i>
W0303	16:55	The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients <i>Şiran Keske (Istanbul, Türkiye)</i>
W0304	17:15	HTLV-1 and T-cell lymphoma - predict & prevent <i>Lucy Cook (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EF065	16:15 – 17:15	Arena 1
ePoster Flash Session		

ANT TRN

The Antibiotic bakery: Novel compounds in the pipeline

Chair	Susanne Haeussler (Braunschweig, Germany)
-------	---

E0471	<i>In vitro</i> activity and <i>in vivo</i> proof-of-efficacy of epimutillin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens <i>S. Paukner* (Vienna, Austria), W.W. Wicha</i>	
E0472	SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections <i>Y. Hui Hui* (Taipei, Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu</i>	
E0473	<i>In vitro</i> potency of ceftibuten with xeruboractam against β -lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme <i>O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley</i>	
E0474	Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on <i>Pseudomonas aeruginosa</i> biofilm formation <i>A. Fontanot* (Rotterdam, Netherlands), W. Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani, A. Pini, R. Ecker, I. Ellinger</i>	

E0475	Broad spectrum coverage of serine β -lactamase and high <i>in vitro</i> potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabicyclooctane β -lactamase inhibitor ANT3310 <i>L. Sánchez-Peña* (A Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-Martín, L. González-Pinto, M. Outeda-García, P. Aja-Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G. Bou, A. Beceiro, J. Arca-Suárez</i>	
E0476	Antibacterial potential of D-limonene and diallyl disulfide and their interaction with gentamicin against multidrug-resistant <i>Pseudomonas aeruginosa</i> in rat pneumonia model <i>Y. Almuhanha* (Shaqra, Saudi Arabia), M. Asad</i>	
E0477	<i>In vivo</i> pharmacokinetic/pharmacodynamic targets of a novel macrolide antibiotic nafithromycin, determined in neutropenic murine lung infection model of <i>Streptococcus pneumoniae</i> <i>A. Muller* (The Hague, Netherlands), R. Chavan, S. Takalkar, V. Zope, K. Umkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel, B. Veerarahavan</i>	
E0478	NiPharmins: novel low resistance-inducing antimicrobials with antibiofilm activity against <i>Staphylococcus aureus</i> <i>A. Nunes* (Lisbon, Portugal), B. Alves, J.P. Carrilho, N.R. Candeias</i>	
EF066	16:15 – 17:15	Arena 2
	ePoster Flash Session	
	VAX	
Modelling infectious disease burden and impact of vaccination		
Chair	David Fisman (Toronto, Canada)	
E0480	Evaluating the Impact of Re-vaccination on Pneumococcal Disease in Individuals Previously Vaccinated with PPSV23 in Germany: Comparative Approach <i>O. Sharomi* (Mt Carmel, United States), S. Oluwaseun, M. De Lepper, S. Mihm, T.C. Reuter, C. Solleder, G. Meleleo, T. Malik, K. Bakker, R. Oidtman</i>	
E0481	Modeling the public health impact of a 21-valent PCV in the Canadian adult population <i>O. Sharomi* (Rahway, United States), R. Oidtman, M.C. Meilleur, S. Weinrich, K. Bakker</i>	
E0482	Estimating the health and economic burden of pneumococcal diseases attributable to PCV21 (V116) vs. PCV20 or PPSV23 serotypes among adults in Norway <i>Z. Yi* (Rahway, United States), A.A. Tajik, S.T. Klitkou, E. Tsoumani, K. Owusu-Edusei</i>	
E0483	Shifting from risk-based to age-based approach for pneumococcal vaccination in adults in France: a comprehensive evaluation <i>O. Sharomi* (Mt Carmel, United States), S. Oluwaseun, M. Breau-Brunel, F. Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O. Rachel, M. Tufail, B. Kevin</i>	
E0484	The socio-economic value of adult respiratory immunisation programmes in the United Kingdom – Are we measuring what matters to society? <i>C. Harrison* (Tadworth, United Kingdom), T. Hu, J. Yang, J. Vietri, D. Mendes, S. Chowdhury, C. Theakston, S. Brassel, L. Steuten</i>	
E0485	Improving Danish all-cause mortality monitoring by nowcasting weekly deaths <i>A. Kalnæs* (Copenhagen, Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard</i>	
E0486	Modelling to identify an optimal ring vaccination strategy to mitigate a smallpox outbreak <i>V. Costantino* (Sydney, Australia), M. Kunasekaran, T. Leroyd, K. Yeo, R.C. Macintyre</i>	
E0487	The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study <i>F. Günther* (Berlin, Germany), U. Reinacher, S. Chisholm, M. Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O. Wichmann, T. Harder, F.G. Sandmann</i>	
E0488	Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis <i>L. Geng* (Singapore, Singapore)</i>	

ESCMID Global 2025 - Programme

CLN

ePoster Flash Session

Blood parasitology at its best

Chair *Miriam José Álvarez-Martínez (Barcelona, Spain)*

- E0489** **Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areas***A. Busni* (Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara*
- E0490** **A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with *Plasmodium vivax* and *Plasmodium falciparum****U.A. Zainulabid* (Pahang, Malaysia), X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris*
- E0491** **Trick or Treat? An unrelenting malaria case***C. Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy, A. Brown*
- E0492** **"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"***F. Murphy* (Dublin, Ireland), A. Albadi, P. Coakley, C. McNally*
- E0493** **Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)***F. Sabaini* (Milan, Italy), A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori*
- E0494** **The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients***S. Vita* (Rome, Italy), A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri*
- E0495** **Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study***J. De Larminat* (Paris, France), N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye*
- E0496** **Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement***A. Mohta* (Bikaner, India)*
- E0497** **Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection***N. T R* (Jodhpur, India), T. Kanagiri, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra*

EF068 **16:15 – 17:15** **Arena 4**

ePoster Flash Session

AMR

PHEI

A global perspective on antimicrobial resistance surveillance

Chair *Mirfin Mpundu (Lusaka, Zambia)*

- E0498** **Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS)***E. Van Kleef* (Geneva, Switzerland), O. Tosas Auguet, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolli*
- E0499** **Comparative analysis of antimicrobial resistance (AMR) burden across european countries***A. Dörre* (Berlin, Germany), A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns*
- E0500** **Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities***C. Van Rossum* (Nijmegen, Netherlands), C. Meijer, P. Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs-Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Tostmann, C. Van Der Veer, S. Pas*
- E0501** **Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade***R. Janssen* (Bilthoven, Netherlands), S. Woudt, D. Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M.*

Gelormini

- E0502** **Global, regional, and national temporal trends in mortality for carbapenem-resistant bacteria from 1990 to 2021: An age-period-cohort analysis***C. Zhihui* (Shanghai, China), Z. Mingchen, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong*
- E0503** **Global Trends and Impact of Antimicrobial Resistance in Paediatric Populations: An Analysis Using WHO AWaRe Classification and Priority Pathogens***Joseph Harwell (North Melbourne, Australia)*
- E0504** **Antibiotic resistance profile and comparative evaluation of WHO AWaRe Guidelines at the Emergency's Children's Surgical Hospital in Uganda***L. Barcellini* (Milan, Italy), F. Riccaboni, V. Fabiano, F. Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A. Mohammed Zain, G.V. Zuccotti, L. Folgori, L. Napolitano*
- E0505** **Initiatives in antimicrobial resistance surveillance: Using automated bacteraemia surveillance for hospital-wide multidrug resistance monitoring***F.D. Ruether* (Berlin, Germany), L.A. Peña Díaz, M. Behnke, C. Geffers, S.J.S. Aghdassi*
- E0506** **Global and regional prevalence of antimicrobial resistance in GLASS target bacterial pathogens for bloodstream, urinary tract and gastrointestinal infections: a systematic review of the global literature (2019-2024)***B. Caddey* (Calgary, Canada), G. Lazarus, S. Bertagnolio, D.B. Nobrega, R.L. Hamers, A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly, H.W. Barkema, E. Van Kleef, O. Tosas-Auguet*

KN103 **16:15 – 17:15** **Hall 1**
Keynote Lecture

CLN

Tuberculosis: where are we now and where should we be

Chairs *Jon S. Friedland (London, United Kingdom)*
Delia Goletti (Rome, Italy)

K0290 **16:15** *Guy Thwaites (Ho Chi Minh City, Vietnam)*

OS063 **16:15 – 17:15** **Hall 11**
1-hour Oral Session

DX

Improving blood culture diagnostics: rethinking the basics

Chairs *Direk Limmathurotsakul (Bangkok, Thailand)*
Pilar Retamar Gentil (Seville, Spain)

- O0461** **Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany***J. Forster* (Würzburg, Germany), A.L. Sieg, V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V. Le Saout – Chapot, M. Hogardt, B. Spielberger, E.A. Idelevich, M. Christner, S. Zimmermann, S. Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U. Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M. Krone*
- O0462** **Changing the paradigm: are two sets of blood cultures always needed?***R. Rosa* (Miami, United States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello, L. Abbo*
- O0463** **Evaluating clinical and economic impact of reducing blood culture incubation timings: Time to shift the paradigm?***R. Gupta (bagga)* (London, Canada), R. Gupta, J. Delpont, T. Mazzulli*
- O0464** **Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study***S. Kwon* (Seoul, Korea, Republic of), K. Sunghoon, K. Dong Young, J. Jisung, K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan Beom*
- O0465** **Human *in vivo* footprints from blood plasma for improved diagnostics in sepsis***M. Sonntag* (Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y. Vainshtein, S.O. Decker, T. Brenner, K. Sohn*

ESCMID Global 2025 - Programme

ME108	16:15 – 17:15	Hall 12
	Meet-the-Expert	
	CLN	
Navigating travel medicine: expert tips for safe international travel		
M0299	16:15	Sophie Schneitler (Homburg, Germany)
M0300	16:27	Andreas Neumayr (Basel, Switzerland)
OS062	16:15 – 18:15	Hall 13
	2-hour Oral Session	
	CLN DX TRN	
Heterogeneity and complexity of sepsis		
Chairs	Despoina Koulenti (London, United Kingdom) Sylvain Meylan (Lausanne, Switzerland)	
00451	A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium. Moore* (Emerald Hills, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer	
00452	BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri	
00453	Deciphering the Dynamics of <i>Klebsiella pneumoniae</i> Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients W. Yu* (Beijing, China)	
00454	Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas	
00455	Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups M.H. Øvre* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknacht	
00456	Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam – results from SPECTRA E. Yucel* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul	
00457	Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed	
00458	Is transthoracic echocardiography required in all patients with <i>Staphylococcus aureus</i> bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis M. Verdejo Gómez* (Barcelona, Spain), D. Malano-Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. García-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A. Martínez, L. Morata, A. Soriano	
00459	DNA methylation changes in Sepsis: Potential use as biomarkers I. López-Cruz* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero	
00460	Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia S. Doeleman* (Amsterdam, Netherlands), D. Susanne, E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll	

SY106 **16:15 – 17:15** **Hall 14**

AMR TRN

1-hour Symposium

Strain dynamics in determining gut microbial colonisation resistance

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Li Yang Hsu (Singapore, Singapore)

S0295 **16:15** **Strain dynamics in serious bacterial infections in infants***Drew Schwartz (Saint Louis, United States)*

S0296 **16:45** **Long-term colonisation dynamics of carbapenemase-producing Enterobacterales***Niranjan Nagarajan (Singapore, Singapore)*

OS064 **16:15 – 17:15** **Hall 16**

DX PHEI VAX

1-hour Oral Session

Viral immune response - nature or nurture? Exploring the limits of immune response

Chairs *Malin Flodström-Tullberg (Stockholm, Sweden)*
Florian Krammer (New York, United States)

O0466 **Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination***C. Van Dijck* (Antwerp, Belgium), N. Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J. Marien, L. Liesenborghs*

O0467 **DENG-VAC study: preliminary data on immunogenicity and reactogenicity of Qdenga vaccine versus natural infection***A. D'abramo* (Rome, Italy), S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle, G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M. Fabrizio, N. Emanuele*

O0468 **Long-Lasting Immunity Followed by Natural CCHFV Infection***H. Karakoc* (Trabzon, Türkiye), H.N. Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q. Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A. Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M. Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M. Sajadi*

O0469 **Why does rabies virus not induce an anti-viral immune response : insights from experimental models and a human cohort***C. Geurts Van Kessel* (Rotterdam, Netherlands), C. Embregts, A. Gohar, B. Verstrepen, J. Aijaz, N. Salahuddin, C. Geurtsvankessel*

O0470 **Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses***N. Noulin* (London, United Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt, K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C. Chiu, A. Catchpole*

SY104 **16:15 – 17:15** **Hall 3**

IPC

1-hour Symposium

Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant with MDR Gram-negative colonisation

Chairs *Elda Righi (London, United Kingdom)*
David Van Duin (Chapel Hill, Nc, United States)

S0291 **16:15** **Standard prophylaxis***Maddalena Giannella (Bologna, Italy)*

S0292 **16:45** **Targeted approaches***Maristela P. Freire (Sao Paulo, Brazil)*

Co-organised with: European Association for the study of the liver (EASL)

SY105 **16:15 – 17:15** **Hall 4**

1-hour Symposium

ESCMID Global 2025 - Programme

Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

Chairs Robert A. Bonomo (Cleveland, United States)
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics Anna Sramkova (Pilsen, Czech Republic)

S0294 16:45 Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors Parikshit Prayag (Pune, India)

Co-organised with: EUCAST Steering Committee

LB004 16:15 – 18:15 Hall 9
2-hour Oral Session

Trials in severe infections

Chair Steven Tong (Melbourne, Australia)

L0016 16:15 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial F. Cogliati Dezza* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lopez Cardenas, M.C. Gomez Sanchez, I. Pérez Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. Aller Garcia, M.T. Pérez-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Francisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño

L0017 16:27 HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study M. Ju* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang

L0018 16:39 Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant *Acinetobacter baumannii* G. Dale* (Basel, Switzerland), F. Fratzeskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakyntinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer

L0019 16:51 Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial M. Canetti* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav

L0020 17:03 Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reduction L.A. Edwards* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross

L0021 17:15 Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients

		coinfected with HIV and tuberculosis: a multicentre, open-label, randomised trial <i>Y. Shen* (Shanghai, China), X. Le</i>
L0022	17:27	Initial vancomycin taper for the prevention of recurrent <i>Clostridioides difficile</i> infection: the TAPER-V randomised controlled trial <i>E.G. McDonald* (Montreal, Canada), Y. Chen, B. Coburn, N. Daneman, S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin, V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L. Valiquette, T.C. Lee</i>
L0023	17:39	Beneficial effects of a clinical metagenomics intervention on clinical outcomes, healthcare economics, and quality of life in patients with sepsis/septic shock: results of the DigiSep-trial <i>T. Brenner* (Essen, Germany), A. Skarabis, S.J. Schaller, T. Von Groote, C. Putensen, U. Günther, M. Sauer, S.O. Decker, F. Dusse, M. Weiss, K. Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer, M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M. Feißt, U. Marschall, P. Brandenburg, J. Englisch, P. Stevens, J. Schmidt, M.W. Pletz, J. Brands, A. Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G. Marx, J. Mossanen, T. Breuer, H. Häberle, K. Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T. Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B. Pasioka, U. Jaekel, T. Brandenburger, F. Bach, H. Mutlak, S. Utzolino, M.M. Berger</i>
L0024	17:51	Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial <i>S. Bastrup Israelsen* (Hvidovre, Denmark), L. Hagens Mygind, F. Al-Zergani, B. Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-Ussing, I. S. Johansen, H. Nielsen, P. Ravn, T. Benfield</i>
L0025	18:03	High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial <i>R. Van Crevel* (Nijmegen, Netherlands), D. Meya, R. Rovina, D. Boulware, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A. Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M. Kabahubya, S. Marais, Y. Moosa, N. Bahr, E. Svensson, L. Te Brake, R. Aarnoutse</i>

EF074 **17:30 – 18:30** **Arena 1**

ePoster Flash Session



New methods for rapid pathogen detection and typing

Chair *Sylvain Brisse (Paris, France)*

E0532	Rapid detection of Shiga toxin-producing <i>Escherichia coli</i> (<i>stx2a</i> and <i>stx2d</i>) in korean diarrheal stool samples: a performance evaluation <i>L. Hyeonji* (Seoul, Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J. Choo, H.J. Huh, E.J. Won</i>
E0533	Global prevalence of O-serotypes and antibiotic resistance among extraintestinal pathogenic <i>Escherichia coli</i> isolated from older adult patients with bacteraemia (2011–2021) <i>J. Geurtsen* (Leiden, Netherlands), M. De Been, O. Go, M. Aitabi, C. Willame, E. Weerdenburg</i>
E0534	Strategy for the rapid typing of <i>Salmonella</i> spp using infrared spectroscopy: a one health perspective <i>J. Jiménez* (Santiago, Chile), D. Fredes, A. Piña, I. Mercado, J. Miranda, S. Henríquez, T. González, A. Adell, A. Moreno-Switt, A. Wozniak, P. García</i>
E0535	WGS-based surveillance as a paradigm shift in outbreak detection, AMR monitoring and source attribution in <i>Campylobacter</i> <i>A. Nunes* (Lisbon, Portugal), M.L. Lemos, S. Ortiz, I. Santos, S. Ramos, M. Oleastro</i>
E0536	Prevalence of <i>Staphylococcus aureus</i> clonal complex 97 amongst BORSA isolates in a large UK hospital <i>H. Gareth* (Birmingham, United Kingdom)</i>
E0537	The effectiveness of clinical laboratory tools in the surveillance of nontuberculous mycobacterium isolations within different counties in Taiwan <i>H.W. Chu* (Taipei, Taiwan, China), T.F. Lee, C.C. Shu, Y.T. Huang</i>
E0538	Rapid detection of oxazolidinone-resistance-related

ESCMID Global 2025 - Programme

- mutations in *Enterococcus* spp. by using High Resolution Melting-qPCR-typing analysis *R. Musumeci** (Monza, Italy), *E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza*
- E0539** **An automated pipeline to genotype bacteriophages using third generation sequencing** *Z. Halász** (Debrecen, Hungary), *E. Szoták, L. Dr. Laczkó, G. Dr. Kardos*
- E0540** **Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy** *N. Mauder** (Bremen, Germany), *M. Cordovana, M. Kostrzewa*

EF075 **17:30 – 18:30** **Arena 2**

ePoster Flash Session

IPC PHEI VAX

Healthcare (workers') safety revisited

Chair *Daniel Diekema (Harpswell, United States)*

- E0541** **Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study** *B. Beishuizen** (Bilthoven, Netherlands), *M. Stein, A. Tostmann, C. Rovers, A. Timen*
- E0542** **Preparing First-Line health care workers for 'Virus X' through targeted training (FILI-VI-X)** *A. Mondelaers** (Antwerp, Belgium), *Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe*
- E0543** **Analysis of the current situation of hospital inspection practices by German health authorities** *A. Schwabe** (Bonn, Germany), *J. Dannenberg, A.D. Wollkopf, F. Droop, S. Engelhart, N.T. Mutters*
- E0544** **A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of hEalth)** *M. Meschiari** (Modena, Italy), *F.V. Segala, E. Ricchizzi, A. Gallerani, V. Scaglione, R. Castoldi, F. Almerigogna, I. Spalliera, A. Parente, S. Coladonato, P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. Murri, C. Mussini*
- E0545** **High level of measles immunity among Dutch healthcare workers with self-reported "unknown" measles immunity status** *C. Meijer** (Nijmegen, Netherlands), *J. Leijser, M. McCall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann*
- E0546** **Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland** *C. Anderson** (Dublin, Ireland), *D. McGee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend*
- E0547** **Systematic review of determinants of vaccine hesitancy among healthcare workers** *V. Gabellone** (Lecce, Italy), *F. Nuccetelli, R. Prato, E. Gabrielli, P.L. Lopalco*
- E0548** **Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines** *P. Shamsrizi** (Hamburg, Germany), *S. Eitze, D. Heinemeier, A. Tänzer, M.A. Jenny*
- E0549** **Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits?** *A. Kearney** (Dublin, Ireland), *H. Humphreys, D. Fitzgerald Hughes*

EF076 **17:30 – 18:30** **Arena 3**

Knowing me, knowing you: behaviour influencing AMS

Chair

Elena Carrara (Verona, Italy)

- E0550** Exploring determinants in deciding the optimal antimicrobial dose in patients receiving CRRT: a mixed method study *T. Yanık Yalçın** (Ankara, Türkiye), *A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö. Azap, H. Arslan, B. Başgüt, P. Zeyneloğlu*
- E0551** Behaviour change vs policy change: Key drivers of inappropriate antibiotic use among health care professionals in LMICs – insights from Indian community setting *N. P Mathew** (Manipal, India), *U. B, M. Varma, V. K E, R. Ruiter, G. Thunga, C. Mukhopadhyay*
- E0552** Contextual determinants to antimicrobial stewardship implementation in 16 hospitals: a four-country analysis in Asia *H. Vu Thi Lan** (Ha Noi, Vietnam), *R. Limato, H.Y. Duong, S. Manandhar, D. Limmathurotsakul, A. Apisarnthanarak, N.T. Pham, V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A. Karkey, M.K. Upadhyaya, E. Dodds Ashley, D. Anderson, H.R. Van Doorn, H. Vu*
- E0553** SpeakAB, a pilot study to encourage nurses to speak up about antibiotic care *M. Bos** (Nijmegen, Netherlands), *J. Schouten, H. Vermeulen, M. Hulscher, C. De Bot*
- E0554** Understanding what matters to patients in antimicrobial stewardship in hospitals. PERSPECT study update *B. Jacob** (Dublin, Ireland), *E. De Barra*
- E0555** Determinants of antibiotic prescribing in hospitals from low, middle and high-income countries in Asia *S. Chhabra** (Singapore, Singapore), *S. Nair, A. Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo*
- E0556** Riding "the antimicrobial rollercoaster": The behavioural and phenomenological science of antimicrobial use in haemato-oncology *C. Eades** (London, United Kingdom), *L. Byrne-Davis, R. Rautemaa-Richardson, T. Felton*
- E0557** Addressing Antimicrobial Resistance: Expert Insights and Policy Recommendations for Effective Interventions *B. Madran** (Istanbul, Türkiye), *F. Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira, G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S. Sakarya*
- E0558** Implementation of hospital antimicrobial stewardship in Europe using a data-driven behaviour change approach: insights from the drive-AMS EU project *I. Pauwels** (Antwerp, Belgium), *R. Janssen, E. Iosifidis, N. Milevska-Kostova, M. Lupşe, J.A. Paiva, E. Roilides, T. Schoffelen, R. Valinteliene, A. Versporten, E. Vlieghe, J. Schouten*

EF077

17:30 – 18:30

Arena 4

Viral aphrodites

Chair

Rémi Charrel (Marseille, France)

- E0559** Potential for international spread of Oropouche virus via commercial air travel *M. Torres Portillo** (Toronto, Canada), *A. Marwah, M. Kraemer, A. Thomas, K. Khan, I. Bogoch*
- E0560** Estimating mpox Clade 1b outbreak size in the Democratic Republic of the Congo to attenuate surveillance gaps during the early stages of the 2024 outbreak *M. Torres Portillo** (English, Canada), *A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan*
- E0561** Disparate epitope recognition between MPXV-infected and Smallpox-vaccinated individuals *A. Otter** (Salisbury, United Kingdom), *S. Jones, B. Hicks, B. Hallis, C. Rowe*
- E0562** Diverse residual and late-onset symptoms of severe fever with thrombocytopenia syndrome: insights

ESCMID Global 2025 - Programme

		from a multicenter questionnaire study in Western Japan <i>R.M. Sada* (Osaka, Japan), S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna</i>
E0563		Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study <i>J.T. Lim* (Singapore, Singapore), I. Wee, W.Z. Tan</i>
E0564		Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina <i>G.A. Méndez* (Posadas, Argentina), J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely</i>
E0565		Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever <i>D. Yigci* (Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündag, M. Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıracı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu, Ö. Ergönül</i>
E0566		Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India <i>P. Venkata Swathi Kiran* (Udupi, India), P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K. Pothumarthu</i>
E0567		Unravelling the aetiology of summer flu-like illness in Czechia <i>M.F. Křihá* (Ceske Budejovice, Czech Republic), V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek</i>

SY112	17:30 – 18:30	Hall 1
	1-hour Symposium	

PHEI

Year in public health

Chairs	<i>Ziad A. Memish (Riyadh, Saudi Arabia)</i> <i>Catherine Moore (Cardiff, United Kingdom)</i>
--------	--

S0309	17:30	<i>Li Yang Hsu (Singapore, Singapore)</i>
S0310	18:00	<i>Rita Oladele (Lagos, Nigeria)</i>

SY111	17:30 – 18:30	Hall 11
	1-hour Symposium	

ANT

PK/PD in drug development: what's in it for me?

Chairs	<i>Sandrine Marchand (Poitiers, France)</i> <i>Sebastian Wicha (Hamburg, Germany)</i>
--------	--

S0307	17:30	PK/PD from the EUCAST/regulatory perspective: what tools do we need? <i>Joseph Meletiadis (Athens, Greece)</i>
S0308	18:00	PK/PD for new anti-TB drugs <i>Elin Svensson (Uppsala, Sweden)</i>

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

OS070	17:30 – 18:30	Hall 12
	1-hour Oral Session	

CLN

DX

What's new in antifungal guidelines and management

Chairs	<i>Sharon Chen (Sydney, Australia)</i> <i>Helmut Salzer (Linz, Austria)</i>
--------	--

O0512		Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in
-------	--	---

	cooperation with ISHAM and ASMR. Sprute* (Cologne, Germany), O.A. Cornely, M. Bassetti, C. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E. Santolaya, L. White, L.P. Zhu
O0513	Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay M. Bassetti* (Genoa, Italy), G.R. Thompson, A. Soriano, S. Dickerson, I. Bielicka, O.A. Cornely
O0514	An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI) O.A. Cornely* (Cologne, Germany), B.D. Alexander, P.G. Pappas, T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo
O0515	Novel immunotherapy approach using pan-<i>Candida</i> monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR Y. Zhao* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil
O0516	Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis. K. Stott* (Liverpool, United Kingdom), D. Tembo, C. Kajanga, A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T. Harrison, J. Jarvis, D. Namakhwa, D. Laloo, W. Hope, H. Mwandumba

OS071	17:30 – 18:30	Hall 14
	1-hour Oral Session	

CLN

Intestinal parasitic uncovered: epidemiology and treatment success

<i>Chairs</i>	Kurt Hanevik (Bergen, Norway) Pavla Tůmová (Praha, Czech Republic)
---------------	---

O0517	Giardia- Does the treatment work? The experience from a national tertiary referral centre A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole
O0518	Giardiasis: Who gets it? Experience from a Central London Teaching Hospital. A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole
O0519	Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting <i>E. histolytica</i> cfDNA P. Datta* (Chandigarh, India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S. Khurana
O0520	Longitudinal observation of <i>Blastocystis</i> sp. and <i>Dientamoeba fragilis</i> in children: a very rare occurrence in chronic diseases with gut dysbiosis. J. Hurych* (Prague, Czech Republic), J. Havlova, V. Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M. Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P. Saavalainen, H. Malcova, D. Cebecauerova, P. Dřevínek, Z. Sumnik, O. Cinek
O0521	High prevalence of the zoonotic <i>Angiostrongylus cantonensis</i> in rats in Spain J. Caballero Gómez* (Córdoba, Spain), T. Fajardo-Alonso, I. García-Bocanegra, M. González, A. Beato-Benítez, R. Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R. Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A. González, P. Foronda, J. Caballero-Gómez

OS072	17:30 – 18:30	Hall 15
	1-hour Oral Session	

PRO

Training models - a new model for training

<i>Chairs</i>	Erin Bonura (Portland, United States) Casandra Bulescu (Bucharest, Romania)
---------------	--

O0522	Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases ? S. Villard* (Paris, France), Y. Guedj, L.
-------	--

ESCMID Global 2025 - Programme

	<i>Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja</i>
O0523	Large language model in real-world clinical infectious diseases: are we there yet? <i>G. Carra*</i> (Switzerland, Switzerland), <i>M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco</i>
O0524	Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3 <i>S. Ahmad*</i> (Tampere, Finland)
O0525	A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines <i>J. Molina Gil-Bermejo*</i> (Seville, Spain), <i>J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller</i>
O0526	Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis <i>S. Angirekula*</i> (Jodhpur, India), <i>R. Modi, R. Bora, R. Lohiya, S.K. Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. Bohra</i>

OS073	17:30 – 18:30	Hall 16
	1-hour Case Session	

CLN

Still going viral

<i>Chairs</i>	<i>Ursula Hofer (London, United Kingdom)</i> <i>Yee Sin Leo (Singapore, Singapore)</i>
---------------	---

O0527	Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions. <i>A. Tessitore*</i> (Trieste, Italy), <i>N. Maximova, S. Braidotti, M. Granzotto, R. Simeone</i>
O0528	Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia <i>J. Heylen*</i> (Leuven, Belgium), <i>B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters</i>
O0529	Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina. <i>L. Barcan*</i> (Buenos Aires, Argentina), <i>S. Villamandos, R. Gago, M. Aguirre, A. Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán</i>
O0530	Rash without borders: waning immunity in a travelling physician <i>R. Ville Benavides*</i> (Mexico City, Mexico), <i>R. Ville-Benavides, I. Avendaño-Gutiérrez</i>
O0531	A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient <i>A. Kaya*</i> (Izmir, Türkiye), <i>G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan</i>

SY110	17:30 – 18:30	Hall 3
	1-hour Symposium	

VAX

Immune reconstitution syndrome in infectious diseases: Who. Are. You?

<i>Chairs</i>	<i>Elisa Borghi (Milan, Italy)</i> <i>Justyna Kowalska (Warsaw, Poland)</i>
---------------	--

S0305	17:30	IRIS in HIV Immunocompromised hosts: a failure of
-------	-------	---

		success <i>Paola Maria Cinque (Milan, Italy)</i>
S0306	18:00	Dysregulated host responses to infection <i>Michal Holub (Praha, Czech Republic)</i>
<hr/>		
OS069	17:30 – 18:30	Hall 4
	1-hour Oral Session	
	<div>AMR</div> <div>ANT</div>	
Determining new and revising old breakpoints		
<i>Chairs</i>	<i>Jaroslav Hrabak (Plzen, Czech Republic)</i> <i>Erika Matuschek (Växjö, Sweden)</i>	
O0507	EUCAST disk diffusion testing of ten additional species of anaerobic bacteria <i>J. Ahman* (Växjö, Sweden), J. Åhman, E. Matuschek, B.J. Holzkecht, P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T. Morris, G. Kahlmeter</i>	
O0508	Standardised antimicrobial susceptibility testing protocol for <i>Legionella pneumophila</i> validated across ten European reference laboratories <i>M. Sewell* (Cardiff, United Kingdom), C. Farley, A.V. Krøvel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller</i>	
O0509	Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods <i>L. Chan* (Kennedy Town, Hong-Kong SAR, China), D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow</i>	
O0510	Determination of optimal disk diffusion mass for zosurabalpin <i>M. Castanheira* (North Liberty, United States), J. Maher, Y. Edah, A. Trauner</i>	
O0511	The clinical significance of aminoglycoside susceptibility breakpoints modification <i>O. Henig* (Tel Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-Ami</i>	

Monday, 14 April 2025

SY116	08:30 – 10:30	Hall 15
	2-hour Symposium	
	PHEI	
Climate Change: changing risks and adaptation strategies for a world on the move		
Chairs	Rachel Lowe (Barcelona, Spain) Giacomo Stroffolini (Lausanne, Switzerland)	
S0323	08:30	Vector-borne diseases in Europe and clinical consequences Tuba Dal (Ankara, Türkiye)
S0324	09:00	Rising temperatures and risks of fungal disease Anuradha Chowdhary (New Delhi, India)
S0325	09:30	Strategies for climate prevention and adaptation in a moving world Kristie Ebi (Seattle, United States)
S0326	10:00	AMR in climate change-affected countries Esmita Charani (London, South Africa)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

EF079	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	CLN	
AMS around the world: what we can learn from each other		
Chair	Benedikt Huttner (Geneva, Switzerland)	

E0578	Battlefield Stewardship: Implementing Antimicrobial Management in the Ukrainian Trauma Pathway <i>H.</i>	
-------	---	--

ESCMID Global 2025 - Programme

	<i>Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych</i>
E0579	Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study <i>M. Alyazji* (Abudhabi, United Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljasmi, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali</i>
E0580	Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza A H1N1 season in northern Italy <i>R. Corsini* (Reggio Emilia, Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri</i>
E0581	Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country <i>S. Qureshi* (Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar</i>
E0582	Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study <i>M.S. Kabir* (Dhaka, Bangladesh), R. Farzana, S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh</i>
E0583	Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital <i>P. Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco</i>
E0584	Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment <i>M. Krauss* (Vienna, Austria), C. Labut, G. Brunhofer-Bolzer, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E. Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler</i>
E0585	Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CARbapenem Sparing Antimicrobial Stewardship) Project <i>M. Bongiovanni* (Lugano, Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi</i>
E0586	"Prescribing antibiotics is a gamble...": A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital <i>L. Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo</i>

EF080	08:30 – 09:30	Arena 3
-------	---------------	---------

   ePoster Flash Session

Acinetobacter baumannii, still a strong knight to be knocked

Chair *Parikshit Prayag (Pune, India)*

E0587	Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against <i>Acinetobacter baumannii</i> <i>H. Haddad* (Sousse, Tunisia)</i>
E0588	Clonal dissemination of highly resistant <i>Acinetobacter baumannii</i> ST2: Insights from the BALANCE study <i>C. Abdellaoui* (Oxford, United Kingdom), R. Farzana, M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh</i>
E0589	Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant <i>Acinetobacter baumannii</i> in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam <i>D. Nurjadi* (Luebeck, Germany), S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P.</i>

Velavan

- E0590** **In vitro activity of nitroxoline among *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* clinical isolates***E. Wohlfarth* (Cologne, Germany), P.G. Higgins, M. Kresken*
- E0591** **Assessing biocide resistance genes and susceptibility to biocides in carbapenem-resistant *Acinetobacter baumannii* isolates from Thai hospitals***M.R.D. Wiradiputra* (Bangkok, Thailand), K. Thirapanmethee, P. Khuntayaporn, M.T. Chomnawang*
- E0592** **Epidemiological and Genomic Characteristics of *Acinetobacter baumannii* in a Hospital in Zhejiang, China: A Study from 2015 to 2020***Y. Zhang* (Hangzhou, China), X. Hua*
- E0593** **Evaluation of the susceptibility of Carbapenem-resistant *Acinetobacter baumannii* to sulbactam-durlobactam***J. Caierão* (Porto Alegre, Brazil), L. Silva Dornelles, G. Da Silva Collar, M. Preussler Mott, A. Luís Barth*
- E0594** **Clonal dissemination of *Acinetobacter baumannii* International Clone 2 Carrying ArmA and emergence of OXA-23-NDM1 co-producers in India***G. Nagaraj* (Bangalore, India), N. Geetha, S. Varun, K. Ravikumar*
- E0595** **Insight into *Acinetobacter baumannii*'s phenotypic and genotypic traits in oncological patients***F. Sivori* (Rome, Italy), I. Cavallo, M. Truglio, G. Fabrizio, M. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico, F. Pimpinelli*

EW119 **08:30 – 10:30** **Hall 11**

Educational Session

AMR DX

This bacterium might harbour AmpC, what should I do?!

Chairs *Sören G. Gatermann (Bochum, Germany)*
Pranita Tamma (Ellicott City, United States)

- W0335** **08:30** **Laboratory identification of AmpC and its impact on**
/i>In vitro resistance*Ana Gales (Sao Paulo, Brazil)*
- W0336** **08:50** **Divergent levels of AmpC expression in Gram-negative pathogens***Antonio Oliver (Palma De Mallorca, Spain)*
- W0337** **09:10** **Rational choice of antimicrobial therapy against AmpC-producing pathogens***Patrick Harris (Herston, Australia)*
- W0338** **09:30** **Novel antimicrobials active against AmpC: what RCTs tell us in support of their use?***Amy Mathers (Charlottesville, United States)*

SY114 **08:30 – 10:30** **Hall 13**

2-hour Symposium

CLN

Sepsis Global 2025

Chairs *Brigitte Lamy (Bobigny, France)*
Willem Joost Wiersinga (Amsterdam, Netherlands)

- S0315** **08:30** **The ESCMID-ISF Sepsis Award Lecture***Andrew Moore (Emerald Hills, United States)*
- S0316** **08:45** **The WHO Global Maternal Sepsis Study***Carolina Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)*
- S0317** **09:15** **Sepsis: year in review***Sylvain Meylan (Lausanne, Switzerland)*
- S0318** **09:45** **How to design and implement a Sepsis National Action Plan (SNAP)***Erika Vlieghe (Edegem, Belgium)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY115 **08:30 – 10:30** **Hall 14**

2-hour Symposium

CLN DX

Challenges in infection management, prevention and antimicrobial

ESCMID Global 2025 - Programme

stewardship in long-term care facilities

Chairs *Gaetan Gavazzi (Grenoble, France)*
Giusy Tiseo (Pisa, Italy)

- S0319

08:30

The burden of nosocomial infections in long-term facilities *Virginie Prendki (Genève-Thônex, Switzerland)*
- S0320

09:00

Pneumonia in the elderly: management and prevention *Marcos Restrepo (San Antonio, United States)*
- S0321

09:30

Challenges in the clinical diagnosis of infection in the elderly *Maheen Abidi (Denver, United States)*
- S0322

10:00

Challenges in implementing antimicrobial stewardship in long-term care facilities *Elena Carrara (Verona, Italy)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SY117

08:30 – 10:30

Hall 16

2-hour Symposium

AMR CLN

Survival of the parasites: is treatment failure due to antimicrobial resistance?

Chairs *Hanne Brekke (Oslo, Norway)*
Jaco J. Verweij (Tilburg, Netherlands)

- S0327

08:30

Nitroimidazole refractory *Giardia intestinalis* infection *Pavla Tůmová (Praha, Czech Republic)*
- S0328

09:00

Treatment failure in scabies *Francisco Bravo (Lima, Peru)*
- S0329

09:30

Recurrent *Enterobius* infections *Sarah Eisen (London, United Kingdom)*
- S0330

10:00

Recent advances in the treatment of Visceral Leishmaniasis and PKDL *Shyam Sundar (Varanasi, India)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW118

08:30 – 10:30

Hall 2

Educational Session

DX IPC

How can we infer and track plasmid outbreaks?

Chairs *Alessandra Carattoli (Rome, Italy)*
Jacob Moran-Gilad (Beer Sheva, Israel)

- W0331

08:30

Evolutionary modelling of plasmids *Manuel Ares Arroyo (Paris, France)*
- W0332

08:50

How plasmids shape the emergence of nosocomial pathogens *Jukka Corander (Oslo, Norway)*
- W0333

09:10

Understanding the complexity of plasmid outbreaks using bioinformatics *Torsten Seemann (Melbourne VIC), Australia)*
- W0334

09:30

Plasmid transmission at the One Health interface *Nicole Stoesser (Oxford, United Kingdom)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

SY113

08:30 – 10:30

Hall 3

2-hour Symposium

PHEI

Haemorrhagic viral infections

Chairs *Önder Ergönül (Istanbul, Türkiye)*
Catherine Houlihan (Porton Down, United Kingdom)

- S0311

08:30

Filovirus disease: evolving therapeutic strategies *Ian Crozier (Frederick, United States)*
- S0312

09:00

Jack in the box: Re-emergence of Kyasanur Forest Disease in India *Kavitha Saravu (Manipal, India)*

S0313	09:30	Crimean Congo Haemorrhagic Fever: Newer insights into pathogenesis leading to new vaccines and therapeutics <i>Ali Mirazimi (Stockholm, Sweden)</i>
S0314	10:00	Venezuelan Equine Encephalitis: Impact of newer strategies for vector control <i>Carlos Seas (Lima, Peru)</i>

OS078	08:30 – 10:30	Hall 5
2-hour Oral Session		
CLN DX TRN		

Trending topics in tuberculosis

<i>Chairs</i>		<i>Delia Goletti (Rome, Italy)</i> <i>Sean Wasserman (London, United Kingdom)</i>
O0568		Lineage-specific immune responses to <i>Mycobacterium tuberculosis</i>: Insights into L4 and L6 pathogenesis <i>M. Silva* (Porto, Portugal), J. Couto, M. Cardoso, B. Cá, M. Saraiva</i>
O0569		Deciphering the functional role of distinctive <i>Mycobacterium tuberculosis</i> peptidoglycan modifications in modulating antibiotic resistance and the immune response <i>C. Silveiro* (Lisbon, Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes, M.J. Catalão</i>
O0570		Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitis. <i>J. Barnacle* (London, United Kingdom), A. Davis, R.J. Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula, N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S. Wasserman, G. Meintjes, A. O’ Garra</i>
O0571		Subpopulations in clinical samples of <i>Mycobacterium tuberculosis</i> can give rise to rifampicin resistance and shed light on how resistance is acquired <i>V. Brunner* (Oxford, United Kingdom), P. Fowler</i>
O0572		A systematic comparison of automated <i>Mycobacterium tuberculosis</i> complex whole genome sequencing analysis pipelines <i>R. Spies* (Ho Chi Minh City, Vietnam), D. Crook, T. Peto, P. Fowler, R. Turner, H. Thai, J. Watson, T. Walker</i>
O0573		Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretation <i>Veronique Suttels (Lausanne, Switzerland)</i>
O0574		Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of <i>Mycobacterium tuberculosis</i>: Evaluating Novel Benzothiazinone Derivatives. <i>A. Vocat* (Lausanne, Switzerland), A. Luraschi-Eggemann, C. Antoni, G. Cathomen, D. Cichocka, G. Greub, O. Riabova, V. Makarov, O. Opota, A. Mendoza, S. Cole, A. Sturm</i>
O0575		Rapid drug susceptibility testing of <i>Mycobacterium tuberculosis</i> directly from clinical samples using targeted next-generation sequencing <i>E. Rosendal* (Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo</i>
O0576		Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studies <i>K. Jadhav* (Sas Nagar, India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma</i>
O0577		Multi-drug resistant tuberculosis among migrants in Europe <i>S. Hayward* (London, United Kingdom), K. Rustage, L.B. Nellums, J.S. Friedland, S. Hargreaves</i>

SY120	09:30 – 10:30	Hall 1
1-hour Symposium		
DX		

Year in clinical microbiology

<i>Chairs</i>		<i>Fidelma Fitzpatrick (Dublin, Ireland)</i> <i>Maurizio Sanguinetti (Rome, Italy)</i>
S0339	09:30	<i>Mario Ramirez (Lisbon, Portugal)</i>
S0340	10:00	<i>Anna Papa-Konidari (Thessaloniki, Greece)</i>

ESCMID Global 2025 - Programme

EF081

09:30 – 10:30

Arena 2

ePoster Flash Session

ANT DX

Clinical features and outcome of invasive fungal infections

Chair

Marcus De Melo Teixeira (Brasília, Brazil)

E0596

Management, outcomes and predictors of mortality of *Cryptococcus* infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New ZealandJ. Coussement* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen

E0597

Incidence of invasive fungal infections in hospitalised paediatric patients in EnglandA. Warris* (Exeter, United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz, M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J. Owczarek, C. Castillo, I. Jimenez

E0598

Invasive fungal disease in critically ill patients with cirrhosis: an autopsy studyL. Maessen* (Leuven, Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, M. Peetermans, G. Hermans, Y. Debaveye, E. Van Wijngaerden, S. Van Der Merwe, G. De Hertogh

E0599

Non-*Aspergillus* mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomesC.F. Neoh* (Melbourne, Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Douglas, K. Urbancic, M. Menon, A. Stewart, P. Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, T. Spelman, L. Worth, M. Slavin

E0600

Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective studyL. Nwankwo* (London, United Kingdom), N. Pinnock, A. Shek, C. Hemsley, J. Periselnieris, S. Schelenz, D. Armstrong-James

E0601

How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 yearsS. Wurster* (Houston, United States), T.M. John, J. Ying, D.P. Kontoyiannis

E0602

Emergence of *Wickerhamomyces anomalus* invasive infections in injecting drug usersM. Lefranc* (Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Imbert

E0603

Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French Candida ICU multicenter studyJ.P. Gangneux* (Rennes, France), F. Reizine, J. Henry, L. Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, G. Eustache, T. Belleville, A. Marc, J. Malherbe, P. Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A. Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. Launey, C. Aubron

E0604

Population-based longitudinal study over two decades of *Candida* and *Candida*-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistanceA. Stewart* (Boston, United States), K. Laupland, F. Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, M. Slavin, S. Chen

FO129 11:00 – 12:00 Arena 1
Open Forum

PRO

Predatory journals in CM/ID: from symptoms to cure

Chair Emily G. McDonald (Montreal, Canada)

- F0356 11:00 The genesis of predatory journals: symptoms and root problems Leonard Leibovici (Petah-Tiqva, Israel)
- F0357 11:10 The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals? Till Bärnighausen (Heidelberg, Germany)
- F0358 11:20 The roles of authors and academic institutions: towards governance and regulation Luigia Scudeller (Pavia, Italy)
- F0359 11:30 Bibliometric literacy in scientific publication Lauren Maggio (Chicago, United States)

Co-organised with: CMI Communications Board of Editors

EF089 11:00 – 12:00 Arena 2
ePoster Flash Session

PHET

Emerging Infectious Diseases, Zoonoses and Outbreaks

- E0640 Seasonality of Influenza and Respiratory Syncytial Virus related hospital contacts in Denmark (1999-2021) O. Reza Hosseini* (Hillerod, Denmark), C.L. Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C. Roed, J.G. Holler, B. Lindegaard Madsen, D.M. Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B. Harboe
- E0641 Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us? I. Sanz-Muñoz* (Valladolid, Spain), J. Sánchez-Martínez, C. Rodríguez-Crespo, I. Arroyo-Hernández, C.S. Concha-Santos, M.L. De Dlego, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, A. Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M. Eiros, A. Nogales
- E0642 The UK Imported Fever Service (IFS): National VHF testing 2023-2024 A. Belfield* (Salisbury, United Kingdom), A. Thompson, H. Umpleby, B. Hack, S. Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou, T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E. Warrel
- E0643 Reemergence of Poliovirus in Pakistan: Challenges and Implications for Global Health Security S. Ahmad* (Tampere, Finland)
- E0644 Preparing an emerging infectious diseases unit for high-consequence infectious diseases A. Silva-Pinto* (Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L. Santos
- E0645 Correlation between clinical and wastewater measles positivity rate in three towns of Karachi, Pakistan F. Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S. Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J. Gauld, S. Kroiss, J. Giles
- E0646 Salmonella serovars in wild European hedgehogs (Erinaceus europaeus): an over 12-year monitoring in the Ferrara Province, Italy E. Massella* (Piacenza, Italy), M. Munari, S. Russo, L. Cirasella, C. Torreggiani, R. Taddei, A. Luppi, S. Rubini
- E0647 Clinico-epidemiological and Microbiological Investigation of Diphtheria Outbreak in Odisha, India, 2024 I. Praharaj* (Bhubaneswar, India), S. Panda, S. Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S. Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati
- E0648 Seroprevalence of nine causes of acute febrile illness in rural Cambodia and Thailand using a multiplex assay M. Zhang* (Bangkok, Thailand), R. Tripura, L. Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon, S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude, S. J. Lee, Y. Lubell, T. J. Peto

ESCMID Global 2025 - Programme

EF090

11:00 – 12:00

Arena 3

DX

ePoster Flash Session

Addressing the need for speed: advances in point-of-care testing

Chair

Jennifer Dien Bard (Los Angeles, United States)

- E0649

Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT*E. Brown** (Bristol, United Kingdom), *A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe*
- E0650

Evaluation of the prototype BIOFIRE® nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid hoSt gene expression test*G. Storch** (Saint Louis, Missouri, United States), *M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin*
- E0651

Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnosis of bacterial intestinal infections*P. Lehours** (Bordeaux, France), *Q. Beaufils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain*
- E0652

Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis*N. Younes** (Doha, Qatar), *G. Nasrallah*
- E0653

A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)*S. Y. Choi** (Daejeon, Korea, Republic of), *C. Lee, H.O. Park*
- E0654

Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device*A. Van Der Linden** (Eindhoven, Netherlands), *Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko*
- E0655

Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens*C. Singhal** (Faridabad, India), *S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri*
- E0656

Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein*L. Pommiers** (Gif Sur Yvette, France), *H. Boutal, D. Fras, H. Volland*
- E0657

A smartphone app for point-of-care quantification of lateral flow assays*R. Armiger** (London, United Kingdom), *R. Reid, P. Georgiou, A. Holmes, J. Herberg*

KN121

11:00 – 12:00

Hall 1

PHEI

Keynote Lecture

HIV: from needle parks to injectables

Chairs

Mary Horgan (Dublin, Ireland)
Gölsen Özkaya Sahin (Lund, Sweden)

K0341

11:00

Huldrych Günthard (Zürich, Switzerland)

OS085

11:00 – 12:00

Hall 10

CLN PHEI

1-hour Oral Session

Planes, Pains, and Pathogens: The Perils of Travel Medicine

Chairs

Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)

O0620

Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology*S. Caronni** (Milan, Italy), *M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori*

O0621

Tracing the Itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data*S. Gupta** (Auckland, New Zealand), *S. Thornley, G. Sundborn, C. Grant*

O0622	Molecular epidemiological characterization of enterotoxigenic and enteroaggregative <i>Escherichia coli</i> causing traveller's diarrhoea and their relationship with clinical features <i>P. Oliveras Julia* (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath, R.M. Albarracín, M.E. Valls, M.J. Álvarez-Martínez, M. Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J. Vila</i>
O0623	Bites and bytes – can digital surveillance of travellers' illness predict outbreaks? <i>N. Hedrich* (Zürich, Switzerland), T. Lovey, P. Schlagenhauf</i>
O0624	Travel-associated infections and diseases: a retrospective cross-sectional study <i>M. Trojanek* (Prague, Czech Republic), M. Trojánek, V. Grebenyuk, V. Jegorova, P. Hubacek, A. Briksí, J. Havlova, K. Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O. Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z. Uhříková, M. Vidlička, M. Štefan, F. Stejskal</i>

OS086	11:00 – 12:00	Hall 11
	1-hour Oral Session	

Marker based diagnostics: forget the pathogen		
Chairs	Virginie Prendki (Genève-Thônex, Switzerland) Suzanne Van Asten (Nijmegen, Netherlands)	

O0625	A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infections <i>N. Whitfield* (Sunnyvale, United States), C. Lu, O. Liesenfeld</i>
O0626	Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infection <i>T. Gottlieb* (Tirat Carmel, Israel), L. Bont, A. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden, B.P. Muller</i>
O0627	Diagnostic accuracy of combined urine lipocalin 2 and copper test in acute pyelonephritis or cystitis <i>V. Havlicek* (Prague, Czech Republic), J. Hrbacek, T. Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A. Stevens, J. Novak, R. Dobias, R. Zachoval</i>
O0628	Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung Disease <i>P. Escalante* (Rochester, Mn, United States), B. Piatkowski, B. Pathakumari, V. Van Keulen, N. Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T. Peikert</i>
O0629	Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort study <i>O. Beránek* (Prague, Czech Republic), R. Prusa, M. Trojánek, O. Beranek, Z. Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan, V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V. Grebenyuk</i>

PM2	11:00 – 12:00	Hall 12
	Panel Discussion	

AMR and vaccines		
Chairs	Charlotte Vernhes (Brussels, Belgium) Ghada Zoubiane (London, United Kingdom)	

L005	11:00	Overview of the current evidence of the impact of vaccines on AMR <i>Adam Cunningham (Birmingham, United Kingdom)</i>
L006	11:20	Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR <i>Adam Cunningham (Birmingham, United Kingdom), Sipho Kenneth Dlamini (Observatory, South Africa), Erin Duffy (Boston, United States), Mateusz Hasso-Agopsowicz (Geneva, Switzerland)</i>

ESCMID Global 2025 - Programme

SY126 **11:00 – 12:00** **Hall 13**
1-hour Symposium

CLN

Why is the concept of complicated UTI so complicated?

Chairs *Gernot Bonkat (Basel, Switzerland)*
Maeve Doyle (Waterford, Ireland)

S0350 **11:00** **The concept of complicated UTI: underlying conditions matter** *Suzanne Geerlings (Amsterdam, Netherlands)*

S0351 **11:30** **The concept of complicated UTI: the site of infection matters most** *Jesús Rodríguez-Baño (Seville, Spain)*

Co-organised with: ESCMID Education Subcommittee

ME128 **11:00 – 12:00** **Hall 14**
Meet-the-Expert

TRN

How to apply organoid models to study infectious disease

M0354 **11:00** *Jennifer Rohn (London, United Kingdom)*

M0355 **11:12** *Nathalie Sauvonnnet (Paris, France)*

OS087 **11:00 – 12:00** **Hall 15**
1-hour Oral Session

AMR

TRN

Antimicrobial resistance around birth

Chairs *Julia Anna Bielicki (London, United Kingdom)*
Surbhi Malhotra-Kumar (Antwerp, Belgium)

O0630 **Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs** *A. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray*

O0631 **Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk** *A. Chakraborty* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora*

O0632 **Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units** *A. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar*

O0633 **Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut** *V. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg*

O0634 **Dynamics of gut resistome and mobilome in early life: A meta-analysis** *V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov*

OS088 **11:00 – 12:00** **Hall 16**
1-hour Oral Session

CLN

DX

VAX

Advancing diagnostics and preventive measures in hemato-oncological patients

Chairs *Dina Averbuch (Jerusalem, Israel)*
Malgorzata Mikulska (Genoa, Italy)

O0635 **Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy** *M. Freire* (Sao Paulo, Brazil), A. Villani, Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin*

O0636	Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the cause of fever? <i>A. Douglas* (Melbourne, Australia), L. Caly, M.A. Slavin, I. Savic, J. Moselen, A. Aziz, G. Papadakis, G. Ng, J. Druce, K. Thursky</i>
O0637	Results of Optifil study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosis <i>F. Lanternier* (Paris, France), C. Maunoury, F. Montravers, F. Marquant, S. Poiree, C. Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E. Blanchard, O. Lortholary</i>
O0638	Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort study <i>S. Haggenburg* (Amsterdam, Netherlands), J. Schnyder, H. Garcia Garrido, M. Schoordijk, A. Reiners, B. Meek, M. Hazenberg, A. Goorhuis</i>
O0639	Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantation <i>J. Lötscher* (Basel, Switzerland), C.S. Walti, J. Halter, N. Khanna, S. Heller, S. Schmid, K. Leuzinger</i>

O082	11:00 – 12:00	Hall 2
	1-hour Oral Session	

New insights in bloodstream infections and endocarditis		
Chairs	Barbara Hasse (Zurich, Switzerland) José M. Miro (Barcelona, Spain)	

O0605	Different from the start – Sex differences in Staphylococcus aureus bacteremia mortality <i>A. Westgeest* (Leiden, Netherlands), M. Lambregts, F. Ruffin, V.G. Fowler, J.T. Thaden</i>
O0606	Tracking evolution in action during invasive Staphylococcus aureus infections: the BARISTA study <i>S. Giuliani* (Melbourne, Australia), D. Daniel, M. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A. Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen, M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S. Tong, J. Kwong, B. Howden</i>
O0607	Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trial <i>S. Ong* (Melbourne, Australia), R. Pinto, A. Rishu, S. Tong, R. Commons, J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-Wiens, T. Lee, S. Lothar, D. Macfadden, J. Marshall, V. Martel-Laferrrière, M. Mayette, E. McDonald, J. Neary, J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L. Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young, R.A. Fowler, N. Daneman</i>
O0608	Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology study <i>N. Macesic* (Melbourne, Australia), J. Hawkey, J.A. Wisniewski, A. Peleg</i>
O0609	Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohort <i>A. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D. Monzón, M. Valerio, M. Hernandez Meneses, J.M. Miró, M. Cobo Belastegui, A. De Alarcón, R. Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L. Garcia-Alvarez, L. Boix</i>

SY122	11:00 – 12:00	Hall 3
	1-hour Symposium	

Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?		
Chairs	Pavel Drevinek (Prague, Czech Republic) Helle Krogh Johansen (Copenhagen, Denmark)	

ESCMID Global 2025 - Programme

S0342	11:00	The lung microbiome of people with cystic fibrosis receiving modulator therapy <i>Sebastien Boutin (Lübeck, Germany)</i>
S0343	11:30	Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary? <i>Alessandra Bragonzi (Milano, Italy)</i>
Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology		

SY123	11:00 – 12:00	Hall 4
	1-hour Symposium	

IPC

Infection prevention and control and intensive care: challenges and solutions		
Chairs	<i>Antonios Katsounas (Bochum, Germany)</i> <i>Claire Roger (Nimes, France)</i>	

S0344	11:00	Intensive care unit (ICU) and infection: two sides of a coin <i>Reto Schuepbach (Zurich, Switzerland)</i>
S0345	11:20	Ventilator- associated pneumonia (VAP) and ICU enviroment: how can we improve practices? <i>Despoina Koulenti (London, United Kingdom)</i>
Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee		

OS083	11:00 – 12:00	Hall 5
	1-hour Oral Session	

CLN

DX

PHEI

Don't 'rash' it		
Chairs	<i>Heli Harvala (Turku, Finland)</i> <i>Catherine Moore (Cardiff, United Kingdom)</i>	

O0610	Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024 <i>B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca, A. Toyran, S. Aydoğan, B. Dinç</i>	
O0611	Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study <i>M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffioti</i>	
O0612	The dark side of the „fifth disease” endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases <i>B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko</i>	
O0613	Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024 <i>A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey</i>	
O0614	Measles virus in the context of subacute sclerosing panencephalitis (SSPE) <i>J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous</i>	

SY124	11:00 – 12:00	Hall 6
	1-hour Symposium	

CLN

Antimicrobial prescribing: myths or pearls?		
Chairs	<i>Massimo Fantoni (Roma, Italy)</i> <i>Spyros Pournaras (Athens, Greece)</i>	

S0346	11:00	Why treat IV when PO is possible? <i>Bradley Spellberg (Los Angeles, United States)</i>
S0347	11:30	De-escalation of antibiotic therapy to narrow-spectrum IV drugs <i>Flaminia Olearo (Hamburg, Germany)</i>
Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee		

SY125	11:00 – 12:00	Hall 7
	1-hour Symposium	

DX

Cutting edge methods in mycology

Chairs *Katrien Lagrou (Leuven, Belgium)*
Antonio Vena (Genova, Italy)

- | | | |
|-------|-------|---|
| S0348 | 11:00 | Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT <i>Ana Fernández-Cruz (Majadahonda (Madrid), Spain)</i> |
| S0349 | 11:30 | Exploring the intersection of fungal metagenomics and medical mycology <i>Marcus De Melo Teixeira (Brasília, Brazil)</i> |

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP), Società Italiana per la Terapia Antinfett

OS084	11:00 – 12:00	Hall 8
	1-hour Case Session	

CLN

Weird and unusual infections

Chairs *Murat Akova (Ankara, Türkiye)*
Muge Cevik (St Andrews, United Kingdom)

- | | | |
|-------|--|---|
| O0615 | | Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases <i>E. Hasivirwe Vakaniaki* (Kinshasa, Congo, the Democratic Republic of the), N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E. Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti Nundu</i> |
| O0616 | | First case of Oropouche fever in the South of Spain <i>/. Pérez Hernández* (Málaga, Spain), I.A. Pérez-Hernández, E. Basallote Leal, M.A. Sempere Alcocer, B. O´donell Cortés</i> |
| O0617 | | Wild hippopotamus bite and <i>Aeromonas</i> spp. infection: a treatment challenge. First case report <i>.J. Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon, M.V. Montoya Garcia, A. Múnera-Echeverri, F.F. Jiménez Quiroz, J. Alza-Arcila</i> |
| O0618 | | From the sea to the land: an emerging species <i>K. Rodríguez Martínez* (Santo Domingo, Dominican Republic), K. Rodríguez, A. Fernández, K. Espaillat, J. Cruz, X. Rodríguez, T. Flores</i> |
| O0619 | | The first findings of <i>Wohlfahrtiimonas chitiniclastica</i> and <i>Ignatzschineria</i> species bacteremia in two cases with maggot infested wounds in Scandinavia <i>A.L. Engsbros* (Slagelse, Denmark), C. Mortensen, R. Jul, W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp</i> |

ME127	11:00 – 12:00	Hall 9
	Meet-the-Expert	

AMR

DX

EUCAST: What's new in susceptibility testing

- | | | |
|-------|-------|--|
| M0352 | 11:00 | <i>Erika Matuschek (Växjö, Sweden)</i> |
| M0353 | 11:12 | <i>Rafael Canton (Madrid, Spain)</i> |

Co-organised with: EUCAST Steering Committee

ME134	13:30 – 14:30	Hall 16
	Meet-the-Expert	

CLN

VAX

The older solid organ transplant recipient: between frailty, immunosenescence and infection

ESCMID Global 2025 - Programme

M0367 **13:30** *Maheen Abidi (Denver, United States)*

M0368 **13:42** *Alaa Atamna (Petah-Tikva, Israel)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

SY131 13:30 - 14:30 Hall 2

13:30 - 14:30

1-hour Symposium

AMR PHEI VAX

Vaccines and antimicrobial resistance

Chairs *Iva Butic (Zagreb, Croatia)*
Zitta Barrella Harboe (Hillerød, Denmark)

S0361 13:30 The impact of current and future vaccines on AMR: from pneumococcal to COVID-19 *Mateusz Hasso-Agopsowicz (Geneva, Switzerland)*

S0362 14:00 Can vaccines against AMR be translated into policy? *William Hausdorff (Washington DC, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)

EW135 12:30 – 15:30 Hall 3

13:30 - 15:30

Educational Session

PRO

Transforming your research idea into an appropriate study design

Chairs *Casandra Bulescu (Bucharest, Romania)*
Mary Horgan (Dublin, Ireland)

W0369 13:30 **Designing high-quality research studies: methodological skills and knowledge** *Mical Paul (Haifa, Israel)*

W0370	13:50	How to design and run scientific studies using AI agents as research assistants <i>Alyssa Bilinski</i> <i>(Cambridge, United States)</i>
-------	-------	---

W0371	14:10	Designing your first study: how to construct a workable project when your work environment may not help <i>Thomas Tånadén (Uppsala, Sweden)</i>
-------	-------	---

W0372	14:30	Bridging early-career professionals with partners and seniors <i>Giorgia Caruana (Sion, Switzerland)</i>
-------	-------	---

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee

FO136	13:30 - 14:30	Arena 1
--------------	----------------------	----------------

13:30 - 14:30

Open Forum

PRO

Diversity in CM and ID: gender gaps and policy traps

Chair Andre Fuchs (Augsburg, Germany)

F0373	13:30	How to avoid parity traps in ID/CM research? <i>Muge Cevik (St Andrews, United Kingdom)</i>
--------------	--------------	--

F0374 13:40 Gender gaps in visibility at scientific conferences *Sarah Delliere (Paris, France)*

F0375	13:50	Psychological determinants of empowerment at individual and societal level <i>Tba</i>
--------------	--------------	--

Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission

EF093 **13:30 – 14:30** **Arena 2**

13:30 – 14:30

ePoster Flash Session

CLN
DX

Real world experience with modern HIV treatment: the art of ART

E0668 **Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysis** *M. Bongiovanni** (Lugano, Switzerland), *B. Barda, G. Barilaro, E.*

- E0669** **Assessment of HIV-DNA, immune activation and senescence biomarkers during injectable cabotegravir/rilpivirine treatment***M. Mazzitelli* (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset, D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan*
- E0670** **Impact of Cabotegravir plus Rilpivirine Long-Acting on Body Composition: Results from a Prospective Study***A. De Vito* (Sassari, Italy), A. Marongiu, A. Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A. Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A. Spanu, G. Madeddu*
- E0671** **Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Older Woman with Polypharmacy and Comorbidities***M. Rosas Cancio-Suárez* (Madrid, Spain), A. Moreno, S. Del Campo Terrón, M.J. Vivancos, A. G. García De Morales, J. Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano, R. Ron, M.J. Cárdenas-Isasi, M. Vélez-Díaz-Pallarés, S. Moreno, M.J. Pérez-Elías*
- E0672** **Two-year comparative analysis of lipid profile changes between INSTI-based single tablet regimens in treatment-naïve people living with HIV: real-world evidence from South Korea***S. Y. Lim* (Seoul, Korea, Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J. Bang*
- E0673** **Long-acting antiretroviral therapy in PLWH with prior HBV exposure***J. Mateo Gonzalez* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D. Martinez-Perez, J. Martinez-Andres, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, M. Garcia-Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro*
- E0674** **Protease inhibitors in today's antiretroviral landscape: are we tracking resistance?***J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-Martin, M. Montero-Alonso, J.L. López-Hontangas*
- E0675** **Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial***L. Srikham* (Sakon Nakhon, Thailand), S. Sriphoosanaphan, O. Putcharoen*
- E0676** **Impact of maternal dolutegravir on growth outcomes of HIV-exposed uninfected children: A prospective study***E. Yoram* (Morongoro, Tanzania, United republic of), E. Luoga, S. Glanzman, F. Vanobberghen, M. Weisser, E. Dotto, G.J. Mollel, G. Sigalla, E. Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris*

EF094

13:30 - 14:30

Arena 3

ePoster Flash Session



Speed, convenience and performance of virus diagnostic methods

Chair

Hans H. Hirsch (Basel, Switzerland)

- E0677** **Prospective evaluation of a rapid diagnostic test in a tertiary hospital and prospects for reinforced dengue surveillance in Catalonia (Northeastern Spain)***L. Horvath* (Barcelona, Spain), L. Horvath Ruiz, J. Naverro, M. Navarro, M. Pujada, A. Navarro, M. Garrido, B. Herreras, P. Rodríguez, N. Zancada, B. Escudero-Perez, M.J. Martinez*
- E0678** **Sequence-Independent Single-Primer Amplification (SISPA) followed by Next-Generation Sequencing for Diagnosing Viral Respiratory Tract Infections***P. Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A.V. Schwarzbold*
- E0679** **Seasonal trends and co-infection dynamics of respiratory pathogens: insights from a yearlong study***Z. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Meletis, A. Greco, T. Chatziantoniou, R. Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*
- E0680** **Speed meets reliability in respiratory infections diagnosis with a new nucleic acid extraction workflow***L. Pastor-Bernad* (San Mateo De Gállego, Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-Rodríguez, H. Alonoso, C. Giménez-Rota*

ESCMID Global 2025 - Programme

E0681	Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms <i>L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchi, M. Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri</i>
E0682	Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR <i>C. Cuesta Chasco* (Barcelona, Spain), S. Alex, M. M^a Ángeles, C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina</i>
E0683	Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment <i>E. Vanhulle* (Bilthoven, Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Benschop</i>
E0684	Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States <i>A. Cuber* (Los Angeles, United States), S. Butler-Wu</i>
E0685	Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma <i>F. Garcia* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. García, M. Buti Ferret</i>

KN130	13:30 – 14:30	Hall 1
	Keynote Lecture	

Infectious disease challenges in an ever-changing environment

<i>Chairs</i>	<i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Annelies Zinkernagel (Zurich, Switzerland)</i>
---------------	--

K0360	13:30	<i>Pamela Rendi Wagner (Stockholm, Sweden)</i>
-------	-------	--

PM3	13:30 – 14:30	Hall 12
	Meet-the-Innovators	

Future prospects of electronic clinical decision support systems in stewardship programs

L007	13:30	Opportunities for clinical decision support systems in infectious disease management <i>Nathan Peiffer-Smadja (Paris, France)</i>
L008	14:00	CDSS and AMS programs: the Lumed example <i>Valiquette Louis (Sherbrooke, Canada)</i>

SY132	13:30 – 14:30	Hall 13
	1-hour Symposium	



Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art

<i>Chairs</i>	<i>Werner Ruppitsch (Vienna, Austria)</i> <i>Balaji Veeraraghavan (Vellore, India)</i>
---------------	---

S0363	13:30	Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment <i>Thomas Schön (Kalmar, Sweden)</i>
S0364	14:00	Antimicrobial resistance prediction using whole genome sequencing <i>Patricia Simner (Rochester, United States)</i>

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee

OS092	13:30 – 14:30	Hall 14
	1-hour Case Session	

CLN

Mycobacterial mayhem

Chairs *Seif Al-Abri (Muscat, Oman)*
Linda Aulin (Leiden, Netherlands)

- O0663** **Limitations of the Xpert® MTB/RIF assay: A series of four clinical cases***A. Haas* (Salt Lake City, United States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C. Church, M. Narita, V. Escuyer, S. Shakir*
- O0664** **Pharmacokinetic analysis of blood and cerebrospinal fluid cotrimoxazole concentrations in a patient with tuberculous meningitis***W. Nie* (Beijing, China), N. Chu*
- O0665** **Is this the first case of Mycobacterium abscessus infection in humans?***S. Pérez-Recio* (Barcelona, Spain), M.D. Grijota-Camino, A. Lleras, A. Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé Fernández, F. Alcaide, M. Santin*
- O0666** **Diagnostic Aspects of a Bacillus Calmette-Guérin Infection Following Intravesical Treatment for Bladder Cancer***K.J. Kim* (Seoul, Korea, Republic of), J.H. Cha, S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho*
- O0667** **Mycobacterium abscessus. Is Shorter Antibiotic Therapy Combined with Surgery Sufficient?***M.J. Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M. Caixeiro, M. Alves, R. Macedo, P. Pacheco*

SY133	13:30 – 14:30	Hall 15
	1-hour Symposium	

ANT

Probiotics in infectious diseases: current state-of-play

Chairs *Nicolas Bénéch (Lyon, France)*
Silvia Corcione (Turin, Italy)

- S0365** **13:30** **Probiotics in infectious diseases: the perfect complement to antimicrobial therapies?***Lena Biehl (Cologne, Germany)*
- S0366** **14:00** **The horizon of next generation probiotics for infectious diseases***Cormac Gahan (Cork, Ireland)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

OS091	13:30 – 14:30	Hall 5
	1-hour Oral Session	

AMR

TRN

Genomic and molecular drivers of bacterial virulence and resistance

Chairs *Ecaterina Noroc (Chisinau, Moldova, Republic of)*
Guido Werner (Wernigerode, Germany)

- O0658** **Characterization of the virulence shaping and adaptability in the methicillin-resistant *Staphylococcus aureus* ST9 lineage.***Y. Chen* (Hangzhou, China), L. Sun*
- O0659** **Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology***S. David* (Oxford, United Kingdom), C. Seddon, J. Wong, N. Ishimoto, S. He, J. Bradshaw, W.W. Low, D. Aanensen, G. Frankel, K. Beis*
- O0660** **Clinical carbapenem-resistant *Klebsiella pneumoniae* (CRKP) strains carrying a mutH mutation are hypermutators that have heightened virulence and readily develop β -lactam/ β -lactamase resistance.***S. Cheng* (Pittsburgh, United States), C. Clancy, M.H. Nguyen, B. Hao, G. Liu*
- O0661** **Genomic insights into the new prophages of MDR *Pseudomonas aeruginosa*: an example of phage-host-phage interaction***A. Uskudar Guclu* (Ankara,*

ESCMID Global 2025 - Programme

Türkiye), S. Unlu

O0662

Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis*R. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk*

EF099

14:45 – 15:45

Arena 1

ePoster Flash Session



Infection Prevention in Action: Innovations, Insights, and Global Intervention

Chair Allison Mcgeer (Toronto, Canada)

E0706

A *Candida auris* cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking*C. Harless* (Silver Spring, United States), J. Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. Bennett, P. McGann, F. Lebreton*

E0707

Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios*A. Rearte* (Buenos Aires, Argentina), F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi*

E0708

Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023–2024 winter season*C. Savulescu* (Paris, France), M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone*

E0709

Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital*N. Khanafer* (Lyon, France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud*

E0711

Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay*V. Khillan* (New Delhi, India), V.G. Nag P, P. Kale, A. Paul, A. Saran*

E0712

Air and surface sampling around mpox Clade 1b in hospitals in the UK*S. Gould* (Liverpool, United Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning*

E0713

Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024*A. Baller* (Geneva, Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton Hurwitz, M. Moon*

E0714

The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization*M. Colaneri* (Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, R. Bruno*

EF100

14:45 – 15:45

Arena 2

ePoster Flash Session



Cefiderocol: an efficient Trojan horse?

Chair Anna Sramkova (Pilsen, Czech Republic)

E0715

Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System*B. Li* (Beijing, China), S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang*

E0716

The hidden link between cefiderocol resistance and increased virulence in *Klebsiella pneumoniae*. Insights from a TraDIS-based investigation*E. Eger**

(Greifswald, Germany), L. Guardabassi, K. Schaufler, J.U. Müller, B. Jana, M. Schwabe, Y. Ma, M. Pirolo

- E0717** **Resistance profiles of Carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?** I. Baltas* (London, United Kingdom), T. Patel, A.L. Soares
- E0718** **Impact of cefiderocol therapy on patient survival across different multi-drug resistant Gram-negative bacilli infections: insights from the SUSANA cohort.** N. Corti* (Monza, Italy), M. Faltoni, L. Mezzadri, E. Ricci, M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro, S. Rusconi, A. Mastroianni, M.A. Carleo, G. Cenderello, L. Bisi, G. Madeddu, P. Bonfanti
- E0719** **Decoding resistance: investigating cefiderocol's battle against carbapenem-resistant *Acinetobacter baumannii*** Y.T. Lee* (Taipei, Taiwan, China)
- E0720** **Long-read sequencing reveals novel genetic factors in cefiderocol resistance in *Pseudomonas aeruginosa* ATCC 27853: A stepwise adaptive evolution study** M. Cardoso* (Groningen, Netherlands), B.B. Xavier, B. Sinha, J. W. A. Rossen, A. Kumar Bari, T. T. Severs
- E0721** **Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales clinical isolates causing infection in hospitals in Europe and adjacent regions** R. Mendes* (North Liberty, United States), A. Scullin, D. Beekman, Z. Kockler, J.M. Maher, H.S. Sader, M. Castanheira
- E0722** **Cefiderocol activity against planktonic and biofilm forms of β -lactamase-producing *Pseudomonas aeruginosa* from people with cystic fibrosis** G. Fabrizio* (Rome, Italy), M. Truglio, I. Cavallo, F. Sivori, M. Francalancia, R. Riveros Cabral J, S. Petrolo, L. Pamparau, M. Comar, D. Compagnino, M. Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F. Pimpinelli, E.G. Di Domenico
- E0723** **Activity of cefiderocol against clinical isolates of *Pseudomonas aeruginosa* collected from five European countries as part of SENTRY antimicrobial surveillance program 2020-2023** C. Longshaw* (London, United Kingdom), J. Maher, R. Mendes, H. Yamashiro, Y. Yamano

EF101 **14:45 – 15:45** **Arena 3**
ePoster Flash Session

VAX

Immunology of bacterial pathogens

- E0724** **Serotype 38 *Streptococcus pneumoniae* emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands** K. Hajji* (Bilthoven, Netherlands), I. Wróbel-Pawelczyk, J. Van Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens, N. Van Sorge, K. Trzciński, M. Van Der Linden, A. Skoczyńska, L. Visser
- E0725** **Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116: a secondary analysis of five phase 3 studies** M. Esteves Jaramillo* (Rahway, United States), J. Li, H. Platt, W. Hu, W. Xu, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald
- E0726** **Baseline serotype-specific IgG responses to pneumococcal vaccines in type 2 diabetes: implications for vaccine strategy in vulnerable populations** S. Mettingal Ramakrishnan* (Bsk 2nd Stage, Bangalore, India), V. Govindan, M.M. Akhila, N. Geetha, K.L. Ravikumar
- E0727** **Protection against invasive meningococcal disease and gonorrhoea, 5 years post introduction of a 4CMenB immunisation program in infants and adolescents in South Australia** H. Marshall* (Adelaide, Australia), B. Wang, L. Giles, P. Andraweera, M. Mcmillan, S. Almond, R. Beazley, J. Mitchell, J. Sisnowski, C. Bell, L. Flood, J. Ward
- E0728** **Molecular epidemiology and correlates of protection among group B *Streptococcus* from carriage and disease: assessing vaccine coverage in Brazil** T. Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E. Bressan, A. Rio Tinto, S. Fracalanza, L. Teixeira

ESCMID Global 2025 - Programme

E0729		Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants. <i>R. Namakula*</i> (Bergen, Norway), <i>V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik</i>
E0730		Immune signature against <i>Klebsiella pneumoniae</i> proteins in a mother-baby cohort from Blantyre, Malawi. <i>E. Heinz*</i> (Glasgow, United Kingdom), <i>J. Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey</i>
E0731		A comprehensive computational mapping of B-cell epitopes in the <i>Klebsiella pneumoniae</i> porinome. <i>S. Prieto Martín Gil*</i> (Madrid, Spain), <i>S. Prieto Martín Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín Galiano</i>
E0732		Chronic infection induces a broadly neutralizing antibody response to Elastase B of <i>Pseudomonas aeruginosa</i>. <i>A. Albus*</i> (Cologne, Germany), <i>D. Kolling, K. Rox, D. Holzmänn, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybníček, A. Simonis</i>
<hr/>		
KN137		14:45 – 15:45 Hall 1
	TRN	Keynote Lecture
<i>Staphylococcus aureus</i> host-microbe interaction: ecology, disease, and vaccine development		
Chairs	<i>Werner Ruppitsch</i> (Vienna, Austria) <i>Annelies Zinkernagel</i> (Zurich, Switzerland)	
K0376	14:45	<i>Juliane Bubeck Wardenburg</i> (St. Louis, United States)
<hr/>		
ME140		14:45 – 15:45 Hall 11
	DX TRN	Meet-the-Expert
Bioinformatic tools from start to finish		
M0381	14:45	<i>Vítor Borges</i> (Lisbon, Portugal)
M0382	14:57	<i>Clare Sloggett</i> (Melbourne, Australia)
<hr/>		
ME141		14:45 – 15:45 Hall 13
	AMR CLN	Meet-the-Expert
AI use in antimicrobial stewardship		
M0383	14:45	<i>Shruti Gohil</i> (Irvine, United States)
M0384	14:57	<i>Jose Ramon Pano-Pardo</i> (Zaragoza, Spain)
<hr/>		
OS097		14:45 – 15:45 Hall 14
	PHEI	1-hour Oral Session
Update on zoonotic and enteric infections		
Chairs	<i>Steen Ethelberg</i> <i>Kavitha Saravu</i> (Manipal, India)	
O0696		A large-scale epidemiological study of <i>Campylobacter</i> employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK. <i>B. Lopes*</i> (Middlesbrough, United Kingdom), <i>A.S. Boatey-Biko</i>
O0697		Population dynamics and evolution of multidrug resistant clones of <i>Shigella sonnei</i> in Metropolitan France. <i>C. Silva Nodari*</i> (Paris, France), <i>I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill</i>

O0698	Shiga toxin-producing <i>Escherichia coli</i> O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data <i>L. Mcgeoch*</i> (London, United Kingdom), O. Quinn, C. Sawyer, A. Douglas, C. Jenkins, S. Balasegaram
O0699	Incidence, clinical presentation, and outcomes of <i>Pasteurella</i> infections: a population-based Danish study <i>L. Øbo Larsen*</i> (8200, Denmark), L.Ø. Larsen, H.L. Nielsen, K.K. Søgaaard
O0700	Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study <i>H. Wang*</i> (Shanghai, China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang

OS098	14:45 – 15:45	Hall 15
	1-hour Case Session	

Opportunistic infections in the Immunocompromised		
Chairs	<i>Aleksandra Barac</i> (Belgrade, Serbia) <i>Olivier Lortholary</i> (Paris, France)	
O0701	Dog scratch disease? A case of <i>Vibrio vulnificus</i> in a liver transplant patient <i>E. Kim*</i> (Galveston, United States), A. Covington	
O0702	Mpox infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility <i>J. Bini Viotti*</i> (Miami, United States), J. Bini	
O0703	Histoplasmosis in Hansen's Disease: Thalidomide for TNF-alpha Inhibition in ENL with a Risk of Opportunistic Infections <i>K.K. Vaitheeswaran*</i> (Delhi, India), M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal, R. Kumar, Y. Dharmashaktu	
O0704	Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid <i>M. Pellegrino*</i> (Modena, Italy), V. Todisco, S. Generoso, L. Benassi, E. Franceschini, F. Damiano, G. Donati, C. Mussini, A. Cervo	
O0705	Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges <i>M. Meroi*</i> (Verona, Italy), M. Morra, M.E. De Rui, E. Tacconelli, F. Soldani	

SY139	14:45 – 15:45	Hall 16
	1-hour Symposium	

How to manage bacterial meningitis in low resource settings		
Chairs	<i>Joseph Donovan</i> (Ho Chi Minh City, Vietnam) <i>Christina Obiero</i> (Kilifi, Kenya)	

S0379	14:45	Bacterial meningitis diagnosis and surveillance <i>Divya Deodhar</i> (Muscat, Oman)
S0380	15:05	Clinical presentation and management of CNS infections <i>Kartika Maharani</i> (Jakarta, Indonesia)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)

OS095	14:45 – 15:45	Hall 2
	1-hour Oral Session	

Community respiratory tract infections: latest trends and approaches		
Chairs	<i>Catia Cilloniz</i> (Barcelona, Spain) <i>Aurélien Dinh</i> (Garches, France)	

O0686	<i>Mycoplasma pneumoniae</i> increase in 2023/24 causes disease in adults in Europe <i>B.M.M. Streng*</i> (Utrecht, Netherlands), C. Prat Aymerich, L. Bont, P. Meyer Sauteur, M. Bonten, A. Van Rossum	
O0687	Serotype distribution of pneumococcal community-	

ESCMID Global 2025 - Programme

	acquired pneumonia in hospitalized adults in Germany <i>D. Karssen* (Utrecht, Netherlands), L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich</i>
O0688	Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis <i>J. Wei* (Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker, D. Eyre</i>
O0689	Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia <i>F. Al-Zergani* (Hvidovre, Denmark), C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield</i>
O0690	Oropharyngeal carriage of gut-derived Enterobacterales increases RTI risk in long-term aged care residents <i>S. Miller* (Adelaide, Australia), F. Zhang, S. Taylor, A. Shoubbridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers</i>

SY138	14:45 – 15:45	Hall 4
	1-hour Symposium	

AMR

Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading?

<i>Chairs</i>	<i>Yesim Besli (Istanbul, Türkiye)</i> <i>Spyros Pournaras (Athens, Greece)</i>
---------------	--

S0377	14:45	Carbapenemase-producing Enterobacterales: the not so good, the bad and the ugly <i>Arjana Tambic Andrasevic (Zagreb, Croatia)</i>
S0378	15:15	The <i>P. aeruginosa</i> frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome <i>Katy Jeannot (Besançon, France)</i>

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

OS096	14:45 – 15:45	Hall 5
	1-hour Oral Session	

AMR

Trends in antifungal resistance

<i>Chairs</i>	<i>Alexandre Alanio (Paris, France)</i> <i>Ana Alastruey-Izquierdo (Madrid, Spain)</i>
---------------	---

O0691	Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies <i>K. Schmidlin* (Tempe, United States), K. Geiler-Samerotte</i>
O0692	Role of the C2585G substitution in the <i>MRR1</i> gene in the development of azole resistance in <i>Candida parapsilosis sensu strictu</i> <i>I. Franconi* (Pisa, Italy), P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone</i>
O0693	Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years <i>J. Guinea* (Madrid, Spain), P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz</i>
O0694	A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against <i>Candida auris</i> with EUCAST broth microdilution reference methodology <i>J. Meletiadis* (Haidari, Greece), J. Guinea, S. Arikani-Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup</i>
O0695	Decoding <i>Candida auris</i> Resistance in Latin America: <i>Candida.app</i> vs. <i>Pathogenwatch</i> <i>J. Acosta España* (Quiro, Ecuador), P. Eduarda, J.D. Acosta-España, A.</i>

SY144 16:15 – 17:15 Hall 14

1-hour Symposium

PHEI VAX

What's the role of infant and maternal immunisation for paediatric RSV prevention?

Chairs

Joanne M. Langley (Halifax, Canada)
 Peter Openshaw (London, United Kingdom)

S0391 16:15 Pros and cons of passive infant immunisation with mAb before their first RSV season *Federico Martín-Torres (Santiago De Compostela, Spain)*

S0392 16:45 Pros and cons of maternal vaccination in preventing severe RSV infections in infants. *Anne Vergison (Luxembourg, Luxembourg)*

EF104 16:15 – 17:15 Arena 1

ePoster Flash Session

DX PHEI

Cutting-edge technologies to improve viral diagnostics

Chair

Patricia Alvarez (Rio De Janeiro, Brazil)

E0743 How straightforward is the switch from qPCR to dPCR in a routine lab setting for quantification of Varicella-zoster virus in CSF samples? *A. Baumhögger* (Bochum, Germany), T. Bähr, G. Geis, S. Gatermann*

E0744 A novel biosensor for the detection of RSV infection *C. Zannella* (Naples, Italy), F. Passeggio, F. Napolitano, A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L. Zeni, M. Galdiero, G. Portella, N. Cennamo*

E0745 Insufficient sexual health bloods don't always need throwing away! *S. Hutchings* (Bristol, United Kingdom), R. Hopes, P. North, W. Stoate, M. Murphy, G. Beckley, J. Gabb*

E0746 A comparison of 4 HAV serology assays: the value of consensus results as a reference standard *T. Chin* (Ghent, Belgium), E. Padalko*

E0747 Advancing herpesvirus diagnostics: clinical evaluation of a high-performance real-time PCR assay *H. Alonso-Ezcurra* (Zaragoza, Spain), S. Lucea, C. Escolar, H. Alonso*

E0748 Evaluation of microbiological techniques for the diagnosis of West Nile Virus in the Virgen del Rocío hospital area (Sevilla, Spain). *M. Aznar Fernandez* (Seville, Spain), M. Aznar, C. Lozano, L. Merino, M.J. Pérez, J.L. García, C. Cintora, J.A. Lepe*

E0749 Development of Non-Cross-Reactive Monoclonal Antibodies Against West Nile Virus and Usutu Virus Non-Structural Protein 1 to Improve Early Diagnosis *M. Ceconi* (Antwerp, Belgium), K. Ariën, P. Delputte*

E0750 Enhancing Diagnostics and Global Standards through the QCMD Viral Metagenomics EQAG. *Sutton* (Glasgow, United Kingdom), D. Montgomery, E. McCulloch, A. Ricketts*

E0751 Analysis of HIV-1 drug-resistance in newly diagnosed subjects using Next Generation Sequencing *V. Micheli* (Milan, Italy), F. Bracchitta, L. Morelli, A. Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci*

EF105 16:15 – 17:15 Arena 2

ePoster Flash Session

ANT CLN TRN

New data in non-tuberculous mycobacterial disease

Chair

Lorenzo Guglielmetti (Paris, France)

E0752 Deciphering genotypic resistance to amikacin in *Mycobacterium abscessus* using whole genome sequencing and a specific pipeline (GenoMAB) *C.*

ESCMID Global 2025 - Programme

	<i>Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau</i>
E0753	<i>Pseudomonas aeruginosa</i> rapidly kills <i>Mycobacterium abscessus</i> in dual-species biofilms <i>in vitro</i> <i>M. Mcdaniel* (Nijmegen, Netherlands), J. Scoffield, J. Van Ingen</i>
E0754	Distribution of contezolid in different tissues of mice and human patients infected with <i>Mycobacterium abscessus</i> <i>W. Nie* (Beijing, China), N. Chu</i>
E0755	Exploration of clofazimine and bedaquiline activity against clinical strains of <i>Mycobacterium abscessus</i> to advance innovative therapeutic strategies <i>C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea</i>
E0756	Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria <i>S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan</i>
E0757	Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany <i>N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus</i>
E0758	Deciphering the Epidemiology of <i>Mycobacterium chimaera</i>: Genetic Lineages, Environmental Sources, and Infection Prevention Insights <i>G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo</i>
E0759	Evaluation of a novel media for susceptibility testing of <i>Mycobacterium avium-intracellulare</i> complex isolates <i>T. Grams* (Salt Lake City, United States), S. Shakir</i>
E0760	Emerging cases of <i>Mycobacterium chelonae</i> endocarditis associated with BioIntegral bioprostheses <i>J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter</i>

EF106	16:15 – 17:15	Arena 3
	ePoster Flash Session	

ANTCLN

The ABC (allergy, bloodstream infections and clinical decision support) in AMS

Chair	<i>Céline Pulcini (Nancy, France)</i>
E0761	Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study <i>D. Wets* (Leuven, Belgium), R. Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Breynaert, T. Ieven, P. De Munter</i>
E0762	Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial <i>J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt</i>
E0763	Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage <i>X. Li* (Toronto, Canada), K. Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky</i>
E0764	Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Staphylococcus aureus</i> (PRIMEKA): A Retrospective Single-Center Cohort Study <i>F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti</i>

E0765	The inappropriate use of antibiotics for blood culture contamination and colonisation by multidrug-resistant microorganisms: the role of counselling on antibiotic prescription <i>R.R. Peña-Zalbidea* (Palma (balearic Islands), Spain), L. Martin, H. Vilchez, L. Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera, X. Mulet, A. Oliver, J. Murillas</i>
E0766	Factors influencing meropenem prescription following the 2020 EUCAST « I » definition update : a multicentric observational study in Belgian hospitals <i>L. Catteau* (Brussels, Belgium), L. Bonacini</i>
E0767	Impact of an Antimicrobial Stewardship Mobile Application on Antimicrobial Prescribing, Length of Hospital Stay, and Cost Savings <i>Z.O.E. Babiker* (Abu Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, J. Shamseddine, R. Ali</i>
E0768	Evaluation of a model-based clinical decision support system for empirical antimicrobial therapy <i>M.L. Mogensen* (Aalborg, Denmark), S.N. Søgaaard, L. Ward, H. Skjøl-Årtil</i>
E0769	A rapid systematic review of criteria to facilitate prompt intravenous-to-oral antimicrobial switch in children and young people in England. <i>R. Oettle* (London, United Kingdom), S. Patel, A. Demirjian, M. Mcleod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-Oredope</i>

EA	16:15 – 17:30	Hall 1
	Awards	

PRO

Excellence Award Lectures

<i>Chairs</i>	<i>Jon S. Friedland (London, United Kingdom) Robert Leo Skov (Copenhagen, Denmark)</i>
---------------	--

A006	16:15	Towards pandemic prevention, moonshot or utopia? <i>Marion Koopmans (Rotterdam, Netherlands)</i>
A007	16:50	Can global warming bring new infectious diseases? <i>Arturo Casadevall (Baltimore, United States)</i>

SY143	16:15 – 17:15	Hall 11
	1-hour Symposium	

VAX

ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients

<i>Chairs</i>	<i>Elisa Cordero Matia (Seville, Spain) Zitta Barrella Harboe (Hillerød, Denmark)</i>
---------------	---

S0389	16:15	Vaccination against respiratory pathogens <i>Albert Vollaard (Bilthoven, Netherlands)</i>
S0390	16:45	Other vaccines <i>Olivier Epaulard (Grenoble, France)</i>
Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)		

EW146	16:15 – 18:15	Hall 13
	Educational Session	

How to detect, manage and communicate hospital outbreaks

<i>Chairs</i>	<i>Margaret Ip (Shatin, Hong-Kong SAR, China) Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)</i>
---------------	---

W0395	16:15	How to detect hospital outbreaks <i>David Fisman (Toronto, Canada)</i>
W0396	16:35	How to confirm hospital outbreaks using genomics <i>John W. A. Rossen (Groningen, Netherlands)</i>
W0397	16:55	How to rapidly respond to an ongoing hospital outbreak <i>Ermira Tartari (Msida, Malta)</i>
W0398	17:15	How to communicate hospital outbreaks via scientific publication <i>Ines Steffens (Solna, Sweden)</i>

ESCMID Global 2025 - Programme

ME145

16:15 – 17:15

Hall 15

CLN DX

Meet-the-Expert

Fungal meningitis: recognition and current status of management

M0393

16:15

Olivier Lortholary (Paris, France)

M0394

16:27

Janis Blair (Phoenix, United States)

JS2

16:15 – 17:15

Hall 16

PRO

Journal Session

Late-breaker research from the Lancet group: new interventions for familiar and new infectious diseases

Chairs

Syeda Saleha Hassan (London, United Kingdom)

Ursula Hofer (London, United Kingdom)

J011

16:15

TBA

J012

16:30

The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin AmericaJan Felix Drexler (Berlin, Germany)

J013

16:45

The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistanceHatim Sati (Geneva, Switzerland)

J014

17:00

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPref3 OA) in older adults over three RSV seasons: a randomized trialAlberto Papi (Ferrara, Italy)

Co-organised with: The Lancet group

OS102

16:15 – 17:15

Hall 2

AMR DX

1-hour Oral Session

AI tools empowering AMR prediction in WGS and MALDI-TOF

Chairs

Oliver Nolte (Zürich, Switzerland)

Patricia Simner (Rochester, United States)

O0733

A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing dataY. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope

O0734

Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for *Klebsiella pneumoniae* from Clinical NGS DataJ. Xinmiao* (Beijing, China), X. Jia, J. Zhang, J. Chen, Q. Yang

O0735

AI-Powered Real-Time Plasmid Prediction Using Nanopore SequencingE. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban

O0736

MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence *K. pneumoniae*L. Dortet* (Le Kremlin-Bicêtre, France), L. Mancera Pascual, M.J. Arroyo

O0737

Predicting rifampicin resistance in *Mycobacterium tuberculosis complex*with a machine learning based MALDI-TOF MS approcheY.W. Sun* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu

LB005

16:15 – 17:15

Hall 3

1-hour Oral Session

Emerging pathogens in humans, animals and vectors

L0026

Genome-wide association study identifies *ABCG1* as a susceptibility locus for tick-borne encephalitisP. Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek,

	<p><i>N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová, P. Bogović, J. Zajkowska, L. Krbková, V. Štruncová, A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová, M. Berankova, M. Pychova, D. Zavadska, N. Sallah, A. Pichler, D. Sedláček, A. Chrdle, C. Haudum, B. Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L. Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A. Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz</i></p>
L0027	<p>First detection of tick-borne encephalitis virus in Belgian ticks, May 2024<i>E. Portell-Buj* (Stockholm, Sweden), C. Philippe, S. Van Gucht, F. Dufrasne</i></p>
L0028	<p>Spread of a fusidic acid and methicillin-resistant <i>Staphylococcus aureus</i> clone causing impetigo in Europe<i>A.R. Larsen* (Copenhagen, Denmark), A. Petersen, L. Roer, K. Vendrik, R. Zwitterink, D. Notermans, N. Yin, M. Perrin, K. Khonyongwa, A. Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H. Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M. Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K. Moganeradj, B.J. Holzknecht, H.B. Eriksen, M. Hoppe, M.D. Bartels, J.A. Samaniego Castruita</i></p>
L0029	<p>Increase of PVL-positive livestock-associated MRSA in the Netherlands: a growing concern beyond livestock settings<i>K. Vendrik* (Bilthoven, Netherlands), S. Witteveen, D.W. Notermans, S.C. De Greeff, C.C. Wielders, E. Van Duijkeren, A.S. Schoffelen, A.P. Hendrickx, R.D. Zwitterink</i></p>
L0030	<p>H5N1 human infection in the United Kingdom: a One-Health approach<i>R. Puleston* (London, United Kingdom), N. Hamzaoui, S. Hayward, W. Proto, E. Booth, C. Beck, A. Lackenby, K. Spence, M. Beadsworth, N. Wong, M. Samuel, A. Singanayagam, K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook, N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins, C. Arevalo, D. Blackman, L. Guinness, C. Chatt, M. McGivern, A. Edwards, A. Banyard, R. Jorquera, K. Saville, R. Benee, S. Van Helvoort, E. Brown, L. Leighton McTeague, M. Chand, S. Rokadiya, S. Hopkins, H.I.M. Team, N. National Response Center Team</i></p>

SY142	16:15 – 18:15	Hall 4
	2-hour Symposium	

Precision genomics to improve infectious diseases management		
Chair	Jacob Moran-Gilad (Beer Sheva, Israel)	
S0385	16:15	<p>Human genomics approaches to infection immunity<i>Fergus Hamilton (Bristol, United Kingdom)</i></p>
S0386	16:45	<p>Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance<i>Marco Galardini (Hannover, Germany)</i></p>
S0387	17:15	<p>Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections<i>Stefano Giuliani (Melbourne, Australia)</i></p>
S0388	17:45	<p>Machine learning in bacterial genomics and metagenomics<i>Francesco Asnicar (Trento, Italy)</i></p>

OS103	16:15 – 17:15	Hall 5
	1-hour Oral Session	

Polymicrobial interactions and competition		
Chairs	<p><i>Alessandra Bragonzi (Milano, Italy)</i> <i>Kimberly Kline (Genève, Switzerland)</i></p>	

O0738	<p>The <i>Klebsiella pneumoniae</i> type VI secretion system effector Tle4 facilitates adaptation survival by damaging the cell membrane of competing bacteria<i>W. Li* (Shanghai, China), J. Zhang</i></p>	
O0739	<p><i>Candida albicans</i> promotes TSST-1 production in <i>Staphylococcus aureus</i> by depleting glucose and lifting carbon catabolite repression<i>M. Carriou* (Lyon, France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A. Frugier, K. Dufresne, G. Lina</i></p>	
O0740	<p>Understanding polymicrobial biofilm dynamics: focus</p>	

ESCMID Global 2025 - Programme

	on <i>Pseudomonas aeruginosa</i> and its molecular interactions <i>S. Kansal* (Chandigarh, India), U. Dutta, A. Angrup, P. Ray</i>
O0741	Intra- and interspecific antagonism inhibits growth of <i>Staphylococcus aureus</i> in human nasal microbial communities <i>L. Brülisauer* (Zurich, Switzerland), M. Boumasmoud, S. Brugger, A.R. Hall</i>
O0742	Combination therapy against drug resistance biomimetic dual-species biofilm model of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> <i>P. Mojarad* (Helsinki, Finland), P. Tammela, T. Laaksonen, Z. Gounani</i>
<hr/>	
EF110	17:30 – 18:30 ePoster Flash Session
	Arena 1
	<div>ANTCLNDX</div>
Advancing diagnostics and treatment of endocarditis	
Chair	<i>Benoît Guery (Lausanne, Switzerland)</i>
E0785	18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditis <i>J.M. Prins* (Amsterdam, Netherlands), S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff</i>
E0786	Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials <i>M. Papadimitriou Olivgeris* (Sion, Switzerland), M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourré, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse</i>
E0787	<i>In vivo</i> Dalbavancin efficacy against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and high-level aminoglycoside resistant (HLAR) <i>Enterococcus faecalis</i> (EFAE) experimental endocarditis model. <i>C. García De La María* (Barcelona, Spain), C. García De La Mària, M.A. Cañas, M. Brunet, J. García-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro</i>
E0788	Identification and validation of clinical phenotypes in <i>Staphylococcus aureus</i> blood stream infection and their association with mortality (FEN-AUREUS study) <i>J. Rodríguez-Baño* (Seville, Spain), B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés</i>
E0789	Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes <i>M. Singh* (London, United Kingdom), C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias</i>
E0790	Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort <i>C. Meyer-Schwickerath* (Cologne, Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung</i>
E0791	The optimal management of <i>Enterococcus faecium</i> catheter-related bloodstream infections: a gap to bridge <i>I. Rancan* (Florence, Italy), M. Rinaldi, F. Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella</i>
E0792	Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant <i>Enterococcus faecalis</i> <i>O. Funk* (Brooklyn, United States), I. Khan, J. Li, J. Cusumano</i>
E0793	Risk factors for in- hospital mortality in 500 cases of infective endocarditis <i>C. Lamas* (Rio De Janeiro, Brazil), G. Pompeo, T. De Almeida, M. De Carvalho,</i>

N. Feijoó, R. Garrido, G. Barbosa, B. Zappa, C. Weksler, M. Correia, W. Golebiovski

EF111

17:30 – 18:30

Arena 2

ePoster Flash Session

CLN

Don't blink: STIs are everywhere

Chair

Mathew Beale (Hinxton, United Kingdom)

E0794

Neurosyphilis and Mpox co-infection mimic HIV encephalitisL. Mejdoubi* (Vienna, Austria), A. Nader, L. Mautner, A. Bahrami, F. Hofer

E0796

An unusual cause of transverse myelitisJ. Koleri* (Doha, Qatar), M. Samawi, M. Maslamani

E0798

Ocular Syphilis, an uncommon presentation form of syphilis: two casesR. Kardashi* (Dresden, Germany), A. Frenz, K. De With

E0799

Case report of a severe skin infection in a young man on PrEP and DoxyPEPM. Zlámál* (Prague, Czech Republic), Z. Bartovská, B. Lacmanová, M. Holub

E0800

Serowaffling in PrEP Users: The Difficulty of HIV Diagnosis – A Case Report.P. Pillado Alonso* (Badalona, Spain), G. Fernández Rivas, A. Rivero Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J. Martínez-Picado

E0801

Severe disseminated mpox in a patient with advanced HIV: A case reportM.A. Quadros Flores* (Lisbon, Portugal), R. Diogo, F. Gonçalves, T. Marques, S. Paulo, F. Cota Medeiros, D. Mendes Pedro

E0802

Sensorimotor polyneuropathy in a patient affected by HIV-1: an atypical presentation of neurosyphilis associated to anti-SOX-1 antibodiesA. Lippi* (Siena, Italy), L. Ancillotti, M. Fabbiani, L. Migliorini, S. Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C. Puttini, F. Montagnani

EF112

17:30 – 18:30

Arena 3

ePoster Flash Session

AMR

ANT

CLN

Clinical considerations in resistant organisms

Chair

Divya Deodhar (Muscat, Oman)

E0803

Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicenter clinical experienceF. Serapide* (Catanzaro, Italy), R. Serraino, L. Spadafora, M. Bernardi, G. Brucci, G. Cattardico, S. Corcione, I. De Benedetto, M. Del Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M. Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo, A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C. Mussini, A. Russo

E0804

Clinical outcomes of MSSA bacteremia exhibiting the cefazolin inoculum effect and development of a novel diagnostic methodS. Yoshizawa* (Ota-Ku, Japan), T. Sato, K. Komori, K. Yamada, T. Yamaguchi, K. Tateda

E0805

Third- and fourth-generation cephalosporins for the treatment of infections due to OXA48 carbapenemase-producing EnterobacteralesA. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Sastre-Escolà, J. Camara Mas, F. Tubau Quintano, R. Costa, A. Padulles, E. Shaw, C. Gudiol, M. Puig-Asensio

E0806

Are meropenem or imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections?A. Peters* (Santiago, Chile), S. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino, L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L. Rioseco, J. Moreno, R. Araos, P. García, P.D. Tamma, J.M. Munita

E0807

Oral Fosfomycin after Carbapenems as de-escalating therapy in Complicated Urinary Tract

ESCMID Global 2025 - Programme

		Infection: A randomized controlled trial <i>K. Angkanavisan* (Bangkok, Thailand), B. Sakboonyarat, C. Ungthammakhun</i>
E0808		Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> infections on hospital discharge: the next frontier for oral switch? <i>C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve</i>
E0809		<i>Metallo-β-lactamase</i> colonization and subsequent risk of infection: a retrospective study <i>C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni</i>
E0810		Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study <i>M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yenişol, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi</i>
E0811		Prognostic factors and role of clinical management in carbapenem-resistant <i>Acinetobacter baumannii</i> bacteraemia: results from a prospective, international, multicentre cohort (EURECA) <i>F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goosens, M.J.M. Bonten, J. Rodríguez-Baño</i>

SY147	17:30 – 18:30	Hall 11
	1-hour Symposium	

PHEI

Avian influenza in mammals: jumps under the radar

<i>Chairs</i>	<i>Patricia Antunes (Porto, Portugal)</i> <i>Ana Vale (Dublin, Ireland)</i>
---------------	--

S0399	17:30	Threat of highly pathogenic avian influenza to non-traditional hosts, including humans <i>Thijs Kuiken (Rotterdam, Netherlands)</i>
S0400	18:00	Recent changes in the epidemiology of avian influenza in relation to human health risks <i>Ron Fouchier (Rotterdam, Netherlands)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

SY148	17:30 – 18:30	Hall 15
	1-hour Symposium	

CLN

Echinococcosis: neglected but expanding

<i>Chairs</i>	<i>Daniel Grupel (Jerusalem, Israel)</i> <i>Francesca Tamarozzi (Negrar-Verona, Italy)</i>
---------------	---

S0401	17:30	Expansion and diversity of cystic echinococcosis <i>Pedro Legua (Lima, Peru)</i>
S0402	18:00	Management of echinococcosis: evidence, eminence and new developments <i>Beate Grüner (Ulm, Germany)</i>

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

OS109 17:30 – 18:30 Hall 16
1-hour Oral Session

PRO

Training CM/ID - a global view

*Chairs Mihai Mares (Iasi, Romania)
Priya Nori (New York, United States)*

- O0780** **Specialist training in infectious diseases in Europe.***J. Salmanton-García* (Cologne, Germany), J. Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró, A. Verbon, O.A. Cornely, N. Beeching*
- O0781** **Infectious Diseases Residency Training over the World.***P. Irkören* (Zeytinburnu/Istanbul, Türkiye), P. Irkoren, C. Cimen, S. Keske, Ö. Ergönül*
- O0782** **Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network.***A. Tostmann* (Nijmegen, Netherlands), E. Schoeman, B. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman, C. Azzouz, S. Mehtar*
- O0783** **Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe.***T. Mwaturura* (Harare, Zimbabwe), D. Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer*
- O0784** **Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings.***H. Pailhoriès* (Angers, France), H. Pailhories, C. Zins, R. Chenouard, M. Kempf, M. Eveillard*

ME149 17:30 – 18:30 Hall 2
Meet-the-Expert

AMR

DX

How to perform molecular surveillance of multidrug resistant bacteria

- M0403** 17:30 *Martina Lengerova (Brno, Czech Republic)*
- M0404** 17:42 *Henrik Hasman (Copenhagen, Denmark)*

OS107 17:30 – 18:30 Hall 3
1-hour Oral Session

VAX

Novel vaccines in clinical development

- Chairs Mateusz Hasso-Agopsowicz (Geneva, Switzerland)
Hanna M. Nohynek (Helsinki, Finland)*
- O0770** **Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years.***M. Messier* (Vienna, France), L. Wagner, R. Hochreiter, J. Larcher-Senn, E. Lamberth, R. Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach*
- O0771** **Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial.***H. Hiruy* (Cambridge, United States), R. Lazarus, K. McCafferty, K. Cohen, R. Dhar, T. Rizk, A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav*
- O0772** **Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial.***A. Hannaford* (Boston, United States), D. Leitner, M. Waldor, L. Baden, M. Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H. Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B. Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S. Walsh*
- O0773** **Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years.***L. Oostvogels* (Frederiksberg, Denmark), A. Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux-Roels*

ESCMID Global 2025 - Programme

00774 **Aggregated summary of immunogenicity and safety for the chikungunya virus-like particle (VLP) vaccine development programme***L. Tindale** (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell

OS108 **17:30 – 18:30** **Hall 5**
1-hour Oral Session

CLN IPC

Novel approaches to preventing device-related infections

Chairs *Natividad Benito (Barcelona, Spain)*
Preeti Malani (Ann Arbor, United States)

00775 **Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.***M. Sanz De Mena** (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada

00776 **Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial****AntiRedMen***S. Scheithauer** (Goettingen, Germany), O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr

00777 **Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis***A. Mahajan** (Melbourne, Australia), C. Robson

00778 **A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients***J. Guerrero** (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go

00779 **Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients***N. Imhasly** (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein

Tuesday, 15 April 2025

SY152 **08:30 – 10:30** **Hall 12**
2-hour Symposium

PHEI VAX

Out of the spotlight or out of reach? Vaccination of hard-to-reach groups

Chairs *Olivier Epaulard (Grenoble, France)*
Justyna Kowalska (Warsaw, Poland)

S0413 **08:30** **Ukrainian war refugees and vaccination attitudes: experience from Poland***Maria Ganczak (Zielona Gora, Poland)*

S0414 **09:00** **Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama***Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

S0415 **09:30** **Are penitentiary systems ready for introducing vaccination programmes?***Lara Tavoschi (Pisa, Italy)*

S0416 **10:00** **HPV and other essential vaccinations for sex workers***Debora Konopnicki (Brussels, Belgium)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SY153 **08:30 – 10:30** **Hall 13**
2-hour Symposium

CLN

Breaking new ground in febrile neutropaenia management

Chairs *Murat Akova (Ankara, Türkiye)*
Stefan Schwartz (Berlin, Germany)

S0417	08:30	Do we need to redefine the concept of febrile neutropaenia in the era of immunotherapy? <i>Manuela Aguilar-Guisado (Seville, Spain)</i>
S0418	09:00	Should some patients be empirically treated with combination therapy? <i>Dina Averbuch (Jerusalem, Israel)</i>
S0419	09:30	Role of new antibiotics in febrile neutropaenia <i>Malgorzata Mikulska (Genoa, Italy)</i>
S0420	10:00	Can treatment strategies be personalised using AI or new diagnostic tools? <i>Carolina Garcia Vidal (Barcelona, Spain)</i>

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)

EW156	08:30 – 10:30	Hall 5
	Educational Session	

PRO

The rules of the game: how to tackle the peer-review and publication process

<i>Chairs</i>	<i>Christian Kraef (Copenhagen, Denmark)</i> <i>Oana Sandulescu (Bucharest, Romania)</i>
---------------	---

W0429	08:30	Communicating with journals, editors and reviewers <i>Angela Huttner (Geneva, Switzerland)</i>
W0430	08:50	The Wild West of predatory journals <i>Ursula Hofer (London, United Kingdom)</i>
W0431	09:10	Communicating your publications on social media <i>Neil Stone (London, United Kingdom)</i>
W0432	09:30	Re-imagining peer review <i>Amelia Joseph (Nottingham, United Kingdom)</i>

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors

EF114	08:30 – 09:30	Arena 1
	ePoster Flash Session	

DX

Innovations and insights in diagnosing parasitic infections

<i>Chair</i>	<i>Pikka Jokelainen (Copenhagen, Denmark)</i>
--------------	---

E0822	Evaluation of a multiplex beads assay for the simultaneous detection of serum antibodies in neurocysticercosis patients. <i>A. Lopez Alva* (Lima, Peru), P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H. Garcia Lescano</i>	
E0823	Development and evaluation of real-time loop mediated isothermal amplification assay for rapid detection of hookworm (<i>Ancylostoma duodenale</i>) in human fecal samples <i>M. Thakur* (Chandigarh, India), S. Khurana, A. Mewara, L. Pvm</i>	
E0824	Exploring Genotypic Prevalence and Transmission of Cryptosporidium and Giardia In Immunocompromised Patients: A Dual Approach with Modern Molecular Methods: MLST & nested real-time HRM <i>P. Rani* (Chandigarh, India), P. Datta, S.L. Bhasin, P. Malhotra, S.S. Rana, R. Sehgal</i>	
E0825	Prevalence and diagnostic accuracy of different diagnostic tests for Chagas disease in the Paraguayan Chaco <i>S. Ardiles Ruesjas* (Saarbruecken, Germany), S. Ardiles-Ruesjas, V. Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C. Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S. Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I. Losada</i>	
E0826	Development and validation of an artificial intelligence model for detection of gastrointestinal parasites from concentrated wet-mount stool examinations <i>M.R. Couturier* (Salt Lake City, Ut, United States), B. Mathison, K.A. Knight, J.R. Potts, F. Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L. Bess, W. Hymas</i>	
E0827	Evaluation of KU-F40 automated microscope for diagnosis of intestinal parasitic infections : will AI	

ESCMID Global 2025 - Programme

	rescue old-time microscopy ? <i>A. Aupaix*</i> (Hornu, Belgium), <i>L. Filippin, I. Mansoor, M. Chemaïs, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner</i>
E0828	Improving vector surveillance: evaluating a real-time PCR assay for <i>Leishmania</i> DNA detection in sandflies <i>H. Alonso-Ezcurra*</i> (Zaragoza, Spain), <i>M.P. Peris, I. Ruiz-Arondo, J.A. Castillo, D. Martínez-Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso</i>
E0829	Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess <i>R. Fleury*</i> (Besançon, France), <i>M.P. Brenier-Pinchart, P. Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet</i>
E0830	Human piroplasmosis: diagnostic lessons from a national parasitology reference laboratory in South Africa. <i>C. Sriruttan-Nel*</i> (Johannesburg, South Africa), <i>J. Frean</i>

EF115	08:30 – 09:30	Arena 3
	ePoster Flash Session	

DX **PHEI**

New genomic methods in clinical microbiology

Chair *Natacha Couto (Oxford, United Kingdom)*

E0831	Prediction of antimicrobial minimum inhibitory concentration from <i>Escherichia coli</i> whole genome sequence data using machine learning <i>A. Gerada*</i> (Liverpool, United Kingdom), <i>N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope</i>
E0832	Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing <i>A. Ramette*</i> (Bern, Switzerland), <i>L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander</i>
E0833	Prediction of antibiotic resistance in <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> from genomic data using machine learning and deep learning approaches <i>E. Denakpo*</i> (Gif-Sur-Yvette, France), <i>N. Dias, F. Jay, B. Iorga</i>
E0834	Machine learning pipeline accelerates identification of diagnostic targets for <i>Neisseria gonorrhoeae</i> <i>A. Verich*</i> (Sydney, Australia), <i>T. Applegate, D. Bauer, P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany</i>
E0835	Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cgMLST Polisher <i>N. Scherff*</i> (Muenster, Germany), <i>J. Rothgänger, D. Harmsen</i>
E0836	Developing a core genome MLST (cgMLST) for <i>Mycoplasma pneumoniae</i> <i>C. Dixon*</i> (Cardiff, United Kingdom), <i>R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauter, G. Greub, N. Couto, M.L. Beeton</i>
E0837	Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space <i>S. Branders*</i> (Hamar, Norway), <i>M. Grabherr, R. Ahmad</i>
E0838	VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome <i>J. Li*</i> (Shenzhen, China), <i>F. Yang, L. Xiong, X. Feng, H. Zhong</i>
E0839	Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens <i>A. Skoulakis*</i> (Lamia, Greece), <i>K. Daniilidis, S. Digenis, A. Hatzigeorgiou</i>

CGR	08:30 – 10:30	Hall 1
	Special Session	

CLN

Clinical Grand Round

Experts *Nina Khanna (Basel, Switzerland)*
Dimitrios P. Kontoyiannis (Houston, Tx, United States)
Lior Neshet (Beersheba, Israel)
David L. Paterson (Singapore, Singapore)

Priscilla Rupali (Vellore, India)
Monica Slavin (Melbourne, Australia)

- CGR01 **Case 1** Kruthi Malur Kumaraswamy (Mumbai, India)
CGR02 **Case 2** Christopher Wong (Victoria, Australia)
CGR03 **Case 3** Filipa Ferreira (Porto, Portugal)
CGR04 **Case 4** Jia Arng Lee (Zhongzheng Dist, Taipei City, Taiwan, Taiwan, China)
CGR05 **Case 5** Lorenzo Bertolino (Naples, Italy)
CGR06 **Case 6** Armani Hawes (Baltimore, United States)
CGR07 **Case 7** Sima Sharara (Baltimore, United States)

Co-organised with: Infectious Diseases Society of America (IDSA)

OS113 08:30 – 10:30 Hall 11

2-hour Oral Session

AMR ANT TRN

Knockin' on Science's Door: New Antimicrobial Solutions

Chairs Sandrine Marchand (Poitiers, France)
Ursula Theuretzbacher (Vienna, Austria)

- O0812 **Chimerbactin: a hybrid antibiotic for persistent Gram-positive infections that overcomes resistance development.** R. Lee* (Memphis, United States), Y. Zhao, A. Arya, M. Lafleur, R. Conlin, G. Phelps, C. Dunn, E. Griffith, J. Portelinha, N. Chumbler, V. Loudon, I. Lister, S. Zia, K. Urish, K. Lewis
- O0813 **A Novel Klebicin Cocktail to Treat Lung Infection Caused by *Klebsiella pneumoniae*** V.D. Paul* (Bangalore, India), A. Ambady, U. Chopra
- O0814 **Thiophene derivatives: A promising solution against MDR Gram-negative bacilli** Y. Smani* (Seville, Spain), I. Molina Panadero, Á. Rey Hidalgo, M. Morales-Tenorio, A. García-Rubia, T. Samernate, P. Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón, C. Gil
- O0815 **Molecular insight into non-lytic polyproline peptide disruption of *Klebsiella pneumoniae* biofilms** R. Fleeman* (Orlando, United States), R. Beckman Iv, B. Victoria, L. Suits, P. Eswara
- O0816 **Reverting cefotaxime resistance in CTX-M-15-producing *Escherichia coli* using Targeted-Antibacterial-Plasmids (TAPs): a CRISPR-Cas9 approach.** N. Roson Calero* (Barcelona, Spain), N. Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P. Bogaerts, C. Lesterlin
- O0817 **Structural and functional characterization of LysSM5: An innovative endolysin from Salmonella Phage vB_SenA_SM5** K. Sharma* (Chandigarh, India), H. Kaur, N. Chaudhary, S. Prajapati, B. Mohan, N. Taneja
- O0818 **Rational step-by-step design of a two-phage cocktail against a contemporary *A. baumannii* strain recovered from a burned patient at CHUV.** G. Resch* (Lausanne, Switzerland), H. De Villiers De La Noue, G. Golliard, X. Vuattoux
- O0819 **A novel antibiotic class targeting the enolase of *Acinetobacter baumannii*** Molina Panadero* (Seville, Spain), A. Moreno Rodríguez, Á. Rey Hidalgo, L. Tomás Gallardo, M. De La Cruz, P. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic, O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani
- O0820 **Reviving antibiotic potency: Pharmacological Assessment of JS238 a newly designed potentiator against *P. aeruginosa*** P. Rasouli* (Brussels, Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke
- O0821 **Advancements in combating tularemia: Novel therapeutic strategies targeting *Francisella tularensis*** S. Guillier* (Brétigny-Sur-Orge, France), M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde, C. Demeure, J. Pizarro Cerda, G. Guichard, G. Compain, D. Burnouf, O. Gorgé, J. Wagner

SY154 08:30 – 10:30 Hall 14

ESCMID Global 2025 - Programme

AMR

PHEI

2-hour Symposium

Using mathematical and epidemiological models to identify the drivers of AMR

Chairs

Marc J.M. Bonten (Utrecht, Netherlands)

Sarah Tschudin Sutter (Basel, Switzerland)

S0421	08:30	Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution? <i>Roger Kouyos (Zürich, Switzerland)</i>
S0422	09:00	Inferring the determinants of AMR dynamics across bacterial pathogens <i>Lulla Opatowski (Paris, France)</i>
S0423	09:30	Modelling the evolution of resistance <i>Erida Gjini (Lisbon, Portugal)</i>
S0424	10:00	Assessing the associations of microbiome and socio-demographic dynamics on AMR <i>Katariina Pärnänen (Helsinki, Finland)</i>

EW157		08:30 – 10:30	Hall 15
		Educational Session	
		<div>DX</div> <div>PHEI</div>	
Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases			
Chairs		Ana Alastruey-Izquierdo (Madrid, Spain) Rita Oladele (Lagos, Nigeria)	
W0433	08:30	Advances and gaps in the diagnosis and treatment of histoplasmosis <i>Diego Rodrigues Falci (Porto Alegre, Brazil)</i>	
W0434	08:50	Paracoccidioidomycosis: an update on diagnostic challenges <i>Beatriz L. Gomez (Bogota, Colombia)</i>	
W0435	09:10	What is new in Talaromycosis <i>Brown Lottie (London, United Kingdom)</i>	
W0436	09:30	Mycetoma: treatment challenges of a unique neglected tropical disease <i>Borna Nyaoke-Anoke (Nairobi, Kenya)</i>	

EW155

08:30 – 10:30

Hall 2

Educational Session

DX

PHEI

An update on arboviral disease challenges

Chairs

Misa Korva (Ljubljana, Slovenia)

Anna Papa-Konidari (Thessaloniki, Greece)

W0425

08:30

The global epidemiology of arboviral diseases

Chantal B.E.M. Reusken (Bilthoven, Netherlands)

W0426

08:50

Arboviral diseases transmitted by mosquitoes

Luisa Barzon (Padua, Italy)

W0427

09:10

Arboviral diseases transmitted by ticks

Joanna Maria Zajkowska (Białystok, Poland)

W0428

09:30

Arboviral diseases transmitted by sandflies

Rémi Charrel (Marseille, France)

Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists

SY150		08:30 – 10:30	Hall 3
		2-hour Symposium	
	ANT		
Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges			
Chairs		Lindsey Ann Edwards (London, United Kingdom) Ed J. Kuijper (Leiden, Netherlands)	
S0405	08:30	How can we recognise and deal with adverse events of Faecal Microbiota Transplantation? <i>Serena Porcari (Roma, Italy)</i>	
S0406	09:00	What to check? – An attempt at evidence-based donor screening <i>Elisabeth Terveer (Leiden,</i>	

Netherlands)

- S0407 09:30 What are the right bugs – Developing LBPs out of FMTs *Lena Biehl (Cologne, Germany)*
- S0408 10:00 What's up next? – Hot LBP candidates *Ilan Youngster (Beer Yaakov, Israel)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)

SY151 08:30 – 10:30 Hall 4
2-hour Symposium

CLN

News in endocarditis care

Chairs *Michele Bartoletti (Milan, Italy)*
Pilar Retamar Gentil (Seville, Spain)

- S0409 08:30 Endocarditis guidelines: what is new? *Siegbert Rieg (Freiburg, Germany)*
- S0410 09:00 Oral therapy and outpatient care *Laura Escolà-Vergé (Barcelona, Spain)*
- S0411 09:30 PK/PD aspects of endocarditis antibiotic therapy *Fekade Bruck Sime (Brisbane, Australia)*
- S0412 10:00 The Endocarditis Team: there is no way to work alone *Barbara Hasse (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)

EF116 09:30 – 10:30 Arena 2
ePoster Flash Session

CLN

DX

TRN

Sepsis revolutions: from machines to molecules

Chair *Pierluigi Del Vecchio (Roma, Italy)*

- E0840 Machine learning enabled prediction of blood stream infection in emergency department attendees. *C. Rosato* (Liverpool, United Kingdom), S. Aston, A. Velluva, A. Howard, W. Hope*
- E0841 Utilizing Automation to Streamline the Blood Culture Process: Enhancing Efficiency and Patient Outcomes *J. Qin* (Shanghai, China), M. Li, Z. Shen*
- E0842 Implementation of a bundle for Gram-negative bloodstream infection: impact on mortality and MDT/DTT carriage *C. Bonazzetti* (Bologna, Italy), A. Grechi, D. Gibertoni, L. Mangione, F. Todisco, N. Caroccia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi, A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P. Viale, M. Giannella*
- E0843 A matter of time: Impact of time to first follow-up blood cultures in patients with candidemia and *Staphylococcus aureus* bacteremia from a retrospective cohort *P. Valsecchi* (Pavia, Italy), E. Bono, A. Valeretto, S. Resuli, M. Corbella, P. Cambieri, E. Seminari, R. Bruno*
- E0844 Characteristics of infections and outcomes in patients with left ventricular assist devices *N. Sarı* (Ankara, Türkiye), E. Ateş, Ç. Sarıkaş, Ö. Kurt Azap, Ç. Erol, A. Sezgin*
- E0845 Nb₂(Sn_{0.7}Cu_{0.3})C MAX phase for anti-infection therapy via hyperthermia-mediated bacterial metabolic interference *M. Yang* (Chengdu, China)*
- E0846 Age-Dependent Plasma Lipidomic Alterations and Immune Correlations in Sepsis: Insights into Disease Severity and Biomarker Potential *Y. Sun* (Shanghai, China), K. Lin, L. Wang, J. Ai, J. Zhao, X. Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin*
- E0847 Aberrant integrin activation causes transmigration defects in S100A9^{-/-} neutrophils during sepsis *S. Müller* (Münster, Germany), N. Ludwig, J. Rossaint, T. Vogl*

ESCMID Global 2025 - Programme

E0848		Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo- β -lactamase-producing <i>Pseudomonas aeruginosa</i> . S. Herrera-Espejo* (Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos-Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-Ibáñez, P. Nordmann
EF117	09:30 – 10:30	Arena 4
	CLN IPC	ePoster Flash Session
C. diff challenges: insights into treatment, monitoring, and infection prevention		
Chair	Kerrie Davies (Leeds, United Kingdom)	
E0849		Epidemiology, risk factors, and outcomes of nosocomial <i>Clostridioides difficile</i> infections: a cohort study in a tertiary hospital. L. Ruiz Salazar* (Madrid, Spain), T. Mata Forte
E0850		Long-read or short-read sequencing in <i>Clostridioides difficile</i> infection surveillance? M. Brajerová* (Prague, Czech Republic), M. Brajerova, P. Kinross, P. Drevínek, M. Krutova
E0851		"Beyond C. difficile Colitis": Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with <i>Clostridioides difficile</i> colitis. D.F. Bavaro* (Milan, Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Medioli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti
E0853		Comparison of bezlotoxumab versus no-bezlotoxumab on recurrence in high-risk patients with <i>Clostridioides difficile</i> infection C. Arena* (Detroit, United States), A. Abed, R. Kenney, A. Shallal, S. Davis, M. Veve
E0854		Exploring bacterial contributors to C. difficile colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice E. Montenegro-Borbolla* (Lausanne, Switzerland), L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery
E0855		An optimised vancomycin dosing regimen is effective against C. difficile, reduces gut microbiota impact and prevents recurrent C. difficile infection in a human in vitro gut model. J. Freeman* (Leeds, United Kingdom), C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies
E0856		Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory <i>Clostridioides difficile</i> infection M. Engelhard* (Cologne, Germany), I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff
E0857		Impact of a cohorting intervention on the incidence of hospital-acquired <i>Clostridioides difficile</i> infection (CDI): an interrupted time series analysis C.D. Moschopoulos* (Athens, Greece), M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kiani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha
ME165	11:00 – 12:00	Hall 12
	PHEI	Meet-the-Expert
How to use citizen science for public health		
M0450	11:00	Anna Noel-Storr (Leamington Spa, United Kingdom)
M0451	11:12	Jani Sormunen (Turku, Finland)
Co-organised with: European Centre for Disease Prevention and Control (ECDC)		
SY164	11:00 – 12:00	Hall 15

CLN VAX

1-hour Symposium

dsDNA virus infections in immunocompromised patients

Chairs

Lior Nesher (Beersheba, Israel)

Michelle Yong (Melbourne, Australia)

- S0448** **11:00** **Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR?** *Hans H. Hirsch (Basel, Switzerland)*
- S0449** **11:30** **The role of CRISPR-Cas9-edited antiviral T cells against dsDNA virus infections** *Tba*

FO167

11:00 – 12:00

Arena 1

Open Forum

PHEI VAX

Vaccine rollout in low resource settings

Chair

Asma Nasim (Karachi, Pakistan)

- F0454** **11:00** **Typhoid vaccine roll out** *Nginache Nampota (Baltimore, United States)*
- F0455** **11:10** **Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriers** *Bernhards Ogutu Ragama (Nairobi, Kenya)*
- F0456** **11:20** **The story of COVID-19 vaccines in LMIC** *Paul Adepoju (Perton, United Kingdom)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

EF123

11:00 – 12:00

Arena 2

ePoster Flash Session

ANT CLN

Advancing antimicrobials: trials and therapies for resistant infections

Chair

Ursula Theuretzbacher (Vienna, Austria)

- E0888** **11:00** **Efficacy of High Dose Tigecycline-Containing Regimens for the Combination Treatment of Carbapenem Resistance *Enterobacteriales* Bacteremia: a propensity score-matched study** *V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, P. Wanloptaree*
- E0883** **11:06** **Evaluation of CRS3123 compared to vancomycin for the treatment of *Clostridioides difficile* infection (CDI)** *J. Bruss* (Pagosa Springs Co, United States), M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C. Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T. Jarvis, U. Ochsner, M. Wilcox, T. Louie*
- E0884** **11:12** **Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in paediatric patients with gram-negative bacterial infection** *J. Bradley* (San Diego, United States), C.T. Norice, E. Roilides, A. Shevelev, B. Jurkiewicz, J.A. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young, D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno*
- E0885** **11:18** **A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Intravenous Ertapenem (ERT) with Zidebactam (ZID) in Combination (WCK 6777) in Healthy Adult Subjects** *T. Lodise* (Albany, United States), R. Chavan, A. Patel, R. Yeole, S. Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan, M. Kankam, A. Jaunarajs, E. Hammett, H. Howell, R.A. Bonomo*
- E0886** **11:24** **Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing *K. pneumoniae* infections – Results from a retrospective multicentre study** *A. Marino* (Catania, Italy), A.E. Maraolo, M. Mazzitelli, A. Oliva, N. Geremia, A. De Vito, C. Gullotta, V. Scaglione, E. Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori, P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G. Madeddu, B. Cacopardo, G. Nunnari*
- E0887** **11:30** **Phase 3 study of oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese**

ESCMID Global 2025 - Programme

		female participants (EAGLE-J) <i>Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura</i>
E0889	11:36	Efficacy of Ceftolozane/Tazobactam vs. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by <i>Pseudomonas aeruginosa</i>: a multicentric retrospective study from the SUSANA cohort. <i>A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu</i>
E0890	11:42	Experience of dalbavancin use for unlicensed indications in a UK tertiary infectious diseases setting <i>C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong</i>
E0891	11:48	Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired gram-negative bacterial bloodstream Infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons <i>M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris</i>
EF124	11:00 - 12:00	Arena 3
	ePoster Flash Session	
	DX	
Thinking outside the box in urinary tract infection		
	Chair	Özlem Kurt Azap (Ankara, Türkiye)
E0892		Targeted NGS: a promising approach for pathogen detection of urinary tract infection <i>W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang</i>
E0893		Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics <i>A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner, R. Ahmad</i>
E0894		Identification of Microorganism Types in Urinary Tract Infections Using Machine Learning and Flow Cytometry <i>E. Flores* (Alicante, Spain), I. Gutierrez, R. Torreblanca, A. Blasco, R. Carbonell, M. Lopez-Garrigós</i>
E0895		A New Approach In Diagnosis Of Urinary Tract Infections <i>B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazcı, Ö. Uslu, N. Çöplü</i>
E0896		Diagnosis of urinary tract infections: from machine learning to clinical practice <i>E. Flores* (Alicante, Spain), R. Torreblanca, I. Gutierrez, R. Carbonell, L.G. Maite, A. Blasco</i>
E0897		Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting <i>S. Sarika* (Tamil Nadu, India), B. Rithik Dharan</i>
E0898		Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics <i>S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore</i>
E0899		Unraveling the complexity: Corynebacterium diversity and antimicrobial resistance hub in the urinary tract ecosystem <i>E. Cappelli* (Porto, Portugal), A. Morais, T. Ribeiro, L. Peixe</i>
E0900		Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures <i>A. Castellano Verdasco* (Lleida, Spain),</i>

E. Sánchez Bascónes, E. López González, A. Blanquero-Porras, M. Riesgo Magaña, A. Bernet Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A. Bellés-Bellés, M. García González

EF125 **11:00 – 12:00** **Arena 4**
ePoster Flash Session

CLN TRN

Bugs breaking the blood-brain barrier

Chair Markus Zeitlinger (Vienna, Austria)

- E0901** **Pharmacologic depletion of meningeal macrophages worsens disease in a mouse model of meningitis***U. Koedel* (Munich, Germany), S. Dyckhoff-Shen, I. Masouris, H.W. Pfister, M. Klein*
- E0902** **Pgm1 modulates the inflammatory response of macrophages in experimental pneumococcal meningitis***D. Bakker* (Amsterdam, Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van De Beek*
- E0903** **Heparin-binding protein in cerebrospinal fluid as a biomarker for bacterial meningitis: a study of diagnostic accuracy***S. Olie* (Amsterdam, Netherlands), S.L. Staal, A.C. Da Cruz Campos, J. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer*
- E0904** **Efficacy Analysis of Intraventricular/Intrathecal Polymyxin B sulphate Injections in the Treatment of Post-neurosurgical CNS Infections in Neurocritical Ill Patients: a prospective observational study***L. Yang* (Shanghai, China), J. Song, M. Wang, H. Yuan, Q. Yuan, Z. Du, G. Wu, J. Hu, W. Chen*
- E0905** **Ventriculitis characteristics and outcomes (VELCRO): an international retrospective cohort study***D. Luque Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L. Escut, G. Martin-Blondel, B. Sarton, P. Jaquet, F. Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L. Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B. Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher, F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R. Sonnevile, F. Valour, P. Tattevin*
- E0906** **Clinical Features and Outcomes of *Staphylococcus aureus* Brain Abscess***E. Eriksen* (Aalborg, Denmark), M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, M. Brouwer, J. Bodilsen*
- E0907** **Epidemiology of Adult Intracranial Bacterial Abscess in the Republic of Ireland (2010–2021)***S. Kilgarrieff* (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey, S. O'Donnell, B. Dinesh, C. O'Connor, A. Doherty*
- E0908** **Corticospinal tract involvement in Neuromelioidosis: A Retrospective cohort Study from South India and a Systematic Review of Literature***P.K. Tirlangi* (Manipal, India), N. Gupta, V. Muralidhar, C. Mukhopadhyay*
- E0909** **A multicenter prospective study to develop and validate clinical prediction models for diagnosis of scrub typhus and treatment with doxycycline in children with acute encephalitis syndrome in southern India***T. Damodar* (Bangalore, India), L. Turtle, R. Kolamunnage-Dona, M. Jose, U. Kinhal, B. Singh, A. L. S. Marate, N. Prabhu, L. A V, F.S. D'souza, S.V. Sajjan, K. Mallesh, R.S. Mani, T. Solomon, V.K. Gowda, R. Vasanthapuram, R. Yadav*

KN158 **11:00 – 12:00** **Hall 1**
Keynote Lecture

TRN

What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer

*Chairs Emmanuelle Cambau (Paris, France)
Kathryn Holt (London, United Kingdom)*

K0437 **11:00** *Stewart T. Cole (Paris, France)*

ESCMID Global 2025 - Programme

SY162	11:00 – 12:00	Hall 11
	1-hour Symposium	
	AMR	
Antimicrobial stewardship across the lifespan from paediatrics to geriatrics		
Chairs	Lucy Catteau (Brussels, Belgium) Priya Nori (New York, United States)	
S0444	11:00	Antimicrobial Stewardship in paediatrics across different settings Taylor Morrisette (Charleston, United States)
S0445	11:30	Stewardship in geriatrics: an exceedingly important target Dafna Yahav (Ramat-Gan, Israel)
ME166	11:00 – 12:00	Hall 13
	Meet-the-Expert	
	DX	
Implementing AI in microbiological diagnostics: practical steps and quality control		
M0452	11:00	Oliver Nolte (Zürich, Switzerland)
M0453	11:12	Jennifer Dien Bard (Los Angeles, United States)
Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)		
SY163	11:00 – 12:00	Hall 14
	1-hour Symposium	
	AMR	
People-centred approach to strengthening the AMR response at primary care		
Chairs	Benedikt Huttner (Geneva, Switzerland) Mirfin Mpundu (Lusaka, Zambia)	
S0446	11:00	Implementation of WHO's people-centred interventions Nienke Van De sanDe Bruinsma (Geneva, Switzerland)
S0447	11:30	Opportunities for strengthening AMR interventions in primary healthcare Sholpan Kaliyeva (Karaganda City, Kazakhstan)
Co-organised with: World Health Organisation (WHO)		
OS122	11:00 – 12:00	Hall 16
	1-hour Oral Session	
	PRO	
Serious games - a serious business		
Chairs	Christian Kraef (Copenhagen, Denmark) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)	
O0878	The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands.A. Tostmann* (Nijmegen, Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers	
O0879	Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge PlatformA. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García	
O0880	Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon	
O0881	'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game.C. Uhomuibhi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra	
O0882	Improvement of learners' confidence in antibiotic	

management by an interdisciplinary annual multi-centred webinar *A. Friedrichs* (Kiel, Germany), E. Kramme, T. Koch, J. Jochum, A. Van Der Linde, H. Gerth, F. Jahn, A. Neubert*

SY159 **11:00 – 12:00** **Hall 2**
1-hour Symposium

CLN TRN

Beat the cancer by beating the infections

*Chairs Daniela Maric (Novi Sad, Serbia)
Mojca Maticic (Ljubljana, Slovenia)*

S0438 **11:00** **Prevention of infection-associated cancer: learning from each other** *Catharina Alberts (Amsterdam, Netherlands)*

S0439 **11:30** **Test and treat early to prevent cancer: hepatitis B and hepatitis C** *Francesco Negro (Geneva, Switzerland)*

SY160 **11:00 – 12:00** **Hall 4**
1-hour Symposium

CLN IPC

Personalised patient management and infection prevention: Current evidence and future perspectives

*Chairs Agnes Hajdu (Budapest, Hungary)
Iris K. Minichmayr (Vienna, Austria)*

S0440 **11:00** **The dosing perspective: towards individualised treatment strategies** *Thomas Tängdén (Uppsala, Sweden)*

S0441 **11:30** **The infection control perspective: advancing patient-centred approaches** *Alessia Savoldi (Verona, Italy)*

SY161 **11:00 – 12:00** **Hall 5**
1-hour Symposium

CLN

Emerging fungal diseases in children: Global challenges and approach to management

*Chairs Andreas H. Groll (Münster, Germany)
Adilia Warris (Exeter, United Kingdom)*

S0442 **11:00** **Emerging fungal infections in immunocompromised and geographically exposed children** *Laura Ferreras-Antolin (London, United Kingdom)*

S0443 **11:30** **Best available treatments and options for children in resource-limited settings** *Fabianne Carlesse (Sao Paulo, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMyKG)

OS118 **11:00 – 12:00** **Hall 6**
1-hour Oral Session

AMR ANT

Plasmids as a powerful tool of antibiotic resistance spread

Chair Monika Dolejska (Pilsen, Czech Republic)

O0858 **Co-anchorage of antibiotic resistance genes and mobile genetic elements on bacterial plasmids boosts horizontal gene transfer across sewage interfaces** *M. Shafiq* (Shantou, China)*

O0859 **The emergence of *tet(X4)* and *mcr* co-harbored on the same plasmid and its clinical significance** *N. Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T. Walsh*

O0860 **The plasmidome of a global collection of convergent *K. pneumoniae* and its impact on virulence** *F. Lebreton* (Silver Spring, United States), M. Martin, A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B.*

ESCMID Global 2025 - Programme

Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann

- O0861

Factors that affect plasmid transfer in multispecies biofilms*H.Y. Liu* (Norwich, United Kingdom), M. Yasir, E. Trampari, G. Langridge, M. Webber*
- O0862

Identification of the *czc* metal efflux operon on a new plasmid type in a *Pseudomonas aeruginosa* clinical isolate belonging to ST357 O11A.*Valcek* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst*

OS119

11:00 - 12:00

Hall 7

CLN

1-hour Case Session

Looking inside endovascular infections

Chairs

Claus Moser (Copenhagen, Denmark)
Matthaios Papadimitriou Olivgeris (Sion, Switzerland)

- O0863

A Case of Persistent *Legionella micdadei* Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges*V. Zwart* (Breda, Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen*
- O0864

Management and Prognosis of Vascular Endograft Infections: Case Series*N. Scarpulla* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni*
- O0865

Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis*I. Cafarella* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-Mangoni*
- O0866

Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by *Enterococcus* spp.: Experience from Seven Cases in a Referral Center*F. Frondizi* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti*
- O0867

Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital*G. Oliva* (Rome, Italy), F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti*

OS120

11:00 - 12:00

Hall 8

AMR TRN

1-hour Oral Session

Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence

Chairs

Giovanni Delogu (Rome, Italy)
Simon Foster (Sheffield, United Kingdom)

- O0868

Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid *pvirhs1* in hypervirulent Carbapenem-resistant *Klebsiella pneumoniae**Y. Zhang* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang*
- O0869

Presence and role of hypervirulence-associated markers in *Klebsiella pneumoniae* groups based on LD50 value in mouse septic model*A. Avdeeva* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, V. Ageevets, S. Sidorenko*
- O0870

Meta-transcriptomic insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis*T. Vashist* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora*
- O0871

Unveiling the hidden virulence of *Acinetobacter baumannii*: how the lipooligosaccharide core modulates immune responses and enhances interferon- γ production*Y.T. Lee* (Taipei, Taiwan,*

China), Y.C. Wang

O0872

Platelets drive neutrophil-mediated neuroinflammation in tuberculous meningitis*K. Skolimowska* (London, United Kingdom), R. Wilkinson, J.S. Friedland, D. Kirwan, T. Reid, D. De Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed, A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P. Renner, M. Panchoo, C. Stek, R. Johnson, M. Maxebengula*

OS121

11:00 – 12:00

Hall 9

1-hour Oral Session

AMR IPC

Shaping the future of IPC - digitalisation of surveillance

Chairs

*Diamantis Plachouras (Solna, Sweden)
Maaïke S.M. Van Mourik (Utrecht, Netherlands)*

O0873

11:00

PRAISE hospital-onset bacteraemia and fungaemia algorithm as novel automated surveillance indicator: results from four European university hospitals*S. Van Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, M. Behnke, M.S.M. Van Mourik, G. Catho, M. Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D. Dinis Teixeira, D. Sjöholm, P. Naucélér*

O0874

11:12

Transforming hospital-onset bacteremia and fungemia data to the OMOP common data model*H. Düsseldorf* (Vienna, Austria), G. Duftschmid, E. Presterl*

O0876

11:24

Dutch Electronic Health Records in primary care: the Nivel general practitioners database*F.F. Stelma* (Utrecht, Netherlands), J. Van Summeren, M. Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S. Van Beusekom*

O0877

11:36

Local signs at catheter insertion sites: Insights from the multicenter DeepCath cohort study with 4,256 pictures*N. Buetti* (Geneva, Switzerland), S. Ruckly, A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar, J.F. Timsit*

O0875

11:48

Prospective evaluation of a machine learning-based real-time multidrug-resistant organism prediction system*V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, A. Holmes, R.L. Peach, K. Bhangananda, A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee, J. Price, B. Mauricio, T.M. Rawson*

EF131

13:30 – 14:30

Arena 1

ePoster Flash Session

AMR

The current landscape of carbapenem resistance: from genotype to phenotype and virulence determinants

Chair

Amy Mathers (Charlottesville, United States)

E0940

Molecular Insights into the Growing Threat Carbapenem-Resistant Hypervirulent *Klebsiella pneumoniae* and the Rising Challenge of Ceftazidime-Avibactam Resistance*C. Vatansever* (Istanbul, Türkiye), A. Akpınar, J. Boral, S. Belge, N. Kardan, B. Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö. Ergönül, F. Can*

E0941

Global large-scale genomic snapshot on the diversity of carbapenem-resistant and hypervirulent *Klebsiella pneumoniae* strains*R. Elias* (Lisboa, Portugal), T. Clark, I. Portugal, J. Perdigao*

E0942

Carbapenem-resistant *Enterobacter cloacae* complex: genetic determinants of resistance and molecular epidemiology*D. Pinheiro De Sousa Santos* (Lisbon, Portugal), D. Santos, A. Bruschy-Fonseca, E. Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C. Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo-Cristino, C. Caneiras*

E0943

Molecular epidemiology of carbapenemase-producing *Escherichia coli* in Hungary*A. Hanczvikkel* (Budapest, Hungary), D. Göbhardter, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K. Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G.*

ESCMID Global 2025 - Programme

	<i>Jakab, Á. Sonnevend, Á. Tóth</i>
E0944	Genomic multicentre surveillance of VIM-producing <i>Enterobacterales</i> shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021 <i>A. Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter</i>
E0945	Three distinct routes of virulence-resistance convergence in ST-395 <i>K. pneumoniae</i> from Eastern Europe over the last decade <i>A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton</i>
E0946	Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria <i>N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok, A. Anders, S. Gatermann</i>
E0947	Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022 <i>V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakk, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng</i>
E0948	2011-2017 vs 2018-2024: comparison of carbapenem non-susceptibility trends among bloodstream <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> isolates from Greek hospitals: data from the Electronic System for the AMR surveillance-WHONET-Greece <i>M. Polemis* (Vari, Greece), A. Vatopoulos, K. Tryfinopoulou</i>

EF132	13:30 – 14:30	Arena 2
	ePoster Flash Session	

CLN

Difficult-to-treat cases in the immunocompromised

Chair Nicolas Mueller (Zurich, Switzerland)

E0949	A case of IRIS nocardiosis <i>S.K. Dlamini* (Cape Town, South Africa), P. Namale, P. Arnab</i>
E0951	Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing long-term glucocorticoid therapy for autoimmune thrombocytopenia: A case report <i>N. Zhang* (Bengbu, China)</i>
E0952	Subcutaneous paeohyphomycosis due to <i>Alternaria infectoria</i> in an immunosuppressed renal transplant recipient: successful multidisciplinary management <i>E. Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli, M. Arias</i>
E0953	Lung nodules in a patient with breast cancer history... Not everything is cancer. <i>E. Muñoa Hernández* (Chiapas, Mexico), E. Muñoa</i>
E0954	Treatment of fulminant <i>Clostridioides difficile</i> infection using bacteria-free stool supernatant in adult hematological patients during chemotherapy-induced aplasia <i>B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko</i>
E0955	Eradication of multidrug resistant <i>Pseudomonas aeruginosa</i> pneumonia in acute lymphoblastic leukemia patient with broad host-range phage <i>P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola</i>
E0956	An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by <i>Chondrostereum purpureum</i> <i>P. Kitjacharoenchai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan</i>
E0957	Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico <i>E. Sienna Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J. Corredor Nassar, A.P. Rodriguez Zulueta</i>

Viral infections in special populations

Chair

Federico Garcia (Granada, Spain)

- E0958** **ORCHESTRA Delphi Consensus: Therapeutic and Diagnostic Management of SARS-CoV-2 Infection in Rheumatological Patients** *M.G. Caponcello* (Seville, Spain), P. Olivares Navarro, J. Rodríguez Baño, Z.R. Palacios Baena, C. Bonazzetti, C. Campoli, A. Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L. Otero-Varela, I. Castrejón, E. Tacconelli*
- E0959** **Immunogenicity, reactogenicity and safety of booster vaccinations with BNT162b2 or full-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report** *J. Stemler* (Cologne, Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K. Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E. Romero Rodriguez, J. Moltó, I. Vergara Mitxeltoarena, T. Welte, B. Zablockiené, M. Akova, U. Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L. Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J. Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhaus, R. Sprute, J. Frias-Iniesta, R. Negí, C. Gaillard, G. Saini, A. García León, P.W.G. Mallon, C. Lammens, A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H. Goossens, S. Kumar-Singh, F. König, M. Posch, P. Koehler, O.A. Cornely*
- E0960** **Effectiveness of adjuvanted recombinant zoster vaccine in adults aged ≥50 years in the United States** *L. Qian* (Pasadena, United States), L.S. Sy, B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng, J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A. Cohen, H. Yun, D. Oraichi, H. Seifert, H.F. Tseng*
- E0961** **Differential SARS-CoV-2 RNAemia features and humoral immune response analysis of acute COVID-19 in solid organ transplant recipients and patients with hematological malignancies** *A. Ruiz-Molina* (Seville, Spain), J. Martín-Escolano, C. Infante-Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F. Martín-Domínguez, G. Bernal-Blanco, B. Villacorta-Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D. Rangel-Sousa, C. Rodríguez-Urbistondo, B. Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N. Maldonado, S. Salto-Alejandro, B. Gallego, L. Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A. Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes*
- E0962** **Prevalence of and risk factors for persisting COVID-19 in patients with B-cell malignancies** *A. Toschi* (Bologna, Italy), Z. Pasquini, A. Amicucci, N. Carocchia, M. Di Chiara, F. Simone, B. Casadei, C. Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M. Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E. Nicastri, M. Krampera, P.L. Zinzani, J. Rodriguez Baño, E. Tacconelli, M. Giannella*
- E0963** **Clinical characteristics and predictors of severe outcome among older adults hospitalized with respiratory syncytial virus (RSV) infection– a retrospective study from Israel** *M. Jurkiewicz* (Tel Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper, I. Royzman, S. Uppal, C. Liang, E. Begier, I. Ganiel, M. Mandelboim, D. Yahav*
- E0964** **RSV and bronchiolitis associated primary care and emergency department visit rates in children under 5 years: Estimates for Europe and other high-income countries** *F.F. Stelma* (Utrecht, Netherlands), S. Heemskerk, L. Van Heuvel, P. Spreeuwenberg, L. Bont, J. Van Summeren*
- E0965** **Higher incidence of post-transplant EBV infection in pediatric liver transplant recipients compared to pediatric kidney transplants: a retrospective analysis from a tertiary pediatric transplant center** *S. Mercadante* (Rome, Italy), L. Romani, A. Pietrobattista, I. Guzzo, R. Labbadia, A. Cappoli, A. Mosca, L. Lancella, M. De Luca*
- E0966** **Insights from a single center's experience in hepatitis C treatment across four prisons in Slovakia** *I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, M. Novotný, Z. Paraličová,*

ESCMID Global 2025 - Programme

P. Kristian

EF134

13:30 – 14:30

Arena 4

ePoster Flash Session

AMR DX IPC

Infection Controller's Daily

Chair Cansu Cimen (Oldenburg, Germany)

- E0967

Mortality and length of stay associated with antimicrobial-susceptible and resistant hospital-onset bloodstream infections at a tertiary referral hospital in Melbourne, Australia*A. Stewardson* (Melbourne, Victoria, Australia), S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg*
- E0968

MRSA on the rise in neonatal care departments*E. Herkes* (Amsterdam, Netherlands), A. Schoffelen, R. Zwiittink, J. Kluytmans, D. Notermans*
- E0969

Risk factors for OXA-carbapenemase-producing *Enterobacteriaceae* acquisition in Israel: a retrospective case control study*M. Amar* (Haifa, Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked-Mishan, O. Barnett-Griness*
- E0970

Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UK*S. Raharison* (Nice, France), A. Alcolea-Medina, L.B. Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter*
- E0971

Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-*Escherichia coli*/Enterobacteriales*J. Männer* (St.Gallen, Switzerland), V. Steinacher, T. Dörr, M. Schlegel, P. Kohler*
- E0972

A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant *Enterococcus faecium* from bloodstream infections at three tertiary care hospitals in Bavaria, Germany*A. Rath* (Regensburg, Germany), B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider-Brachert*
- E0973

Molecular epidemiology and transmission dynamics of vancomycin-resistant *Enterococcus faecium* in Belgian hospitals (2022-2023)*S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheeussen*
- E0974

Increasing Prevalence of Linezolid-resistant Enterococci: Outbreak or Overuse?*R. Traynor* (Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey*
- E0975

Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPA-filtered/positive pressure rooms*M.H. Nguyen* (Pittsburgh, United States), C. Clancy, Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham*

EW174

13:30 – 15:30

Hall 11

Educational Session

CLN IPC

Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia

Chairs Fusun Can (Istanbul, Türkiye)
Jeroen Schouten (Nijmegen, Netherlands)

- W0481

13:30

Artificial Intelligence to predict VAP*Miia Jansson (Oulu, Finland)*
- W0482

13:50

Metagenomic approach to VAP diagnosis*Jacques*

		<i>Schrenzel (Geneva, Switzerland)</i>
W0483	14:10	Viruses in VAP and HAP: should we worry about them? <i>Catia Cilloniz (Barcelona, Spain)</i>
W0484	14:30	Optimising antibiotic therapy in VAP <i>Pinyo Rattanaumpawan (Bangkok, Thailand)</i>

SY170	13:30 – 15:30	Hall 13
	2-hour Symposium	

	TRN	
Novel strategies for eliminating the ‘worst films ever’		
<i>Chairs</i>	<i>Elisa Borghi (Milan, Italy)</i> <i>Markus Zeitlinger (Vienna, Austria)</i>	

S0465	13:30	What answers can biofilm PK/PD modelling provide? <i>Coen Van Hasselt (Leiden, Netherlands)</i>
S0466	14:00	subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant? <i>Francoise Van Bambeke (Brussels, Belgium)</i>
S0467	14:30	PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm models <i>Maria Dolores Macia Romero (Palma De Mallorca, Spain)</i>
S0468	15:00	Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategies <i>Claus Moser (Copenhagen, Denmark)</i>

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee

SY171	13:30 – 15:30	Hall 14
	2-hour Symposium	

	DX	
Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing		
<i>Chairs</i>	<i>Mauricio Farfan (Santiago, Chile)</i> <i>Chiara Minotti (Basel, Switzerland)</i>	

S0469	13:30	Congenital cytomegalovirus detection by pool testing in saliva <i>Giannina Izquierdo (Santiago, Chile)</i>
S0470	14:00	Detection of blood-corne pathogens in asymptomatic blood donors by pool testing <i>Patricia Alvarez (Rio De Janeiro, Brazil)</i>
S0471	14:30	Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis <i>Melissa Sander (Bamenda, Cameroon)</i>
S0472	15:00	Pool testing for screening of bacterial sexually transmitted infections <i>Tba</i>

OS130	13:30 – 14:30	Hall 16
	1-hour Oral Session	

	CLN	DX	
Advances in fungal diagnostics			
<i>Chair</i>	<i>Sarah Delliere (Paris, France)</i>		

O0935	BAL galactomannan dynamics predict survival in critically ill patients with virus-associated pulmonary aspergillosis <i>V. Delanote* (Leuven, Belgium), J. Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs, L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans, P. Meersseman, M. Peetermans, E. Van Wijngaerden, A. Wilmer, K. Lagrou</i>		
O0936	Retrospective Assessment of a New Chemiluminescence Immunoassay for Serum (1, 3)-β-D-Glucan Levels in Patient with Invasive Fungal Infections <i>Z. Zhou* (Tianjin, China), K. Yuan, L. Ye, S. Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q. Wang, G. Zhang, H. Wang, Y. Zhao, G. Li</i>		
O0937	Evaluation of a multiplex PCR assay using barcoded magnetic bead technology for detection of fungal pathogens in bronchoalveolar lavage fluid: a diagnostic aid for invasive fungal infections <i>S. Zhang* (Baltimore, United States)</i>		

ESCMID Global 2025 - Programme

00938	Combined use of (1,3)- β -D-glucan and PCR in oral wash for <i>Pneumocystis jirovecii</i> pneumonia diagnosis in non-HIV populationA. Falcó Roget* (Mataró, Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez
00939	Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort studyH. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk

SY168	13:30 – 15:30	Hall 2
	2-hour Symposium	

TRN

Staphylococcus aureus: its expansion dynamics and interactions with its pals		
Chair	Barbara C. Kahl (Münster, Germany)	

S0457	13:30	S. aureus and its special relationship to S. epidermidis Andreas Peschel (Tübingen, Germany)
S0458	14:00	Computational and in vitro evaluation of probiotic treatments for nasal S. aureus decolonizationSilvio Daniel Brugger (Zurich, Switzerland)
S0459	14:30	Clonal population expansion of S. aureus occurs due to escape from a finite number of intraphagocyte nichesSimon Foster (Sheffield, United Kingdom)
S0460	15:00	How bacteriophages and pathogenicity islands drive the evolution of S. aureus John Chen (Singapore, Singapore)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

EW172	13:30 – 15:30	Hall 3
	Educational Session	

CLN

VAX

Beyond the gift of life: viral infection during pregnancy		
Chairs	Gülsen Özkaya Sahin (Lund, Sweden) Simona Ruta (Bucharest, Romania)	

W0473	13:30	Hepatitis B during pregnancy: diagnosis, management and outcomeTba
W0474	13:50	RSV and Influenza during pregnancy: management and outcomeMonika Redlberger-Fritz (Vienna, Austria)
W0475	14:10	Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guidelineMarianne Leruez-Ville (Paris, France)
W0476	14:30	Novel methods of vaccine administration to newbornsTba

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

SY169	13:30 – 15:30	Hall 4
	2-hour Symposium	

AMR

CLN

Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria		
Chairs	Agnes Maria Sonnevend (Pécs, Hungary) Kyriaki Xanthopoulou (Cologne, Germany)	

S0461	13:30	Globally emerging resistance patterns of EnterobacteralesSasheela Ponnampalavanar (Kuala Lumpur, Malaysia)
S0462	14:00	Non-fermenters still important globally: a review of spread and resistanceAnupa Thampy (Vellore, India)
S0463	14:30	Innovative rapid diagnostic methodologies for Gram-negative pathogensLaurent Dortet (Le Kremlin-

S0464 **15:00** **Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approaches.** *Juan P. Horcajada (Barcelona, Spain)*

EW173	13:30 - 15:30	Hall 5
	Educational Session	

Tropical dermatology: a case-based approach

W0477	13:30	Parasitic diseases: dermatological manifestations in the tropics <i>Kirti Sabnis (India)</i>
W0478	13:50	Madura foot and other implantation mycoses <i>M Ramam (New Delhi, India)</i>
W0479	14:10	Mycobacteria <i>Francisco Bravo (Lima, Peru)</i>
W0480	14:30	Approach to rash in the returning traveller <i>Frank O. D. Pettersen (Oslo, Norway)</i>

OS127	13:30 - 14:30	Hall 6
	1-hour Oral Session	

The good, the bad and the itchy: update on STIs

00920	<p>High frequency of Nichols-like strains of <i>Treponema pallidum</i> subsp. <i>pallidum</i> circulating in Barcelona, Spain <i>P. Nadal-Baron* (Barcelona, Spain), P. Nadal-Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M. Valverde Espinal, A. Canals Quintana, J.J. González-López, A. Antón, M. Alberny, O. Mitjà, N. Larrosa, Y. Hoyos-Mallecot</i></p>
00921	<p>Doxycycline post-exposure prophylaxis (doxy-PEP) use and outcomes in metropolitan Detroit <i>C. Arena* (Detroit, United States), N. Everson, R. Kenney, I. Brar, S. Gudipati, N. Yared, S. Davis, M. Veve</i></p>
00922	<p>The Gonococcus Bacterial Load Measured by the Cycle Threshold (Ct) in Urinary Samples Correlates with Symptomatology <i>G. Beraud* (Orleans, France), T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L. Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E. Carbonelle, C. Guillaume</i></p>
00923	<p>STI pathogen interactions and viability in men who have sex with men (MSM) <i>E. Rayo* (Zurich, Switzerland), D. Onorini, C. Leonard, H. Marti, T. Pesch, B. Hampel, N. Low, N. Borel</i></p>
00924	<p>Epidemiology of bacterial genitourinary infections among women with recurrent vulvovaginal Candidiasis (RVVC) in Nigeria. <i>S. Fayemiwo* (Ibadan, Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-Richardson</i></p>

OS129	13:30 - 14:30	Hall 7
	1-hour Oral Session	

Biofilm biology and control

O0930 Influence of non-coding small RNA00203 in biofilm cells of *Acinetobacter baumannii*. Transcriptomic and phenotypic. *D. Gebrelibanos** (Hong Kong, China), *P. Leung, A.M. Shenkutie, F. Chow*

O0931 Sub-MIC antibiotic effects on *Pseudomonas aeruginosa* biofilm streamer formation. *A. Di Claudio** (Pieve Emanuele, Italy), *R. Rusconi, E. Secchi, G. Savorana*

ESCMID Global 2025 - Programme

O0932	Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of <i>Klebsiella pneumoniae</i> <i>X. Chu* (Beijing, China), Q. Yang</i>
O0933	Exploring structural differences in biofilms of smooth and rough <i>Mycobacterium abscessus</i> clinical strains through confocal laser scanning microscopy <i>C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea</i>
O0934	Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsions <i>Z. Najmi* (Novara, Italy), A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin</i>
<hr/>	
OS126	13:30 – 15:30 2-hour Oral Session
<div>CLN DX PHEI</div>	
Emerging viruses, diverse threats	
<i>Chairs</i>	<i>Luisa Barzon (Padua, Italy) Karin Stiasny (Vienna, Austria)</i>
O0910	Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study <i>I. Brosius* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijk, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum</i>
O0911	Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023 <i>G. Romano* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti</i>
O0912	Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024 <i>M. Torres Portillo* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan</i>
O0913	Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023 <i>L. Mueller* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. John, V.M. Corman</i>
O0914	Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein <i>A. Hirvonen* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Bens Chop</i>
O0915	Health-economic impacts of chikungunya vaccination in 34 countries <i>J. Zhou* (Oxford, United Kingdom), N. Salant, D. Smith, D. Hollingsworth, K. Pouwels, S. Radoykova, J. Lord, K. French</i>
O0916	Clinical importance of a new tick-borne <i>flaviviridae</i> virus, Alongshan Virus: retrospective serologic and molecular study in Switzerland <i>F. Tagini* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub</i>
O0917	From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach <i>S. Ahmad* (Tampere, Finland)</i>
O0918	Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection <i>G. Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci</i>

O0919 **Substantial viral diversity in bats and rodents from East Africa: insights into conservation, recombination, and co-circulation***D. Wang** (Shenzhen, China)

OS128 **13:30 – 14:30** **Hall 9**
1-hour Oral Session

ANT CLN

AI Aiding AMS

Chairs *Marlieke De Kraker (Geneva, Switzerland)*
Bhanu Sinha (Groningen, Netherlands)

O0925 **Using natural language processing to understand free-text antibiotic prescriptions***A. Martin** (Middlesbrough, United Kingdom), *L. Christopher*

O0926 **Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease Experts***H.M. Wei** (Taichung, Taiwan, China), *Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang*

O0927 **Augmented Intelligence in Infectious Diseases (AI²D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infections***J.L. Lim** (Singapore, Singapore), *P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa*

O0928 **Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learning***K. Yuan** (Oxford, United Kingdom), *J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre*

O0929 **Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switching***W. Bolton** (London, United Kingdom), *R. Wilson, P. Georgiou, A. Holmes, T.M. Rawson, M. Gilchrist*